TYK2 inhibitor preparation and preparation method thereof
By using a combination of solubilizers such as vitamin E TPGS and fillers in TYK2 inhibitors, spray-dried dispersion preparations with high dissolution were prepared, which solved the problems of low solubility of existing TYK2 inhibitors and safety of JAK inhibitors, and achieved the More efficient TYK2 inhibition and safer treatment effects.
Patent Information
- Application Number
- CN202380029975.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-25
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-08
AI Technical Summary
The existing TYK2 inhibitors have low solubility, which affects bioavailability and therapeutic effects, and JAK inhibitors have problems with target safety, which limits their clinical application.
开发了一种包含化合物1的药物组合物,通过与增溶剂如维生素E TPGS、填充剂、稀释剂和粘合剂的组合,制备出喷雾干燥分散体(SDD)形式的制剂,提高化合物1的溶出性和选择性,优化其体内分布。
Improve the dissolution and bioavailability of compound 1, provide higher TYK2 inhibition effect, reduce the safety risks associated with JAK inhibitors, and is suitable for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis and Autoimmune disease.
Smart Images

Figure CN118922192A_ABST
Abstract
Description
[0001] Priority declaration
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 269,945, filed on March 25, 2022, which is incorporated by reference in its entirety. Technical Field
[0003] The present invention relates to a pharmaceutical composition of a tyrosine protein kinase 2 (TYK2) inhibitor and a method for preparing the composition. The present invention also provides a method for treating a disease using the pharmaceutical composition. Background Art
[0004] Protein kinases constitute a large family of structurally related enzymes responsible for controlling a variety of signal transduction processes in cells. Protein kinases are believed to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar catalytic domain of 250-300 amino acids. They can be classified into many families according to the substrates phosphorylated by the kinases (e.g., protein-tyrosine, protein-serine / threonine, lipids, etc.).
[0005] In general, protein kinases mediate intracellular signal transduction by achieving phosphoryl transfer from nucleoside triphosphates to protein receptors involved in signal transduction pathways. These phosphorylation events act as molecular on / off switches that can regulate or control target protein biological functions. These phosphorylation events are ultimately triggered in response to a variety of extracellular stimuli and other stimuli. Examples of such stimuli include environmental and chemical stress signals (e.g., osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxins, and H2O2), cytokines (e.g., interleukin-1 (IL-1), interleukin-8 (IL-8), and tumor necrosis factor α (TNF-α)), and growth factors (e.g., granulocyte macrophage colony stimulating factor (GM-CSF) and fibroblast growth factor (FGF)). Extracellular stimuli can affect one or more cellular responses related to the following: cell growth, migration, differentiation, hormone secretion, transcription factor activation, muscle contraction, glucose metabolism, control of protein synthesis, and regulation of the cell cycle.
[0006] Many diseases are associated with abnormal cellular responses triggered by kinase-mediated events. These diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases.
[0007] TYK2 catalyzes the phosphorylation of STAT proteins downstream of multiple cytokine receptors, including type I interferon receptors and IL-12 and IL-23 receptors. TYK2-dependent receptors are activated by their cytokine ligands, leading to STAT-dependent transcription and activation of cell function responses specific to the receptors and the cell types expressing the receptors. The cytokine signaling pathways regulated by TYK2 play a key role in several immune-mediated disorders. Cytokine IL-12 is essential for the development of type 1 T helper cells (Th1), which produce interferon-γ, a major effector molecule in systemic autoimmune disorders such as systemic lupus erythematosus. Cytokine IL-23 is essential for the expansion and survival of Th17 cells and innate lymphoid cells, and the two cells have been shown to play a key pathogenic role in autoimmunity. IL-23 stimulation drives Th17 cells to produce key proinflammatory cytokines, including IL-17A, IL-17F, and IL-22, all of which are effector molecules important in the pathogenesis of conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Because TYK2 has effects on the IL-23 / Th17 / Th22 axis, IL-12-mediated Th1 function, and type I interferon-driven regulation of different immune pathways and cell types, inhibition of TYK2 is expected to affect a variety of immune-mediated conditions. Summary of the invention
[0008] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0009] (a) Compound 1:
[0010]
[0011] or a solvate or a pharmaceutically acceptable salt thereof;
[0012] (b) one or more fillers or diluents (e.g., microcrystalline cellulose);
[0013] (c) one or more solubilizing agents (e.g., D-α-tocopheryl polyethylene glycol succinate [vitamin E TPGS]); and
[0014] (d) One or more binders (eg, povidone).
[0015] In another aspect, the present disclosure provides a method of preparing a unit dosage form, the unit dosage form comprising:
[0016] (a) Compound 1:
[0017]
[0018] or a solvate or a pharmaceutically acceptable salt thereof;
[0019] (b) one or more fillers or diluents (e.g., microcrystalline cellulose);
[0020] (c) one or more solubilizing agents (e.g., D-α-tocopheryl polyethylene glycol succinate [vitamin E TPGS]); and
[0021] (d) one or more binders (eg, povidone).
[0022] In another aspect, pharmaceutical compositions, formulations and unit dosage forms may comprise:
[0023] (a) Compound 1:
[0024]
[0025] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0026] Wherein compound 1 is in the form of a spray dried dispersion (SDD).
[0027] In some embodiments, the SDD may include a cellulose polymer such as hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methylcellulose acetate succinate, hydroxyethyl methylcellulose succinate, hydroxyethyl cellulose acetate succinate, or carboxymethyl ethyl cellulose. In some embodiments, the SDD may include a cellulose polymer that is at least partially ionized at a physiologically relevant pH, such as hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, or carboxymethyl ethyl cellulose. In some embodiments, the SDD may include hydroxypropyl methylcellulose acetate succinate (HPMCAS). In some embodiments, the SDD may include HPMC-AS-M (hydroxypropyl methylcellulose acetate succinate, M grade; also known as hydroxypropyl methylcellulose acetate succinate).
[0028] In some embodiments, the SDD may be a spray-dried mixture of about 2:1 to about 1:2 (w / w) Compound 1 and HPMC-AS-M.
[0029] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0030] a) about 1-4 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0031] b) about 35-140 mg of a first bulking agent, such as mannitol;
[0032] c) optionally, about 35-140 mg of a second filler, such as microcrystalline cellulose;
[0033] d) about 4-18 mg of a disintegrant, such as croscarmellose sodium;
[0034] e) about 0.5-3.0 mg of a glidant such as colloidal silicon dioxide;
[0035] f) about 0.4-2.0 mg of a lubricant, such as sodium stearyl fumarate; and
[0036] g) Optionally, about 0.5-2 mg of a wetting agent such as sodium lauryl sulfate.
[0037] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0038] a) about 2.5-10 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0039] b) about 30-130 mg of a first bulking agent, such as mannitol;
[0040] c) optionally, about 30-130 mg of a second filler, such as microcrystalline cellulose;
[0041] d) about 4-20 mg of a disintegrant, such as croscarmellose sodium;
[0042] e) about 0.5-4.0 mg of a glidant such as colloidal silicon dioxide;
[0043] f) optionally, about 0.5-4.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0044] g) about 0.4-2.5 mg of a lubricant such as sodium stearyl fumarate.
[0045] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0046] a) about 7.5-30 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0047] b) about 25-130 mg of a first bulking agent, such as mannitol;
[0048] c) optionally, about 25-130 mg of a second filler, such as microcrystalline cellulose;
[0049] d) about 4-20 mg of a disintegrant, such as croscarmellose sodium;
[0050] e) about 0.5-4.0 mg of a glidant such as colloidal silicon dioxide;
[0051] f) optionally, about 0.5-4.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0052] g) about 0.4-4.0 mg of a lubricant such as sodium stearyl fumarate.
[0053] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0054] a) about 12.5-50 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0055] b) about 20-95 mg of a first bulking agent, such as mannitol;
[0056] c) optionally, about 20-95 mg of a second filler, such as microcrystalline cellulose;
[0057] d) about 4-20 mg of a disintegrant, such as croscarmellose sodium;
[0058] e) about 0.5-4.0 mg of a glidant such as colloidal silicon dioxide;
[0059] f) optionally, about 0.5-4.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0060] g) about 0.4-4.0 mg of a lubricant such as sodium stearyl fumarate.
[0061] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0062] a) about 25-75 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0063] b) about 24-96 mg of a first bulking agent, such as mannitol;
[0064] c) optionally, about 24-96 mg of a second filler, such as microcrystalline cellulose;
[0065] d) about 6-25 mg of a disintegrant, such as croscarmellose sodium;
[0066] e) about 1.0-5.0 mg of a glidant such as colloidal silicon dioxide;
[0067] f) optionally, about 1.0-5.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0068] g) about 0.7-2.6 mg of a lubricant, such as sodium stearyl fumarate.
[0069] In some embodiments, a pharmaceutical composition, formulation, or unit dosage form may comprise the ingredients indicated below in one of the following w / w %.
[0070]
[0071]
[0072] The spray-dried intermediate may comprise spray-dried solids of Compound 1 and a cellulosic polymer, such as Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a 1.5:1 to 1:1.5 w / w ratio.
[0073]
[0074] The spray-dried intermediate may comprise spray-dried solids of Compound 1 and a cellulosic polymer, such as Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a 1.5:1 to 1:1.5 w / w ratio. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 Graphs depicting dissolution of Compound 1 formulations in aqueous media. The "0.1N HCl" curve indicates the dissolution % of a blend of crystalline Compound 1 and microcrystalline cellulose (MCC), while the other two curves indicate the dissolution % of granules of crystalline Compound 1 with 5% or 20% Vitamin E TPGS and MCC.
[0076] Figure 2 To depict a flow chart of the formulation process, the formulation process includes wet granulation of Compound 1 with MCC (microcrystalline cellulose, diluent, Avicel PH101), Vitamin E TPGS (solubilizer), PVP K30 (polyvinyl pyrrolidone, binder) and water. After granulation, the wet granules are dried in a fluid bed dryer until LOD≤1.5%, passed through a Comil to break up any aggregates, and blended to provide bulk capsule filling material. Based on the weight of the input material, Compound 1 5 mg capsules are filled using the Xcelodose system. Based on volume, Compound 1 25 mg capsules are filled using the Profill system. Content uniformity testing is performed after capsule filling. Capsules of 5 mg and 25 mg strength are filled in No. 2 hard shell HPMC-based capsules. Each 60cc HPDE bottle is packaged with 12 counted filled capsules.
[0077] Figure 3 is a graph depicting an XRPD spectrum of the Form C polymorph of Compound 1.
[0078] Figure 4 Figure 1 is a flow chart depicting the formulation process of the spray dried dispersion (SDD) formulation.
[0079] Figure 5 is a graph depicting the XRPD spectrum of Form A of Compound 1. DETAILED DESCRIPTION
[0080] Compound 1:
[0081]
[0082] TYK2 inhibitors previously disclosed by applicants. See U.S. Patent No. 11,046,698. Dissolution of compounds is problematic and may present obstacles when formulating compounds for administration to or treatment of patients because, for example, solubility may affect bioavailability and therapeutic outcomes. The present disclosure satisfies the need to solubilize formulations of Compound 1 and provides other related advantages.
[0083] Compound 1 is an oral, allosteric and selective TYK2 inhibitor that is being studied for the treatment of psoriasis, psoriatic arthritis and other inflammatory and autoimmune diseases. There are currently no approved TYK2 inhibitors, and this compound is the most selective TYK2 inhibitor currently in clinical development. In addition, the selectivity of compound 1 and the potential for once-daily (QD) dosing to provide higher levels of TYK2 inhibition over a longer period of time may give it a clinical and ultimately commercial advantage over other TYK2 inhibitors in development. TYK2 is a member of the Janus kinase (JAK) kinase family, which is a class of intracellular signaling proteins that regulate chronic inflammation in inflammatory and autoimmune diseases. Although JAK inhibition can effectively treat inflammatory and autoimmune diseases, it can also cause on-target safety issues due to the regulation of multiple cytokine pathways. Therefore, although JAK inhibitors have become established oral treatments for a variety of inflammatory and autoimmune diseases, their clinical utility is limited by the increased risk of infection and other side effects, which has led the US Food and Drug Administration (FDA) to mandate boxed warnings and dose restrictions as part of the labeling of the inhibitors. Due to the structural similarities between the catalytic (orthosteric or JH1) sites targeted by drugs on the JAK catalytic domain and due to the specific physical properties (e.g., solubility) of JAK inhibitors (such as Compound 1), it is challenging to design selective JAK inhibitors that directly and specifically inhibit the intended kinase function with optimized formulations for effective dissolution in vivo. Based on human genetic data and increasing clinical evidence of the selectivity of allosteric TYK2 inhibitors, the method of selective allosteric inhibition of TYK2 of the present invention provides an optimal balance of achieving strong efficacy while potentially avoiding safety issues associated with broader JAK inhibition for the treatment of a variety of inflammatory and autoimmune diseases. In addition, when used in treatments requiring the above-mentioned drug therapies, the method of formulating the inhibitor of the present invention promotes the dissolution of the compound.
[0084] The preparations and methods described herein include those described above and are further described by the categories, subclasses and species disclosed herein. Unless otherwise indicated, the following definitions as used herein shall apply. For the purposes of this disclosure, chemical elements are identified according to the periodic table of the elements (CAS version, Handbook of Chemistry and Physics, 75th edition). In addition, the general principles of organic chemistry are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito: 1999 and March's Advanced Organic Chemistry, 5th edition, editors: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.
[0085] As used herein, “ "PH-101" refers to cellulose of formula III:
[0086]
[0087] wherein n is between about 5 and about 2,000. In some embodiments, n is between about 50 and 500.
[0088] As used herein, "PVP30" refers to a compound of formula II:
[0089]
[0090] wherein n is from about 200 to about 1000. In some embodiments, n is from about 250 to about 500.
[0091] As used herein, the term "aliphatic" or "aliphatic group" means a straight chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturated units, or a monocyclic or bicyclic hydrocarbon (also referred to herein as "carbocycle," "cycloaliphatic," or "cycloalkyl") that is fully saturated or contains one or more unsaturated units but is not aromatic, having a single point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, the aliphatic group contains 1 to 4 aliphatic carbon atoms. In other embodiments, the aliphatic group contains 1 to 3 aliphatic carbon atoms, and in other embodiments, the aliphatic group contains 1 to 2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or contains one or more unsaturated units, but is not aromatic, and has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, substituted or unsubstituted straight or branched chain alkyl, alkenyl, alkynyl, and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.
[0092] The term "lower alkyl" refers to a C 1-4 Straight or branched chain alkyl. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.
[0093] The term "lower haloalkyl" refers to a C 1-4 Straight chain or branched chain alkyl.
[0094] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (as in N-substituted pyrrolidinyl)).
[0095] As used herein, the term "unsaturated" means that the moiety has one or more units of unsaturation.
[0096] As used herein, the term "divalent C 1-8 (or C 1-6 ) saturated or unsaturated straight or branched hydrocarbon chain" refers to straight or branched divalent alkylene, alkenylene and alkynylene chains as defined herein.
[0097] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n-, wherein n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2 or 2 to 3. A substituted alkylene chain is a polymethylene chain in which one or more methylene hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0098] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0099] The term "halogen" means F, Cl, Br or I.
[0100] The term "aryl" used alone or as part of a larger moiety (such as in "aralkyl", "aralkyloxy" or "aryloxyalkyl") refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" can be used interchangeably with the term "aryl ring". In some embodiments, the term "aryl" used alone or as part of a larger moiety (such as in "aralkyl", "aralkyloxy" or "aryloxyalkyl") refers to a monocyclic and bicyclic ring system having a total of 5 to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. In certain embodiments of the compound, "aryl" refers to an aromatic ring system, which includes but is not limited to phenyl, biphenyl, naphthyl, anthracenyl, etc., which may bear one or more substituents. As used herein, the term "aryl" also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
[0101] The terms "heteroaryl" and "heteroar-" (e.g., "heteroaralkyl" or "heteroaralkoxy"), used alone or as part of a larger moiety, refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of basic nitrogen. Heteroaryl includes, but is not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. As used herein, the terms "heteroaryl" and "heteroaryl-" also include groups in which a heteroaromatic ring is fused to one or more aryl rings, cycloaliphatic rings, or heterocyclyl rings, wherein the connecting group or point of attachment is located on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, and pyrido [2,3-b] -1,4-oxazine-3 (4H) -one. The heteroaryl group may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which includes rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group, wherein the alkyl and heteroaryl portions are independently optionally substituted.
[0102] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical" and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four heteroatoms as defined above. When used with respect to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur and nitrogen, nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or + NR (as in N-substituted pyrrolidinyl).
[0103] The heterocyclic ring may be attached to its side group at any heteroatom or carbon atom to obtain a stable structure, and any ring atom may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepine, oxazepine, thiazepine, morpholinyl, and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl, wherein the radical or point of attachment is on the heterocyclyl ring. The heterocyclyl group may be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group, wherein the alkyl and heterocyclyl moieties are independently optionally substituted.
[0104] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.
[0105] As described herein, the compounds of the present disclosure may contain "optionally substituted" parts. In general, the term "substituted" means that one or more hydrogens of the specified part are replaced by suitable substituents regardless of whether there is a term "optionally" in front. Unless otherwise indicated, the "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from a specified group, the substituent at each position may be the same or different. The substituent combinations envisioned for the compounds herein are preferably those substituent combinations that form stable or chemically feasible compounds. As used herein, the term "stable" means that for one or more purposes disclosed herein, the compound does not undergo substantial changes when subjected to conditions that allow it to be produced, detected, and in certain embodiments, to be recovered, purified, and used.
[0106] Suitable monovalent substituents on the substitutable carbon atoms of an "optionally substituted" group are independently halogen; -(CH2) 0- 4R o ; -(CH2) 0-4 OR o ; -O(CH2) 0-4 R o ; -O-(CH2)0-4 C(O)OR o ; -(CH2) 0-4 CH(OR o )2; -(CH2) 0-4 SR o ; -(CH2) 0-4 Ph, which can be o Substitution; -(CH2) 0-4 O(CH2) 0-1 Ph, which can be o Substitution; -CH=CHPh, which can be R o Substitution; -(CH2) 0-4 O(CH2) 0-1 -pyridyl, which may be R o Substitution; -NO2; -CN; -N3; -(CH2) 0-4 N(R o )2; -(CH2) 0-4 N(R o )C(O)R o ;-N(R o )C(S)R o ; -(CH2) 0-4 N(R o )C(O)NR o 2;-N(R o )C(S)NR o 2; -(CH2) 0-4 N(R ° )C(O)OR ° ;-N(R o )N(R o )C(O)R o ;-N(R ° )N(R o )C(O)NR o 2;-N(R ° )N(R o )C(O)OR o ; -(CH2) 0-4 C(O)R o ;-C(S)R ° ; -(CH2) 0-4 C(O)OR o ; -(CH2) 0-4 C(O)SR o ; -(CH2) 0-4 C(O)OSiR o 3; -(CH2) 0-4 OC(O)R o ;-OC(O)(CH2) 0-4SR-;SC(S)SR o ; -(CH2) 0-4 SC(O)R o ; -(CH2) 0-4 C(O)NR o 2; -C(S)NR o 2; -C(S)SR o ;-SC(S)SR o ; -(CH2) 0-4 OC(O)NR ° 2; -C(O)N(OR o )R o ; -C(O)C(O)R o ; -C(O)CH2C(O)R o ;-C(NOR o )R o ; -(CH2) 0- 4SSR o ; -(CH2) 0-4 S(O)2R o ; -(CH2) 0-4 S(O)2OR o ; -(CH2) 0-4 OS(O)2R o ; -S(O)2NR o 2; -(CH2) 0-4 S(O)R o ;-N(R o )S(O)2NR o 2;-N(R o )S(O)2R o ;-N(OR o )R o ; -C(NH)NR o 2;-P(O)2R o ;-P(O)R o 2;-OP(O)R o 2;-OP(O)(OR o )2;SiR o 3;-(C 1-4 Straight or branched alkylene)ON(R o )2; or -(C 1-4 Straight or branched alkylene)C(O)ON(R o )2, where each R o may be substituted as defined below and are independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1Ph, -CH2-(5-6 membered heteroaryl ring) or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or, notwithstanding the above definitions, two independent occurrences of R o Together with its central atoms it forms a 3-12 membered saturated, partially unsaturated or aromatic mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, which may be substituted as defined below.
[0107] R o (or two independent occurrences of R o Suitable monovalent substituents on the ring formed by the middle atom thereof are independently halogen, -(CH2) 0-2 R · 、-(halogen R · )、-(CH2) 0-2 OH, -(CH2) 0-2 OR ● 、-(CH2) 0-2 CH(OR · )2; -O(halogen R · )、-CN、-N3、-(CH2) 0-2 C(O)R · 、-(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR · 、-(CH2) 0-2 SR · 、-(CH2) 0- 2SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR · 、-(CH2) 0-2 NR ● 2. -NO2, -SiR ● 3. -OSiR ● 3. -C(O)SR ● 、-(C 1-4 Straight or branched alkylene)C(O)OR ● or -SSR ● , where each R ● unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph and a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur. o Suitable divalent substituents on a saturated carbon atom of include =0 and =S.
[0108] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR * 2. =NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O)2R * , =NR * , =NOR * 、-O(C(R * 2)) 2-3 O-or-S(C(R * 2)) 2-3 S-, where each independent occurrence of R * is selected from hydrogen, C which may be substituted as defined below 1-6 aliphatic and unsubstituted 5-6 membered saturated, partially unsaturated or aromatic rings having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur. Suitable divalent substituents attached to the ortho-substitutable carbon of an "optionally substituted" group include: -O(CR * 2) 2-3 O-, where each independent occurrence of R * is selected from hydrogen, C which may be substituted as defined below 1-6 Aliphatic and unsubstituted 5-6 membered saturated, partially unsaturated or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0109] R * Suitable substituents on the aliphatic group include halogen, -R ● 、-(halogen R · ), -OH, -OR · 、-O(halogen R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R · unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0110] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include or Each of these are independently hydrogen, C which may be substituted as defined below 1-6 aliphatic, unsubstituted -OPh or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or, notwithstanding the above definition, two independent occurrences of Together with its central atoms, it forms an unsubstituted 3-12 membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0111] Suitable substituents on the aliphatic group are independently halogen, -R · 、-(halogen R · ), -OH, -OR · 、-O(halogen R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R · unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0112] As used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with human and lower animal tissues without excessive toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid) or by using other methods used in the art (such as ion exchange) formed salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.
[0113] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1–4 Representative alkali metal salts or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, etc. Where appropriate, other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations, which are formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.
[0114] Unless otherwise stated, the structures depicted herein are also intended to include all isomeric (e.g., enantiomer, diastereomer, and geometric (or conformational)) forms of the structure; for example, R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomer, diastereomer, and geometric (or conformational) mixtures of the compounds of the present invention are within the scope of the present invention. Unless otherwise stated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.
[0115] As used herein, "about" or "approximately" with respect to a numerical value means that the numerical value may vary by up to 10% of the stated value. For example, "about 10" refers to a value of 9.9 to 10.1 (10+ / -0.1).
[0116] The present disclosure contains embodiments that are stated as "comprising" an item. The present disclosure also contemplates "consisting essentially of" or "similar embodiments consisting of" the items.
[0117] As used herein, "nominal particle size" refers to the particle size that represents the mass average of the particles.
[0118] As used herein, "loose bulk density" refers to the mass of loose powder per unit volume.
[0119] As used herein, "solubilizer" may refer to one or more compounds added to a formulation that increase solubility in any given solvent system (eg, water, organic solvents, biological fluids, simulated biological fluids, and mixtures thereof).
[0120] As used herein, "binder" may refer to one or more compounds that promote cohesion between other components in a formulation, also known as adhesives, which help other ingredients in a formulation to mix together. Tablet binders may help turn a powder into granules; this may be achieved during the granulation process.
[0121] As used herein, "surfactant" may refer to one or more compounds that reduce the surface tension between two liquids, between a gas and a liquid, or between a liquid and a solid. Surfactants may be used as cleaning agents, wetting agents, emulsifiers, foaming agents, or dispersants.
[0122] As used herein, a "glidant" is an added substance used to enhance powder flowability by reducing interparticle friction, surface charge and cohesion, thereby reducing the angle of repose. It is usually incorporated in dry powder form just prior to direct compression.
[0123] As used herein, "granulation" refers to the process of producing larger or smaller particles or particles of a substance or mixture of substances. The process can also remove fine particles and improve the flowability within the formulation. Both wet granulation and / or dry granulation can be used. Dry granulation is achieved using only a combination of particles without any liquid on them. Shot compression uses a tablet press to form large tablets, which vary in weight due to the poor flowability of the formulation. The resulting agglomerate is then passed through a granulator to break into granules, and then compressed again to obtain the final granular product.
[0124] The process may include roller compaction, wherein the formulation is fed via a roller compactor, the mixture is fed via a top hopper, where two rollers compact the powder to form a ribbon, which is then passed through a granulator where the powder is pressed against a screen, which produces particles of the desired size. In some embodiments, the average particle diameter of the particles is between about 0.01 mm and about 10 mm. In some embodiments, the average particle diameter of the particles is between about 0.2 mm and about 0.4 mm.
[0125] Wet granulation can be used to promote aggregation of particles. Adhesives, commonly called binders, can be incorporated into a suitable liquid in the form of a solution or suspension.
[0126] Fluidized bed granulators can be used for wet granulation, where hot air is fed into the bed, thereby lifting the particles while spraying the particles, and the particles are bonded together to form bridges between themselves. The initial stage of wet granulation may include the spraying of particles, and the spraying rate may vary. Then, the wetting of the powder may begin to form liquid bridges between the particles. The process is continued until particles of the desired size are formed, with solid bridges between the particles. Once the complete particles can enter the drying process, the spraying process can be turned off, and the hot air will continue to flow through the bed of the dry particles. Wet granulation can be implemented in a high shear wet granulator known to a person of ordinary skill in the art or commercially available, such as Liu et al., "A review of high shear wet granulation for better process understanding, control and product development", Powder Technology, 381, March 2021, pp. 204-223, the entire disclosure of the document is incorporated herein by reference. With regard to the drying process, such methods and equipment for implementing the process are known to those of ordinary skill in the art. Drying can be carried out in a fluidized bed dryer, for example as described in Srivastava et al., "Fluid Bed Technology: Overview and Parameters for Process Selection", International Journal of Pharmaceutical Sciences and Drug Research 2010; 2(4): 236-246, the entire disclosure of which is incorporated herein by reference.
[0127] For example, after drying, screen milling of the process material can be used. Screen milling procedures and equipment are known to those of ordinary skill in the art, such as described in Kotamarthy, LVG, (2018). "Understanding the effect of granulation and mill process parameters on granule critical quality attributes", [Master's thesis, Rutgers University]. Rutger's Library, the entire disclosure of which is incorporated herein by reference.
[0128] As used herein, "blending" refers to techniques for blending solid materials that are well known to those of ordinary skill in the art. Such techniques and machines for blending are described in the art, for example, Mendez et al., "Evaluation of powder mixing operation during batch production: application to operational qualification procedure in the pharmaceutical industry." Powder Technol. 2009; 198: 310-3. Harn by N. "An engineering view of pharmaceutical powder mixing." Pharm Sci Technol Today. 2000; 3: 303-9. Remy B. et al., "Discrete element simulation of free flowing grains in a four-bladed mixer." AIChE J. 2009; 55: 2035-48; and StieβM. "Mechanische Verfahrenstechnik-Partikeltechnologie 1.", 3rd edition, Berlin: Springer; 2009, the entire disclosure of each of which is incorporated herein by reference in its entirety.
[0129] Other granulation methods are known to those skilled in the art and are described in Miyazaki S et al., "Drug release from oral mucosal adhesive tablets of chitosan and sodium alginate." Int J Pharm 1995; 118: 257-263; Selmeczi B. "The influence of the compressional force on the physical properties of tablets made by different technological processes." Arch Pharm (Weinheim) 1974; 307(10): 755-760; and Beg et al., 2021, "Handbook of Analytical Quality by Design", Elsevier Inc., the entire disclosure of each of which is incorporated herein by reference in its entirety.
[0130] As used herein, "de-agglomeration" refers to a process by passing a powder formulation through a screen. The screen used herein for a process such as blending or de-agglomeration may have a mesh size of about 1 to about 100 μm, about 100 to about 500 μm, about 500 to about 1,000 μm, about 1,000 to about 5,000 μm, about 5,000 μm to about 10,000 μm, about 10,000 to about 50,000 μm, or about 50,000 to about 100,000 μm.
[0131] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms, which may comprise:
[0132] (a) Compound 1:
[0133]
[0134] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0135] (b) one or more fillers or diluents;
[0136] (c) one or more solubilizing agents;
[0137] (d) one or more adhesives;
[0138] (e) optionally, one or more glidants;
[0139] (f) optionally, one or more lubricants; and
[0140] (g) Optionally, one or more surfactants.
[0141] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0142] (a) Compound 1:
[0143]
[0144] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0145] (b) one or more fillers or diluents;
[0146] (c) one or more solubilizing agents; and
[0147] (d) one or more binders.
[0148] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms consisting essentially of:
[0149] (a) Compound 1:
[0150]
[0151] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0152] (b) one or more fillers or diluents;
[0153] (c) one or more solubilizing agents; and
[0154] (d) one or more binders.
[0155] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms consisting of:
[0156] (a) Compound 1:
[0157]
[0158] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0159] (b) one or more fillers or diluents;
[0160] (c) one or more solubilizing agents; and
[0161] (d) one or more binders.
[0162] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0163] (a) Compound 1:
[0164]
[0165] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0166] (b) one or more fillers or diluents;
[0167] (c) one or more solubilizing agents of formula I:
[0168]
[0169] or a pharmaceutically acceptable salt thereof, wherein R 1 an optionally substituted aliphatic group selected from about 100 Da to about 500 Da, about 500 Da to about 1,000 Da, about 1,000 Da to about 2,000 Da, about 2,000 Da to about 5,000 Da, about 5,000 Da to about 10,000 Da, about 10,000 Da to about 20,000 Da, about 20,000 Da to about 50,000 Da, or about 50,000 Da to about 100,000 Da; and
[0170] (d) one or more binders.
[0171] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0172] (a) Compound 1:
[0173]
[0174] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0175] (b) one or more fillers or diluents;
[0176] (c) one or more solubilizing agents of formula IA:
[0177]
[0178] or a pharmaceutically acceptable salt thereof, wherein n is between about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000. In some embodiments, n is about 1,000; and
[0179] (d) one or more binders.
[0180] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0181] (a) Compound 1:
[0182]
[0183] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0184] (b) one or more fillers or diluents;
[0185] (c) Vitamin E TPGS; and
[0186] (d) one or more binders.
[0187] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0188] (a) Compound 1:
[0189]
[0190] (b) one or more fillers or diluents;
[0191] (c) one or more solubilizing agents; and
[0192] (d) one or more binders.
[0193] In some embodiments, the diluent is selected from microcrystalline cellulose, sucrose, lactose, starch, magnesium stearate, sorbitol, xylitol, and mannitol.
[0194] In some embodiments, compound 1 is in the form of a solvate (e.g., a hydrate) or a pharmaceutically acceptable salt of such a solvate. In some embodiments, compound 1 is in the form of a free base. In some embodiments, compound 1 is in the form of a crystalline solid. In some embodiments, the crystalline solid is Form C.
[0195] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0196] (a) Compound 1:
[0197]
[0198] (b) one or more fillers or diluents;
[0199] (c) Vitamin E TPGS; and
[0200] (d) one or more binders.
[0201] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0202] (a) Compound 1:
[0203]
[0204] (b) microcrystalline cellulose;
[0205] (c) Vitamin E TPGS; and
[0206] (d) one or more binders.
[0207] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0208] (a) Compound 1:
[0209]
[0210] (b) Avicel PH101;
[0211] (c) Vitamin E TPGS; and
[0212] (d) one or more binders.
[0213] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0214] (a) Compound 1:
[0215]
[0216] (b) microcrystalline cellulose;
[0217] (c) Vitamin E TPGS; and
[0218] (d) Povidone.
[0219] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:
[0220] (a) Compound 1:
[0221]
[0222] (b) Avicel PH101;
[0223] (c) Vitamin E TPGS; and
[0224] (d) PVP K30.
[0225] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms consisting essentially of:
[0226] (a) Compound 1:
[0227]
[0228] (b) Avicel PH101;
[0229] (c) Vitamin E TPGS; and
[0230] (d) PVP K30.
[0231] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms consisting of:
[0232] (a) Compound 1:
[0233]
[0234] (b) Avicel PH101;
[0235] (c) Vitamin E TPGS; and
[0236] (d) PVP K30.
[0237] In some embodiments, the solubilizing agent is selected from a vitamin E conjugate. In some embodiments, the solubilizing agent may include one or more solubilizing agents of Formula I:
[0238]
[0239] or a pharmaceutically acceptable salt thereof, wherein R 1 An optionally substituted aliphatic group is selected from a mass of about 100 Da to about 500 Da, about 500 Da to about 1,000 Da, about 1,000 Da to about 2,000 Da, about 2,000 Da to about 5,000 Da, about 5,000 Da to about 10,000 Da, about 10,000 Da to about 20,000 Da, about 20,000 Da to about 50,000 Da, or about 50,000 Da to about 100,000 Da.
[0240] In some embodiments, the solubilizing agent may include one or more solubilizing agents of Formula IA:
[0241]
[0242] or a pharmaceutically acceptable salt thereof, wherein n is between about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000. In some embodiments, n is between about 1 to about 5, about 5 to about 10, about 10 to about 20, about 20 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, or about 500 to about 1,000. In some embodiments, n is about 88. In some embodiments, n is about 100. In some embodiments, n is about 1,000. In some embodiments, the solubilizing agent may include vitamin E polyethylene glycol succinate (vitamin E TPGS).
[0243] In another aspect, pharmaceutical compositions, formulations, and unit dosage forms may include:
[0244] (a) Compound 1:
[0245]
[0246]
[0247] or a solvate thereof, or a pharmaceutically acceptable salt thereof;
[0248] Wherein compound 1 is in the form of a spray dried dispersion (SDD).
[0249] In some embodiments, SDD may include a cellulose polymer such as hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methylcellulose acetate succinate, hydroxyethyl methylcellulose succinate, hydroxyethyl cellulose acetate succinate, or carboxymethyl ethyl cellulose. In some embodiments, SDD may include a cellulose polymer that is at least partially ionized at a physiologically relevant pH, such as hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, or carboxymethyl ethyl cellulose. In some embodiments, SDD may include hydroxypropyl methylcellulose acetate succinate (HPMCAS). In some embodiments, SDD may include HPMC-AS-M (hydroxypropyl methylcellulose acetate succinate, M grade).
[0250] The SDD may include a plurality of particles. The plurality of particles may be powders or granules. The average particle size of the powders or granules may be less than 200 microns, less than 175 microns, less than 150 microns, less than 125 microns, less than 100 microns, less than 75 microns, less than 50 microns, less than 25 microns, less than 10 microns, or less than 5 microns. The average particle size of the powders or granules may be greater than 1 micron, greater than 3 microns, greater than 5 microns, greater than 10 microns, greater than 15 microns, greater than 20 microns, greater than 25 microns, greater than 30 microns, greater than 35 microns, or greater than 40 microns.
[0251] In some embodiments, the SDD may include Compound 1 or a solvate or pharmaceutically acceptable salt thereof in a specific ratio to a cellulose polymer, such as about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2.5:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or about 1:10 (as a w / w ratio). In some embodiments, the ratio is about 5:1 to about 1:5. In some embodiments, the ratio is about 10:1 to about 1:10, about 2.5:1 to about 1:2.5, or about 1.5:1 to about 1:1.5. In some embodiments, the ratio is about 1:1 (or expressed as 50:50).
[0252] In some embodiments, the SDD may be a spray-dried mixture of about 2:1 to about 1:2 (w / w) Compound 1 and HPMC-AS-M. In some embodiments, the SDD may be a spray-dried mixture of about 1:1 (w / w) Compound 1 and HPMC-AS-M.
[0253] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:
[0254] a) about 1-4 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0255] b) about 35-140 mg of a first bulking agent, such as mannitol;
[0256] c) optionally, about 35-140 mg of a second filler, such as microcrystalline cellulose;
[0257] d) about 4-18 mg of a disintegrant, such as croscarmellose sodium;
[0258] e) about 0.5-3.0 mg of a glidant such as colloidal silicon dioxide;
[0259] f) about 0.4-2.0 mg of a lubricant, such as sodium stearyl fumarate; and
[0260] g) Optionally, about 0.5-2 mg of a wetting agent such as sodium lauryl sulfate.
[0261] In some embodiments, each of b), c), d), and f) may be distributed between the particles comprising a) and the extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0262] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:
[0263] a) about 2.5-10 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0264] b) about 30-130 mg of a first bulking agent, such as mannitol;
[0265] c) optionally, about 30-130 mg of a second filler, such as microcrystalline cellulose;
[0266] d) about 4-20 mg of a disintegrant, such as croscarmellose sodium;
[0267] e) about 0.5-4.0 mg of a glidant such as colloidal silicon dioxide;
[0268] f) optionally, about 0.5-4.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0269] g) about 0.4-2.5 mg of a lubricant such as sodium stearyl fumarate.
[0270] In some embodiments, each of b), c), d), and g) may be distributed between the particles comprising a) and the extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0271] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:
[0272] a) about 7.5-30 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0273] b) about 25-130 mg of a first bulking agent, such as mannitol;
[0274] c) optionally, about 25-130 mg of a second filler, such as microcrystalline cellulose;
[0275] d) about 4-20 mg of a disintegrant, such as croscarmellose sodium;
[0276] e) about 0.5-4.0 mg of a glidant such as colloidal silicon dioxide;
[0277] f) optionally, about 0.5-4.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0278] g) about 0.4-4.0 mg of a lubricant such as sodium stearyl fumarate.
[0279] In some embodiments, each of b), c), d), and g) may be distributed between the particles comprising a) and the extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0280] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:
[0281] a) about 12.5-50 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0282] b) about 20-95 mg of a first bulking agent, such as mannitol;
[0283] c) optionally, about 20-95 mg of a second filler, such as microcrystalline cellulose;
[0284] d) about 4-20 mg of a disintegrant, such as croscarmellose sodium;
[0285] e) about 0.5-4.0 mg of a glidant such as colloidal silicon dioxide;
[0286] f) optionally, about 0.5-4.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0287] g) about 0.4-4.0 mg of a lubricant such as sodium stearyl fumarate.
[0288] In some embodiments, each of b), c), d), and g) may be distributed between the particles comprising a) and the extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0289] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:
[0290] a) about 25-75 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof, optionally in the form of an SDD, such as one of those SDDs described herein;
[0291] b) about 24-96 mg of a first bulking agent, such as mannitol;
[0292] c) optionally, about 24-96 mg of a second filler, such as microcrystalline cellulose;
[0293] d) about 6-25 mg of a disintegrant, such as croscarmellose sodium;
[0294] e) about 1.0-5.0 mg of a glidant such as colloidal silicon dioxide;
[0295] f) optionally, about 1.0-5.0 mg of a wetting agent, such as sodium lauryl sulfate; and
[0296] g) about 0.7-2.6 mg of a lubricant such as sodium stearyl fumarate.
[0297] In some embodiments, each of b), c), d), and g) may be distributed between the particles comprising a) and the extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0298] In some embodiments, a pharmaceutical composition, formulation, or unit dosage form comprises the ingredients indicated below in one of the following amounts or w / w %.
[0299]
[0300] The spray-dried intermediate may comprise spray-dried solids of Compound 1 and a cellulosic polymer, such as Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a 1.5:1 to 1:1.5 w / w ratio.
[0301]
[0302] The spray-dried intermediate may comprise spray-dried solids of Compound 1 and a cellulosic polymer, such as Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a 1.5:1 to 1:1.5 w / w ratio.
[0303] In some embodiments, a pharmaceutical composition, formulation, or unit dosage form comprises the ingredients indicated below in one of the following amounts or w / w %.
[0304]
[0305] The spray-dried intermediate may comprise spray-dried solids of Compound 1 and a cellulosic polymer, such as Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a 1.5:1 to 1:1.5 w / w ratio.
[0306]
[0307] The spray-dried intermediate may comprise spray-dried solids of Compound 1 and a cellulosic polymer, such as Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a 1.5:1 to 1:1.5 w / w ratio.
[0308] In another aspect, a method of making the formulation described above may include the following steps:
[0309] (1) providing an SDD comprising Compound 1 or a solvate or a pharmaceutically acceptable salt thereof and a cellulose polymer (such as HPMC-AS);
[0310] (2) blending the SDD with intragranular excipients;
[0311] (3) de-agglomerating the mixture;
[0312] (4) blending the mixture;
[0313] (5) dry granulating the mixture, for example, using a roller compactor on a 1.00 mm screen, to produce dry granules;
[0314] (6) blending the dried granules with extragranular excipients; and
[0315] (7) Optionally, the formulation is filled into a suitable unit container (such as a capsule). Different amounts of intragranular and extragranular excipients can be used to produce a blend that constitutes a capsule, such as a 2 mg, 5 mg, 15 mg, 25 mg, and 50 mg strength capsule, such that the 2 mg, 5 mg, 15 mg, and 25 mg blend can be loaded into a size 3 HPMC capsule and the 50 mg blend is loaded into a size 2 HPMC capsule.
[0316] In some embodiments, the SDD is prepared as follows:
[0317] (1) providing a solution of Compound 1 or a pharmaceutically acceptable salt thereof and HPMC-AS;
[0318] (2) filtering the solution, for example, through a 100 mesh screen;
[0319] (3) spray drying the solution to produce SDI (spray drying intermediate);
[0320] (4) optionally, drying the SDI, for example by secondary tray drying;
[0321] The SDD is thereby provided.
[0322] In some embodiments, the manufacturing process is substantially as follows Figure 4 As described in the flowchart shown in .
[0323] In some embodiments, the binder may include one or more binders of Formula II:
[0324]
[0325] Or a pharmaceutically acceptable salt thereof, wherein n is between about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000. In some embodiments, n is about 1,000. In some embodiments, the binder may include a molecular weight between about 10,000Da and about 25,000Da, about 25,000Da and about 50,000Da, about 50,000Da and about 60,000Da, or about 60,000Da and about 70,000Da. In some embodiments, the binder may include povidone. In some embodiments, the binder may include PVP30.
[0326] In some embodiments, the diluent may include cellulose. In some embodiments, the cellulose is microcrystalline cellulose. In some embodiments, the diluent may include PH-101. In some embodiments, the nominal particle size of the diluent may be between about 10 mm to about 20 mm, about 20 mm to about 30 mm, about 30 mm to about 40 mm, about 40 mm to about 50 mm, about 50 mm to about 60 mm, about 60 mm to about 70 mm, or about 70 mm to about 80 mm. In some embodiments, the nominal particle size of the diluent may be about 50 mm. In some embodiments, the moisture content of the diluent may be between about 0.5% w / w to about 1% w / w, about 1% w / w to about 1.5% w / w, about 1.5% w / w to about 2% w / w, about 2% w / w to about 2.5% w / w, about 2.5% w / w to about 3% w / w, about 3% w / w to about 3.5% w / w, about 3.5% w / w to about 4% w / w, about 4% w / w to about 4.5% w / w, or about 4.5% w / w to about 5% w / w. In some embodiments, the moisture content of the diluent may be between about 3% w / w to about 5% w / w. In some embodiments, the loose bulk density of the diluent may be between about 0.1 g / cm 3 To about 0.15g / cm 3 , about 0.15g / cm 3 To about 0.2g / cm 3 , about 0.2g / cm 3 To about 0.25g / cm 3 , about 0.25g / cm 3 To about 0.3g / cm 3, about 0.3g / cm 3 To about 0.35g / cm 3 , about 0.35g / cm 3 To about 0.4g / cm 3 , about 0.4g / cm 3 To about 0.45g / cm 3 or about 0.45g / cm 3 To about 0.5g / cm 3 In some embodiments, the loose bulk density of the diluent may be between about 0.26 g / cm 3 To about 0.31g / cm 3 between.
[0327] In some embodiments, the average molecular weight of the microcrystalline cellulose may be between about 10,000 Da and about 25,000 Da, between about 25,000 Da and about 50,000 Da, between about 50,000 Da and about 60,000 Da, or between about 60,000 Da and about 80,000 Da.
[0328] Capsule unit dosage form
[0329] In certain embodiments, the unit dosage form may include a capsule or a tablet. Capsules, tablets, and other unit dosage forms are described in more detail below. As described above, pharmaceutical compositions, formulations, and unit dosage forms may include:
[0330] (a) Compound 1 or a solvate thereof or a pharmaceutically acceptable salt thereof;
[0331] (b) one or more fillers or diluents;
[0332] (c) one or more solubilizing agents;
[0333] (d) one or more adhesives;
[0334] (e) optionally, one or more glidants;
[0335] (f) optionally, one or more lubricants; and
[0336] (g) Optionally, one or more surfactants.
[0337] In some embodiments, the unit dosage form may include (a), (b), (c), (d), optional (e), optional (f), and optional (g) as described above. In some embodiments, the unit dosage form comprises (a), (b), (c), and (d). In some embodiments, the unit dosage form consists essentially of (a), (b), (c), and (d). In some embodiments, the unit dosage form consists of (a), (b), (c), and (d).
[0338] In some embodiments, the unit dosage form may include about 1 mg to about 2.5 mg, about 2.5 mg to about 5 mg, about 5 mg to about 7.5 mg, about 7.5 mg to about 10 mg, about 10 mg to about 12.5 mg, about 12.5 mg to about 15 mg, about 15 mg to about 17.5 mg, about 17.5 mg to about 20 mg, about 20 mg to about 22.5 mg, about 22.5 mg to about 25 mg, about 25 mg to about 27.5 mg, about 27.5 mg to about 30 mg, about 30 mg to about 32.5 mg, about 32.5 mg to about 35 mg, about 35 mg to about 37.5 mg, about 37.5 mg to about 40 mg, about 40 mg to about 45 mg, or about 45 mg to about 50 mg of Compound 1 or its solvate or pharmaceutically acceptable salt. In some embodiments, the unit dosage form may include an amount of about 5 mg. In some embodiments, the unit dosage form may include an amount of about 25 mg.
[0339] In some embodiments, a unit dosage form may include an amount of about 1% w / w to about 2.5% w / w, about 2.5% w / w to about 5% w / w, about 5% w / w to about 7.5% w / w, about 7.5% w / w to about 10% w / w, about 10% w / w to about 12.5% w / w, about 12.5% w / w to about 15% w / w, about 15% w / w to about 17.5% w / w, or about 17.5% w / w to about 20% w / w of Compound 1, or a solvate or pharmaceutically acceptable salt thereof. In some embodiments, a unit dosage form may include an amount of about 10% w / w.
[0340] In some embodiments, the unit dosage form may include the following amount of (b): about 15 mg to about 17.5 mg, about 17.5 mg to about 20 mg, about 20 mg to about 22.5 mg, about 22.5 mg to about 25 mg, about 25 mg to about 27.5 mg, about 27.5 mg to about 30 mg, about 30 mg to about 32.5 mg, about 32.5 mg to about 35 mg, about 35 mg to about 37.5 mg, about 37.5 mg to about 40 mg, about 40 mg to about 45 mg, about 45 mg to about 50 mg, about 50 mg to about 75 mg, about 75 mg to about 100 mg, about 100 mg to about 125 mg, about 125 mg to about 150 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, or about 200 mg to about 225 mg. In some embodiments, the unit dosage form may include an amount of about 34 mg of (b). In some embodiments, the unit dosage form can include (b) in an amount of about 170 mg.
[0341] In some embodiments, the unit dosage form may include (b) in an amount of about 20% w / w to about 30% w / w, about 30% w / w to about 40% w / w, about 40% w / w to about 50% w / w, about 50% w / w to about 60% w / w, about 60% w / w to about 70% w / w, about 70% w / w to about 80% w / w, or about 80% w / w to about 90% w / w. In some embodiments, the unit dosage form comprises (b) in an amount of about 68% w / w.
[0342] In some embodiments, the unit dosage form comprises (c) in an amount of about 1 mg to about 2.5 mg, about 2.5 mg to about 5 mg, about 5 mg to about 7.5 mg, about 7.5 mg to about 10 mg, about 10 mg to about 12.5 mg, about 12.5 mg to about 15 mg, about 15 mg to about 17.5 mg, about 17.5 mg to about 20 mg, about 20 mg to about 22.5 mg, about 22.5 mg to about 25 mg, about 25 mg to about 27.5 mg, about 27.5 mg to about 30 mg, about 30 mg to about 32.5 mg, about 32.5 mg to about 35 mg, about 35 mg to about 37.5 mg, about 37.5 mg to about 40 mg, about 40 mg to about 45 mg, about 45 mg to about 50 mg, about 50 mg to about 75 mg, about 75 mg to about 100 mg, about 100 mg to about 125 mg, or about 125 mg to about 150 mg. In some embodiments, the unit dosage form comprises (c) in an amount of about 10 mg. In some embodiments, the unit dosage form comprises (c) in an amount of about 50 mg.
[0343] In some embodiments, the unit dosage form comprises (c) in an amount of about 2% w / w to about 5% w / w, about 5% w / w to about 10% w / w, about 10% w / w to about 15% w / w, about 15% w / w to about 20% w / w, about 20% w / w to about 25% w / w, about 25% w / w to about 30% w / w, about 30% w / w to about 35% w / w, or about 35% w / w to about 40% w / w. In some embodiments, the unit dosage form comprises (c) in an amount of about 20% w / w.
[0344] In some embodiments, the unit dosage form comprises (d) in an amount of about 0.25 mg to about 0.5 mg, about 0.5 mg to about 0.75 mg, about 0.75 mg to about 1 mg, about 1 mg to about 2 mg, about 2 mg to about 3 mg, about 3 mg to about 4 mg, about 4 mg to about 5 mg, about 5 mg to about 6 mg, about 6 mg to about 7 mg, about 7 mg to about 8 mg, about 8 mg to about 9 mg, or about 9 mg to about 10 mg.
[0345] In some embodiments, the unit dosage form comprises (d) in an amount of about 0.25% w / w to about 0.5% w / w, about 0.5% w / w to about 0.75% w / w, about 0.75% w / w to about 1% w / w, about 1% w / w to about 1.25% w / w, about 1.25% w / w to about 1.5% w / w, about 1.5% w / w to about 1.75% w / w, about 1.75% w / w to about 2% w / w, about 2% w / w to about 2.5% w / w, about 2.5% w / w to about 3% w / w, about 3% w / w to about 3.5% w / w, or about 3.5% w / w to about 4% w / w. In some embodiments, the unit dosage form comprises (d) in an amount of about 2% w / w.
[0346] In some embodiments, the unit dosage form comprises the following amounts of (a), (b), (c), and (d):
[0347] (a) from about 2.5 mg to about 7.5 mg;
[0348] (b) from about 17 mg to about 51 mg;
[0349] (c) from about 5 mg to about 15 mg; and
[0350] (d) from about 0.5 mg to about 1.5 mg.
[0351] In some embodiments, the unit dosage form comprises the following amounts of (a), (b), (c), and (d):
[0352] (a) about 5 mg;
[0353] (b) about 34 mg;
[0354] (c) about 10 mg; and
[0355] (d) About 1 mg.
[0356] In some embodiments, the unit dosage form comprises the following amounts of (a), (b), (c), and (d):
[0357] (a) from about 12.5 mg to about 37.5 mg;
[0358] (b) from about 85 mg to about 255 mg;
[0359] (c) from about 25 mg to about 75 mg; and
[0360] (d) from about 2.5 mg to about 7.5 mg.
[0361] In some embodiments, the unit dosage form comprises the following amounts of (a), (b), (c), and (d):
[0362] (a) about 25 mg;
[0363] (b) about 170 mg;
[0364] (c) about 50 mg; and
[0365] (d) about 5 mg.
[0366] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form of any embodiment herein may include granules, wherein the pharmaceutical composition, formulation, or unit dosage form may include the following intragranular and extragranular components:
[0367] a) about 4 mg of a 50:50 (w / w) mixture of Compound 1 and HPMC-AS-M (hydroxypropylmethylcellulose acetate succinate, M grade) spray-dried in granules;
[0368] b) about 69.3 mg of intragranular mannitol;
[0369] c) about 69.3 mg intragranular microcrystalline cellulose;
[0370] d) about 9 mg intragranular croscarmellose sodium;
[0371] e) about 1.8 mg intragranular colloidal silicon dioxide;
[0372] f) about 0.9 mg of intragranular sodium stearyl fumarate;
[0373] g) about 16.2 mg extragranular microcrystalline cellulose;
[0374] h) about 9 mg extragranular croscarmellose sodium; and
[0375] i) about 0.5 mg extragranular sodium stearyl fumarate.
[0376] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form of any embodiment herein may include granules, wherein the pharmaceutical composition, formulation, or unit dosage form may include the following intragranular and extragranular components:
[0377] a) about 10 mg of a 50:50 (w / w) mixture of Compound 1 and HPMC-AS-M (hydroxypropylmethylcellulose acetate succinate, M grade) spray-dried in granules;
[0378] b) about 65.6 mg intragranular mannitol;
[0379] c) about 65.6 mg intragranular microcrystalline cellulose;
[0380] d) about 9 mg intragranular croscarmellose sodium;
[0381] e) about 1.8 mg intragranular colloidal silicon dioxide;
[0382] f) about 1.8 mg of intragranular sodium lauryl sulfate;
[0383] g) about 0.9 mg of intragranular sodium stearyl fumarate;
[0384] h) about 16.2 mg extragranular microcrystalline cellulose;
[0385] i) about 8.7 mg extragranular croscarmellose sodium; and
[0386] j) about 0.5 mg extragranular sodium stearyl fumarate.
[0387] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form of any embodiment herein may include granules, wherein the pharmaceutical composition, formulation, or unit dosage form may include the following intragranular and extragranular components:
[0388] a) about 30 mg of a 50:50 (w / w) mixture of Compound 1 and HPMC-AS-M (hydroxypropylmethylcellulose acetate succinate, M grade) spray-dried in granules;
[0389] b) about 56.46 mg intragranular mannitol;
[0390] c) about 56.46 mg intragranular microcrystalline cellulose;
[0391] d) about 9 mg intragranular croscarmellose sodium;
[0392] e) about 1.8 mg intragranular colloidal silicon dioxide;
[0393] f) about 0.9 mg of intragranular sodium stearyl fumarate;
[0394] g) about 5 mg extragranular microcrystalline cellulose;
[0395] h) about 8 mg extragranular croscarmellose sodium; and
[0396] i) about 0.38 mg extragranular sodium stearyl fumarate.
[0397] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form of any embodiment herein may include granules, wherein the pharmaceutical composition, formulation, or unit dosage form may include the following intragranular and extragranular components:
[0398] a) about 50 mg of a 50:50 (w / w) mixture of Compound 1 and HPMC-AS-M (hydroxypropylmethylcellulose acetate succinate, M grade) spray-dried in granules;
[0399] b) about 45.6 mg of intragranular mannitol;
[0400] c) about 45.6 mg intragranular microcrystalline cellulose;
[0401] d) about 9 mg intragranular croscarmellose sodium;
[0402] e) about 1.8 mg intragranular colloidal silicon dioxide;
[0403] f) about 1.8 mg of intragranular sodium lauryl sulfate;
[0404] g) about 0.9 mg of intragranular sodium stearyl fumarate;
[0405] h) about 16.2 mg extragranular microcrystalline cellulose;
[0406] i) about 8.7 mg extragranular croscarmellose sodium; and
[0407] j) about 0.5 mg extragranular sodium stearyl fumarate.
[0408] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form of any embodiment herein may include granules, wherein the pharmaceutical composition, formulation, or unit dosage form may include the following intragranular and extragranular components:
[0409] a) about 100 mg of a 50:50 (w / w) mixture of Compound 1 and HPMC-AS-M (hydroxypropyl methylcellulose acetate succinate, M grade) spray-dried in granules;
[0410] b) about 48 mg of intragranular mannitol;
[0411] c) about 48 mg intragranular microcrystalline cellulose;
[0412] d) about 12.5 mg intragranular croscarmellose sodium;
[0413] e) about 2.5 mg intragranular colloidal silicon dioxide;
[0414] f) about 2.5 mg of intragranular sodium lauryl sulfate;
[0415] g) about 1.3 mg of intragranular sodium stearyl fumarate;
[0416] h) about 22.5 mg extragranular microcrystalline cellulose;
[0417] i) about 12.1 mg extragranular croscarmellose sodium; and
[0418] j) about 0.6 mg extragranular sodium stearyl fumarate.
[0419] In some embodiments, compound 1 may be in the form of a solvate (e.g., a hydrate) or a pharmaceutically acceptable salt of such a solvate. In some embodiments, compound 1 may be in the form of a free base. In some embodiments, compound 1 may be in the form of a crystalline solid. In some embodiments, the crystalline solid may be Form C. In some embodiments, the crystalline solid may be Form A.
[0420] In certain embodiments, Compound 1 may be a crystalline compound of polymorph Form C, which is characterized in that it exhibits a crystalline structure comprising substantially Figure 3 In certain embodiments, Compound 1 may be a crystalline compound of polymorph Form A, characterized in that it exhibits a crystalline structure comprising substantially Figure 5 X-ray powder diffraction (XRPD) pattern with peaks shown in . Any alternative solid form can be used in the formulations described herein; for example, an amorphous form, a crystalline form other than Form C or A, or a mixture thereof.
[0421] In certain embodiments, Compound 1 is amorphous. In some embodiments, Compound 1 may be a hydrate. In some embodiments, Compound 1 may be a monohydrate.
[0422] Preparation production method
[0423] In one aspect, the present disclosure provides a method of producing a pharmaceutical composition, formulation or unit dosage form, the method comprising treating a pharmaceutical composition comprising Compound 1:
[0424]
[0425] or a solvate thereof or a pharmaceutically acceptable salt thereof; and one or more solubilizing agents; and wet granulating the mixture.
[0426] In some embodiments, the method may include:
[0427] (1) wet granulating the mixture; and
[0428] (2) Drying the mixture.
[0429] In some embodiments, the method may include:
[0430] (1) wet granulating the mixture;
[0431] (2) drying the mixture; and
[0432] (3) Dry grinding the mixture.
[0433] In some embodiments, the method may include:
[0434] (1) wet granulating the mixture;
[0435] (2) drying the mixture;
[0436] (3) dry grinding the mixture; and
[0437] (4) Blending the mixture.
[0438] In some embodiments, the method may include:
[0439] (1) wet granulating the mixture;
[0440] (2) drying the mixture;
[0441] (3) dry grinding the mixture;
[0442] (4) blending the mixture; and
[0443] (5) Encapsulating the mixture.
[0444] In some embodiments, the mixture may be de-agglomerated prior to wet granulation. In some embodiments, the mixture may comprise:
[0445] (a) Compound 1;
[0446] (b) one or more diluents;
[0447] (c) one or more solubilizing agents;
[0448] (d) one or more adhesives;
[0449] (e) optionally, one or more glidants;
[0450] (f) optionally, one or more lubricants; and
[0451] (g) Optionally, one or more surfactants.
[0452] In some embodiments, the mixture may include:
[0453] (a) Compound 1;
[0454] (b) one or more diluents;
[0455] (c) one or more solubilizing agents; and
[0456] (d) one or more binders.
[0457] In some embodiments, the mixture may include:
[0458] (a) Compound 1;
[0459] (b) one or more diluents;
[0460] (c) one or more solubilizing agents of formula I:
[0461]
[0462] or a pharmaceutically acceptable salt thereof, wherein R 1 an optionally substituted aliphatic group selected from about 100 Da to about 500 Da, about 500 Da to about 1,000 Da, about 1,000 Da to about 2,000 Da, about 2,000 Da to about 5,000 Da, about 5,000 Da to about 10,000 Da, about 10,000 Da to about 20,000 Da, about 20,000 Da to about 50,000 Da, or about 50,000 Da to about 100,000 Da; and
[0463] (d) one or more binders.
[0464] In some embodiments, the mixture may include:
[0465] (a) Compound 1;
[0466] (b) one or more diluents;
[0467] (c) one or more solubilizing agents of formula IA:
[0468]
[0469] or a pharmaceutically acceptable salt thereof, wherein n is between about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000; and
[0470] (d) one or more binders.
[0471] In some embodiments, n is between about 1 to about 5, about 5 to about 10, about 10 to about 20, about 20 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, or about 500 to about 1,000. In some embodiments, n is about 88. In some embodiments, n is about 100. In some embodiments, n is about 1,000.
[0472] In some embodiments, the mixture may include:
[0473] (a) Compound 1;
[0474] (b) one or more diluents;
[0475] (c) Vitamin E TPGS; and
[0476] (d) one or more binders.
[0477] In some embodiments, the mixture comprises:
[0478] (a) Compound 1;
[0479] (b) microcrystalline cellulose;
[0480] (c) Vitamin E TPGS; and
[0481] (d) one or more binders.
[0482] In some embodiments, the mixture may include:
[0483] (a) Compound 1;
[0484] (b) one or more diluents;
[0485] (c) one or more solubilizing agents; and
[0486] (d) one or more binders.
[0487] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0488] a) about 5% to about 15% (w / w) of Compound 1;
[0489] b) from about 32% to about 100% (w / w) of a diluent;
[0490] c) from about 10% to about 30% (w / w) of a solubilizing agent; and
[0491] d) from about 1% to about 3% (w / w) of a binder.
[0492] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0493] a) about 10% (w / w) of Compound 1;
[0494] b) about 68% (w / w) of a diluent;
[0495] c) about 20% (w / w) of a solubilizing agent; and
[0496] d) about 2% (w / w) binder.
[0497] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0498] a) about 20% (w / w) of Compound 1;
[0499] b) about 58% (w / w) of a diluent;
[0500] c) about 20% (w / w) of a solubilizing agent; and
[0501] d) about 2% (w / w) binder.
[0502] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0503] a) about 30% (w / w) of Compound 1;
[0504] b) about 48% (w / w) of a diluent;
[0505] c) about 20% (w / w) of a solubilizing agent; and
[0506] d) about 2% (w / w) binder.
[0507] In some embodiments, a pharmaceutical composition, formulation or unit dosage form may comprise:
[0508] a) about 40% (w / w) of Compound 1;
[0509] b) about 38% (w / w) of a diluent;
[0510] c) about 20% (w / w) of a solubilizing agent; and
[0511] d) about 2% (w / w) binder.
[0512] In some embodiments, the diluent may be microcrystalline cellulose, the solubilizer may be vitamin G TPGS, and the binder may be povidone.
[0513] In some embodiments, the mixture may include:
[0514] (a) Compound 1;
[0515] (b) Avicel PH101;
[0516] (c) Vitamin E TPGS; and
[0517] (d) one or more binders.
[0518] In some embodiments, the mixture may include:
[0519] (a) Compound 1;
[0520] (b) microcrystalline cellulose;
[0521] (c) Vitamin E TPGS; and
[0522] (d) Povidone.
[0523] In some embodiments, the mixture may include:
[0524] (a) Compound 1;
[0525] (b) Avicel PH101;
[0526] (c) Vitamin E TPGS; and
[0527] (d) PVP K30.
[0528] In some embodiments, the mixture consists essentially of: (a) Compound 1;
[0529] (b) Avicel PH101;
[0530] (c) Vitamin E TPGS; and
[0531] (d) PVP K30.
[0532] In some embodiments, the mixture consists of:
[0533] (a) Compound 1;
[0534] (b) Avicel PH101;
[0535] (c) Vitamin E TPGS; and
[0536] (d) PVP K30.
[0537] In some embodiments, the solubilizing agent may be selected from vitamin E conjugates. In some embodiments, the solubilizing agent may include one or more solubilizing agents of formula I:
[0538]
[0539] or a pharmaceutically acceptable salt thereof, wherein R 1 An optionally substituted aliphatic group is selected from a mass of about 100 Da to about 500 Da, about 500 Da to about 1,000 Da, about 1,000 Da to about 2,000 Da, about 2,000 Da to about 5,000 Da, about 5,000 Da to about 10,000 Da, about 10,000 Da to about 20,000 Da, about 20,000 Da to about 50,000 Da, or about 50,000 Da to about 100,000 Da.
[0540] In some embodiments, the solubilizing agent may include one or more solubilizing agents of Formula IA:
[0541]
[0542] or a pharmaceutically acceptable salt thereof, wherein n is between about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000. In some embodiments, n is about 1,000. In some embodiments, the solubilizing agent may include vitamin E polyethylene glycol succinate (vitamin E TPGS).
[0543] In some embodiments, the binder may include one or more binders of Formula II:
[0544]
[0545] or a pharmaceutically acceptable salt thereof, wherein n is between about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000. In some embodiments, n is about 1,000. In some embodiments, the binder may include povidone. In some embodiments, the binder may include PVP30.
[0546] In some embodiments, the diluent may include cellulose. In some embodiments, the cellulose may be microcrystalline cellulose. In some embodiments, the diluent may include Avicel PH-101. In some embodiments, the nominal particle size of the diluent may be between about 10 mm to about 20 mm, about 20 mm to about 30 mm, about 30 mm to about 40 mm, about 40 mm to about 50 mm, about 50 mm to about 60 mm, about 60 mm to about 70 mm, or about 70 mm to about 80 mm. In some embodiments, the nominal particle size of the diluent may be about 50 mm. In some embodiments, the moisture content of the diluent may be between about 0.5% w / w to about 1% w / w, about 1% w / w to about 1.5% w / w, about 1.5% w / w to about 2% w / w, about 2% w / w to about 2.5% w / w, about 2.5% w / w to about 3% w / w, about 3.5% w / w to about 4% w / w, about 4% w / w to about 4.5% w / w, or about 4.5% w / w to about 5% w / w. In some embodiments, the moisture content of the diluent may be between about 3% w / w to about 5% w / w. In some embodiments, the loose bulk density of the diluent may be between about 0.1 g / cm 3To about 0.15g / cm 3 , about 0.15g / cm 3 To about 0.2g / cm 3 , about 0.2g / cm 3 To about 0.25g / cm 3 , about 0.25g / cm 3 To about 0.3g / cm 3 , about 0.3g / cm 3 To about 0.35g / cm 3 , about 0.35g / cm 3 To about 0.4g / cm 3 , about 0.4g / cm 3 To about 0.45g / cm 3 or about 0.45g / cm 3 To about 0.5g / cm 3 In some embodiments, the loose bulk density of the diluent may be between about 0.26 g / cm 3 To about 0.31g / cm 3 between.
[0547] In certain embodiments, Compound 1 is a crystalline compound of the following formula in polymorph Form C:
[0548]
[0549] It comprises an X-ray powder diffraction (XRPD) pattern comprising substantially Figure 3 Peaks at the diffraction angles shown in .
[0550] In certain embodiments, Compound 1 may be amorphous. In some embodiments, Compound 1 may be a hydrate. In some embodiments, Compound 1 may be a monohydrate.
[0551] In some embodiments, Compound 1 may be in the form of a racemate:
[0552]
[0553] or a mixture of stereoisomers, or a solvate or a pharmaceutically acceptable salt thereof.
[0554] Uses of the pharmaceutical composition
[0555] Compound 1 and compositions described herein are generally useful for inhibiting the kinase activity of one or more enzymes. In some embodiments, the kinase inhibited by Compound 1 and methods described herein is TYK2.
[0556] TYK2 is a non-receptor tyrosine kinase member of the Janus kinase (JAKs) protein kinase family. The mammalian JAK family consists of four members: TYK2, JAK1, JAK2, and JAK3. JAK proteins (including TYK2) are essential for cytokine signaling. TYK2 associates with the cytoplasmic domains of type I and type II cytokine receptors and interferon type I and type III receptors, and is activated by those receptors when cytokines bind. Cytokines involved in TYK2 activation include interferons (e.g., IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ (also known as limitin)) and interleukins (e.g., IL-4, IL-6, IL-10, IL-11, IL-12, IL-13, IL-22, IL-23, IL-27, IL-31, oncostatin M, ciliary neurotrophic factor, cardiotrophin 1, cardiotrophin-like cytokine, and LIF).Velasquez et al., "Aprotein kinase in the interferonα / β signaling pathway", Cell (1992) 70:313; Stahl et al., "Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6βreceptor components", Science (1994) 263:92; Finbloom et al., "IL-10 induces thetyrosine Phosphorylation of Tyk2 and Jak1 and the differential assembly ofStat1and Stat3 complexes in human T cells and monocytes", J. Immunol. (1995) 155:1079; Bacon et al., "Interleukin 12(IL-12) induces tyrosine phosphorylation of Jak2and Tyk2: differential use of Janus family kinases by IL-2and IL-12", J. Exp. Med. (1995) 181: 399; Welham et al., "Interleukin-13 signal transduction in lymphohemopoietic cells: similarities and differences in signal transduction with interleukin-4 and insulin", J. Biol. Chem. (1995) 270: 12286; Parham et al., "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R", J. Immunol. (2002) 168: 5699. Activated TYK2 then goes on to phosphorylate other signaling proteins, such as members of the STAT family, including STAT1, STAT2, STAT4 and STAT6.
[0557] IL-23 activation of TYK2 is associated with inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Duerr et al., "A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene", Science (2006) 314: 1461-1463. TYK2, as a downstream effector of IL-23, is also involved in psoriasis, ankylosing spondylitis, and Behcet's disease ( disease). Cho et al., "Genomics and the multifactorial nature of human auto-immune disease", N.Engl.J.Med(2011) 365:1612-1623; Cortes et al., "Identification of multiple riskvariants for ankylosing spondylitis through high-density genotyping ofimmune-related loci", Nat. Genet. (2013) 45(7):730-738; Remmers et al., "Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with disease”, Nat. Genet. (2010) 42: 698-702. A genome-wide association study of 2,622 individuals with psoriasis identified an association between disease susceptibility and TYK2. Strange et al., “A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1”, Nat. Genet. (2010) 42: 985-992. Knockout or tyrosine phosphorylation inhibitor inhibition of TYK2 significantly reduced both IL-23 and IL-22-induced dermatitis. Ishizaki et al., “Tyk2 is a therapeutic target for psoriasis-like skin inflammation”, Intl. Immunol. (2013), doi: 10.1093 / intimm / dxt062.
[0558] TYK2 also plays a role in respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and cystic fibrosis. Goblet cell hyperplasia (GCH) and mucus hypersecretion are mediated by IL-13-induced TYK2 activation, which in turn activates STAT6. Zhang et al., "Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2 / STAT6 pathway", FASEB J. (2012) 26: 1-11.
[0559] Reduced TYK2 activity protects joints from collagen antibody-induced arthritis, a model of human rheumatoid arthritis. Mechanistically, reduced Tyk2 activity reduces T h 1 / T h 17 related cytokines and matrix metalloproteinases and other key markers of inflammation. Ishizaki et al., “Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice”, Intl. Immunol. (2011) 23(9): 575-582.
[0560] Compared with controls, TYK2 knockout mice showed complete resistance in experimental autoimmune encephalomyelitis (EAE, an animal model of multiple sclerosis (MS)), with no infiltration of CD4 T cells in the spinal cord, indicating that TYK2 is essential for pathogenic CD4-mediated disease development in MS. Oyamada et al., "Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis", J. Immunol. (2009) 183: 7539-7546. This confirms previous studies linking increased TYK2 expression to MS susceptibility. Ban et al., "Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor", Eur J. Hum. Genet. (2009) 17: 1309-1313. Loss-of-function mutations in TYK2 result in reduced demyelination and increased remyelination of neurons, further suggesting a role for TYK2 inhibitors in the treatment of MS and other CNS demyelinating disorders.
[0561] TYK2 is the only signaling messenger common to both IL-12 and IL-23. TYK2 knockout reduces footpad thickness induced by methylated BSA injection, psoriasis-like skin inflammation induced by imiquimod, and colitis induced by dextran sulfate sodium or 2,4,6-trinitrobenzenesulfonic acid in mice.
[0562] Common associations of various type I IFN signaling genes with systemic lupus erythematosus (SLE, an autoimmune disorder) and association studies have shown a strong and significant correlation between TYK2 loss-of-function mutations and reduced prevalence of SLE in families with affected members. Sigurdsson et al., "Polymorphisms in the Tyrosine Kinase 2 and Interferon Regulatory Factor 5 Genes Are Associated with Systemic Lupus Erythematosus", Am. J. Hum. Genet. (2005) 76: 528-537. A genome-wide association study of individuals with SLE against an unaffected cohort showed a highly significant association between the TYK2 locus and SLE. Graham et al., "Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with Systemic Lupus Erythematosus", PLoS Genetics (2011) 7(10): e1002341.
[0563] TYK2 has been shown to play an important role in maintaining tumor surveillance, and TYK2 knockout mice show impaired cytotoxic T cell responses and accelerated tumor development. However, these effects are associated with effective inhibition of natural killer (NK) and cytotoxic T lymphocytes, indicating that TYK2 inhibitors will be highly suitable for treating autoimmune disorders or transplant rejection. Although other JAK family members (such as JAK3) have similar effects in the immune system, TYK2 is considered an excellent target because it involves fewer and more closely related signal transduction pathways, thereby making off-target effects less. Simma et al., "Identification of an Indispensable Role for Tyrosine Kinase 2in CTL-Mediated Tumour Surveillance", Cancer Res. (2009) 69: 203-211.
[0564] However, in contradiction to the reduced tumor surveillance observed by Simma et al., studies in T-cell acute lymphoblastic leukemia (T-ALL) indicate that T-ALL is highly dependent on IL-10 to maintain cancer cell survival via upregulation of anti-apoptotic protein BCL2 via STAT1-mediated signal transduction via TYK2. Knockdown of TYK2, rather than other JAK family members, reduces cell growth. Specific activating mutations of TYK2 that promote cancer cell survival include those of the FERM domain (G36D, S47N, and R425H), the JH2 domain (V731I), and the kinase domain (E957D and R1027H). However, the kinase function of TYK2 has also been identified as being essential for prolonging cancer cell survival, because TYK2 enzymes characterized by kinase-dead mutations (M978Y or M978F) in addition to activating mutations (E957D) lead to transformation failure. Sanda et al., "TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia", CancerDisc. (2013) 3(5):564-577.
[0565] Therefore, selective inhibition of TYK2 has been considered a suitable target for patients with IL-10 and / or BCL2 addicted tumors, such as 70% of adult T-cell leukemia cases. Fontan et al., "Discovering What Makes STAT Signalling TYK in T-ALL", Cancer Disc. (2013) 3:494-496.
[0566] It has also been shown that TYK2-mediated STAT3 signaling mediates neuronal cell death caused by amyloid-β (Aβ) peptide. Reduced TYK2 phosphorylation of STAT3 after Aβ administration reduces neuronal cell death, and increased STAT3 phosphorylation is observed in autopsy brains of Alzheimer's patients. Wan et al., "Tyk / STAT3 Signalling Mediates β-Amyloid-Induced Neuronal Cell Death: Implications in Alzheimer's Disease", J. Neurosci. (2010) 30(20): 6873-6881.
[0567] Inhibition of the JAK-STAT signaling pathway has also been associated with hair growth and reversal of hair loss associated with alopecia areata. Xing et al., “Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition”, Nat. Med. (2014) 20: 1043-1049; Harel et al., “Pharmacologic inhibition of JAK-STAT signalling promotes hair growth”, Sci. Adv. (2015) 1(9): e1500973.
[0568] Therefore, compounds that inhibit TYK2 activity are beneficial, especially those that are selective over JAK2.Such compounds should deliver a pharmacological response that advantageously treats one or more of the conditions described herein without the side effects associated with JAK2 inhibition.
[0569] Even though TYK2 inhibitors are known in the art, there continues to be a need to provide novel inhibitors with more effective or advantageous pharmaceutically relevant properties. For example, compounds with increased activity, selectivity over other JAK kinases (particularly JAK2), and ADMET (absorption, distribution, metabolism, excretion, and / or toxicity) properties. Thus, in some embodiments, a pharmaceutical composition, formulation, or unit dosage form may include a Compound 1 inhibitor of TYK2 that exhibits selectivity over JAK2.
[0570] The activity of compound 1 as described herein as an inhibitor of TYK2 or a mutant thereof can be determined in vitro, in vivo, or in a cell line. In vitro assays include assays for determining the inhibition of phosphorylation activity and / or subsequent functional consequences or ATPase activity of activated TYK2 or a mutant thereof. Alternative in vitro assays quantify the ability of inhibitors to bind to TYK2. Inhibitor binding can be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor / TYK2 complex, and determining the amount of radiolabel bound. Alternatively, inhibitor binding can be determined by running a competition experiment in which a new inhibitor is incubated with TYK2 bound to a known radioligand. Representative in vitro and in vivo assays that can be used to determine TYK2 inhibitors include those described and disclosed in the publication, for example, each of which is incorporated herein by reference in its entirety.
[0571] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset or inhibiting the progression of a disease or disorder as described herein or one or more symptoms thereof. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., in view of a history of symptoms and / or in view of genetic or other susceptibility factors). Treatment may also be continued after the symptoms subside, for example, to prevent or delay their recurrence.
[0572] Compound 1 is a TYK2 inhibitor and can therefore be used to treat one or more conditions associated with the activity of TYK2 or its mutants. Therefore, in certain embodiments, a method for treating a TYK2-mediated condition may include the following steps: administering to a patient in need thereof a pharmaceutical composition, formulation or unit dosage form comprising Compound 1 or a pharmaceutically acceptable salt or hydrate thereof as described herein.
[0573] As used herein, the term "TYK2-mediated" disorder, disease and / or condition as used herein means any disease or other deleterious condition in which TYK2 or a mutant thereof is known to play a role. Thus, another embodiment is directed to treating or lessening the severity of one or more diseases in which TYK2 or a mutant thereof is known to play a role. Such TYK2-mediated disorders include, but are not limited to, autoimmune disorders, inflammatory disorders, proliferative disorders, endocrine disorders, neurological disorders, and transplantation-related disorders.
[0574] In some embodiments, described herein are methods for treating one or more disorders selected from autoimmune disorders, inflammatory disorders, proliferative disorders, endocrine disorders, neurological disorders, and transplantation-related disorders, comprising administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of a pharmaceutical composition, formulation, or unit dosage form comprising Compound 1 as described herein.
[0575] In some embodiments, the disorder is an autoimmune disorder. In some embodiments, the disorder is selected from type 1 diabetes, cutaneous lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, psoriasis, Behcet's disease, POEMS syndrome, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.
[0576] In some embodiments, the disorder is an inflammatory disorder. In some embodiments, the inflammatory disorder is rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, hepatomegaly, Crohn's disease, ulcerative colitis, inflammatory bowel disease.
[0577] In some embodiments, the disorder is a proliferative disorder. In some embodiments, the proliferative disorder is a blood cancer. In some embodiments, the proliferative disorder is a leukemia. In some embodiments, the leukemia is a T-cell leukemia. In some embodiments, the T-cell leukemia is T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the proliferative disorder is polycythemia vera, myelofibrosis, or essential thrombocythemia.
[0578] In some embodiments, the disorder is an endocrine disorder. In some embodiments, the endocrine disorder is polycystic ovary syndrome, Crouzon's syndrome, or type 1 diabetes.
[0579] In some embodiments, the disorder is a neurological disorder. In some embodiments, the neurological disorder is Alzheimer's disease.
[0580] In some embodiments, the proliferative disorder is associated with one or more activating mutations in TYK2. In some embodiments, the activating mutation in TYK2 is a mutation in the FERM domain, the JH2 domain, or the kinase domain. In some embodiments, the activating mutation in TYK2 is selected from G36D, S47N, R425H, V731I, E957D, and R1027H.
[0581] In some embodiments, the disorder is associated with transplantation. In some embodiments, the disorder associated with transplantation is transplant rejection or graft-versus-host disease.
[0582] In some embodiments, the disorder is associated with type I interferon, IL-10, IL-12, or IL-23 signaling. In some embodiments, the disorder is associated with type I interferon signaling. In some embodiments, the disorder is associated with IL-10 signaling. In some embodiments, the disorder is associated with IL-12 signaling. In some embodiments, the disorder is associated with IL-23 signaling.
[0583] Formulations comprising Compound 1 as described herein can also be used to treat inflammatory or allergic conditions of the skin, such as psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, allergic vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, cutaneous lupus erythematosus, systemic lupus erythematosus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, acquired epidermolysis bullosa, acne vulgaris, and other inflammatory or allergic conditions of the skin.
[0584] Formulations comprising Compound 1 as described herein may also be used to treat other diseases or conditions, such as diseases or conditions with an inflammatory component, for example, to treat diseases and conditions of the eye (such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis), diseases affecting the nose (including allergic rhinitis), and inflammatory diseases involving autoimmune reactions or having an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), cutaneous lupus erythematosus, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, syndrome), idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine eye diseases, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary sclerosis, uveitis (anterior and posterior), Sjogren's syndrome, keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, cryptopyrin-associated periodic syndromes, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis (with and without nephrotic syndrome,Examples include idiopathic nephrotic syndrome or minimal change disease), chronic granulomatous disease, endometriosis, leptospirosis nephropathy, glaucoma, retinal disease, aging, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscular dystrophy, cataract, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, antihidrotic ectodermal dysplasia, Behçet's disease, incontinence pigmenti, Paget's disease disease), pancreatitis, hereditary periodic fever syndrome, asthma (allergic and non-allergic, mild, moderate, severe, bronchitis, and exercise-induced asthma), acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivity reactions, anaphylaxis, sinusitis, eye allergies, silica-induced disease, COPD (damage, airway inflammation, bronchial hyperresponsiveness, remodeling, or decreased disease progression), lung disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation combined with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease disease), lichen planus, type 1 or type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergies, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henoch-Schonlein purpura purpura), hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, eustachian tube inflammation, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis.
[0585] In some embodiments, the inflammatory disease that can be treated according to the methods described herein is selected from acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic juvenile idiopathic arthritis (SJIA), cryptopyrin-associated periodic syndrome (CAPS), and osteoarthritis.
[0586] In some embodiments, the inflammatory disease that can be treated according to the methods described herein is T h 1 or Th 17-mediated diseases. In some embodiments, T h The 17-mediated disease is selected from the group consisting of cutaneous lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease (including Crohn's disease or ulcerative colitis).
[0587] In some embodiments, the inflammatory disease treatable according to the methods described herein is selected from Sjögren's syndrome, allergic disorders, osteoarthritis, eye disorders (such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis), and diseases affecting the nose (such as allergic rhinitis).
[0588] Furthermore, a formulation may comprise Compound 1 according to the definition herein for use in the preparation of a medicament for the treatment of an autoimmune, inflammatory or proliferative disorder or a disorder generally associated with transplantation.
[0589] In some embodiments, a method of treating a disease selected from psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and inflammatory bowel disease in a patient in need thereof may comprise administering to the patient a therapeutically effective amount of a pharmaceutical composition, formulation, or unit dosage form described herein. In some embodiments, the disease is psoriasis. In some embodiments, the disease is psoriatic arthritis. In some embodiments, the disease is ulcerative colitis. In some embodiments, the disease is Crohn's disease. In some embodiments, the disease is inflammatory bowel disease.
[0590] In some embodiments, daily administration continues for a period of about 1 day to about 7 days, about 1 week to about 3 weeks, about 3 weeks to about 6 weeks, about 6 weeks to about 9 weeks, about 9 weeks to 12 weeks, about 12 weeks to about 15 weeks, or about 15 weeks to about 18 weeks.
[0591] In some embodiments, the methods relate to the treatment of psoriasis and / or psoriatic arthritis.
[0592] In some embodiments, an average reduction of 25% or greater in the Psoriasis Area Severity Index (PASI) is achieved. In some embodiments, an average reduction of about 45% or greater in the Psoriasis Area Severity Index (PASI) is achieved. In some embodiments, an average reduction of about 25% to 50% in the Psoriasis Area Severity Index (PASI) is achieved. In some embodiments, an average reduction of about 50% to 75% in the Psoriasis Area Severity Index (PASI) is achieved. In some embodiments, an average reduction of about 75% to 100% in the Psoriasis Area Severity Index (PASI) is achieved.
[0593] In some embodiments, a Physician Global Assessment (PGA) of 0, 1, or 2 is achieved. In some embodiments, a Physician Global Assessment (PGA) of 0 or 1 is achieved. In some embodiments, a Physician Global Assessment (PGA) of 0 is achieved. In some embodiments, a Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 1 to about 3, about 3 to about 6, about 6 to about 9, about 9 to about 12, about 12 to about 15, about 15 to about 18, about 18 to about 21, about 21 to about 24, about 24 to about 27, or about 27 to about 30.
[0594] In some embodiments, the patient's body surface area (BSA) is reduced by multiple percentage points between about 1 to about 10, about 10 to about 20, about 20 to about 30, about 30 to about 40, about 40 to about 50, about 50 to about 60, about 60 to about 70, about 70 to about 80, about 80 to about 90, or about 90 to about 100.
[0595] In some embodiments, a reduction of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Numerical Rating Scale (NRS) for pain is achieved.
[0596] In some embodiments, a reduction of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Itch Numeric Rating Scale (NRS) is achieved.
[0597] In some embodiments, inhibition of IL-12 / 18-induced IFNγ production is achieved between about 1% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100%.
[0598] In some embodiments, the patient has both psoriasis and psoriatic arthritis.
[0599] In some embodiments, the patient has psoriasis but does not have psoriatic arthritis.
[0600] In some embodiments, the psoriasis is moderate to severe.
[0601] In some embodiments, the psoriatic arthritis is moderate to severe.
[0602] In some embodiments, the patient has psoriatic arthritis.
[0603] In some embodiments, the method achieves at least an American College of Rheumatology (ACR) 20 response.
[0604] Combination therapy
[0605] Depending on the particular disorder or disease being treated, additional therapeutic agents that are normally administered to treat that disorder may be administered in combination with the formulations comprising Compound 1 described herein. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or disorder are referred to as "appropriate for the disease or disorder being treated."
[0606] In certain embodiments, provided combinations or compositions thereof are administered in combination with another therapeutic agent.
[0607] Other combinations with the formulations and compositions described herein include, but are not limited to, treatments for Alzheimer's disease, such as and Treatments for HIV, such as ritonavir; treatments for Parkinson's Disease, such as L-DOPA / carbidopa, entacapone, ropinirole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating multiple sclerosis (MS), such as beta interferon (e.g. and ), and mitoxantrone; for asthma treatments such as albuterol and Agents used to treat schizophrenia, such as Zyprexa, Risperdal, Seroquel, and Haloperidol; anti-inflammatory agents, such as corticosteroids, TNF blockers, IL-1RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulators and immunosuppressants, such as cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, and tacrolimus. mofetil), interferon, corticosteroids, cyclophosphamide, azathioprine and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferon, anticonvulsants, ion channel blockers, riluzole and anti-Parkinson's disease agents; agents for treating cardiovascular diseases such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers and statins; agents for treating liver diseases such as corticosteroids, cholestyramine, interferon and antiviral agents; agents for treating blood disorders such as corticosteroids, anti-leukemia agents and growth factors; agents that prolong or improve pharmacokinetics such as cytochrome P450 inhibitors (i.e., metabolic destruction inhibitors) and CYP3A4 inhibitors (e.g., ketoconazole and ritonavir); and agents for treating immunodeficiency disorders such as gamma globulin.
[0608] In certain embodiments, the combination therapies described herein, or pharmaceutically acceptable compositions thereof, are administered in combination with a monoclonal antibody or siRNA therapeutic.
[0609] Those other agents may be administered separately from the provided combination therapies as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds described herein in a single composition. If administered as part of a multiple dosage regimen, the two active agents may be presented simultaneously, sequentially, or within a certain time period of each other, typically within five hours of each other.
[0610] As used herein, the terms "combination", "combined" and related terms refer to the simultaneous or sequential administration of therapeutic agents according to the methods described herein. For example, the combinations described herein can be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms or together in a single unit dosage form.
[0611] The amount of the other therapeutic agent present in the compositions described herein will not exceed the amount normally administered in a composition comprising the therapeutic agent as the only active agent. Preferably, the amount of the other therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount normally present in a composition comprising the agent as the only therapeutically active agent.
[0612] In one embodiment, the composition may include compound 1 and one or more other therapeutic agents. The therapeutic agent may be applied together with compound 1, or may be applied before or after compound 1 is applied. Suitable therapeutic agents are further described in detail below. In certain embodiments, compound 1 may be applied up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours or 18 hours before the therapeutic agent. In other embodiments, compound 1 may be applied up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours or 18 hours after the therapeutic agent.
[0613] In another embodiment, a method of treating an inflammatory disease, disorder or condition by administering a formulation to a patient in need thereof may include Compound 1 as described herein and one or more other therapeutic agents. Such other therapeutic agents may be small molecules or recombinant biological agents, and include, for example, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodola c) and celecoxib), colchicine Corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, etc.), probenecid, allopurinol, febuxostat Sulfasalazine Antimalarial drugs (such as hydroxychloroquine) and chloroquine ), methotrexate (R ), gold salts (such as gold thioglucosidase Gold thiomalate ( ) and auranofin )、D-penicillamine or ), Azathioprine Cyclophosphamide Chlorambucil Cyclosporine Leflunomide and "anti-TNF" agents (such as etanercept Infliximab Golimumab Certolizumab pegol and adalimumab ), "anti-IL-1" agents (such as anakinra) and rilonacept ), canakinumab Anti-Jak inhibitors (such as tofacitinib), antibodies (such as rituximab) ), "anti-T cell" agents (such as abatacept ), "anti-IL-6" agents (such as tocilizumab) ), diclofenac, cortisone, hyaluronic acid ( or ), monoclonal antibodies (such as tanezuma b), anticoagulants (such as heparin ( or ) and warfarin ), antidiarrheal drugs (such as diphenoxylate) and loperamide ), bile acid binders (such as cholestyramine), alosetron Lubiprostone (Amitiza Laxatives (such as Milk of Magnesia, polyethylene glycol and ), anticholinergics or antispasmodics (such as dicyclomine) ), beta-2 agonists (such as salbutamol (V HFA, HFA), levosalbutamol Metaproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol xinafoate and formoterol ( )), anticholinergics (such as ipratropium bromide and tiotropium ), inhaled corticosteroids (such as beclomethasone dipropionate ( and ), triamcinolone acetonide Mometasone Budesonide and flunisolide ), Cromolyn sodium Methylxanthines (such as theophylline) and aminophylline), IgE antibodies (such as omalizumab) ), nucleoside reverse transcriptase inhibitors (such as zidovudine) Abacavir Abacavir / lamivudine Abacavir / Lamivudine / Zidovudine Didanosine Emtricitabine Lamivudine Lamivudine / zidovudine Stavudine and zalcitabine Non-nucleoside reverse transcriptase inhibitors (such as delavirdine) Efavirenz Nevairapine and etravirine ), nucleotide reverse transcriptase inhibitors (such as tenofovir ), protease inhibitors (such as amprenavir) Atazanavir Darunavir Fosamprenavir Indinavir Lopinavir and ritonavir ), nelfinavir Ritonavir Saquinavir ( or ) and tipranavir Entry inhibitors (such as enfuvirtide and maraviroc ), integrase inhibitors (such as raltegravir) Doxorubicin Vincristine Bortezomib and dexamethasone With lenalidomide or any combination thereof.
[0614] In another embodiment, a method of treating rheumatoid arthritis may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more other therapeutic agents selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, etc.), sulfasalazine Antimalarial drugs (such as hydroxychloroquine) and chloroquine ), methotrexate Gold salts (such as gold thioglucosidase gold thiomalate Auranofin )、D-Penicillamine( or ), Azathioprine Cyclophosphamide Chlorambucil Cyclosporine Leflunomide and “anti-TNF” agents (such as etanercept Infliximab Golimumab Certolizumab Adalimumab ), "anti-IL-1" agents (such as anakinra and linacept ), antibodies (such as rituximab ), "anti-T cell" agents (such as abatacept ) and “anti-IL-6” agents (such as tocilizumab ).
[0615] In some embodiments, a method of treating osteoarthritis may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more other therapeutic agents selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), diclofenac, cortisone, hyaluronic acid ( or ) and monoclonal antibodies (such as tanezumab).
[0616] In some embodiments, the method of treating cutaneous lupus erythematosus or systemic lupus erythematosus may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more other therapeutic agents selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, etc.), antimalarials (such as hydroxychloroquine and chloroquine ), cyclophosphamide Methotrexate Azathioprine and anticoagulants (such as heparin ( or ) and warfarin ).
[0617] In some embodiments, a method of treating Crohn's disease, ulcerative colitis, or inflammatory bowel disease may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more additional therapeutic agents selected from the group consisting of: mesalamine Sulfasalazine Antidiarrheal drugs (such as diphenoxylate and loperamide ), bile acid binders (such as cholestyramine), alosetron Lubiprostone Laxatives (such as milk of magnesia, polyethylene glycol and ) and anticholinergics or antispasmodics (such as dicyclomine ), anti-TNF therapy, steroids, and antibiotics such as metronidazole (Flagyl) or ciprofloxacin.
[0618] In some embodiments, a method of treating asthma may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more additional therapeutic agents selected from: Beta-2 agonists (such as albuterol ( HFA, HFA), levosalbutamol Iproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol Xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium ), inhaled corticosteroids (such as prednisone, prednisolone, beclomethasone dipropionate ( and ), triamcinolone acetonide Mometasone Budesonide Flunisolide and ), Sodium Cromolyn Methylxanthines (such as theophylline and aminophylline) and IgE antibodies (such as omalizumab ).
[0619] In some embodiments, a method of treating COPD may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more additional therapeutic agents selected from the group consisting of: a β-2 agonist (such as albuterol ( HFA, HFA), levosalbutamol Iproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol Xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium ), methylxanthines (such as theophylline and aminophylline), inhaled corticosteroids (such as prednisone, prednisolone, beclomethasone dipropionate ( and ), triamcinolone acetonide Mometasone Budesonide Flunisolide and ).
[0620] In another embodiment, a method of treating a hematological malignancy may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more additional therapeutic agents selected from the group consisting of: Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, PI3K inhibitors, SYK inhibitors, and combinations thereof.
[0621] In another embodiment, a method of treating a solid tumor may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more additional therapeutic agents selected from the group consisting of: Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, PI3K inhibitors, SYK inhibitors, and combinations thereof.
[0622] In another embodiment, the method of treating a hematological malignancy may include administering to a patient in need thereof a formulation comprising Compound 1 and an inhibitor of a Hedgehog (Hh) signaling pathway. In some embodiments, the hematological malignancy is DLBCL (Ramirez et al., "Defining causative factors contributing in the activation of hedgehog signalling in diffuse large B-cell lymphoma" Leuk. Res. (2012), published online on July 17, and incorporated herein by reference in its entirety).
[0623] In another embodiment, a method of treating diffuse large B-cell lymphoma (DLBCL) may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more additional therapeutic agents selected from the group consisting of: Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, and combinations thereof.
[0624] In another embodiment, a method of treating multiple myeloma may comprise administering to a patient in need thereof a formulation comprising Compound 1 and one or more additional therapeutic agents selected from the group consisting of: bortezomib and dexamethasone Hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, TYK2 inhibitors, PI3K inhibitors, SYK inhibitors and lenalidomide combination.
[0625] In another embodiment, the method of treating or lessening the severity of a disease may comprise administering to a patient in need thereof a formulation comprising Compound 1 and a BTK inhibitor, wherein the disease is selected from inflammatory bowel disease, arthritis, cutaneous lupus erythematosus, systemic lupus erythematosus (SLE), vasculitis, idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, autoimmune thyroiditis, Sjögren's syndrome, multiple sclerosis, systemic sclerosis, Lyme neuroborreliosis, Guillain-Barre syndrome, syndrome), acute diffuse encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, autoimmune gastritis, pernicious anemia, celiac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary sclerosis, Reiter's syndrome, Takayasu's arteritisarteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, generalized alopecia, Behcet's disease, chronic fatigue, dysautonomia, membranous glomerulonephropathy, endometriosis, interstitial cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia, scleroderma, vulvodynia, hyperproliferative disorders, rejection of transplanted organs or tissues, acquired immunodeficiency syndrome (AIDS, also known as HIV), type 1 diabetes, graft-versus-host disease, transplantation, blood transfusion, anaphylaxis, allergies (e.g. to plants) Pollen, latex, drugs, food, insect toxins, animal hair, animal dander, dust mites or cockroach calyx allergy), type I allergic, allergic conjunctivitis, allergic rhinitis and atopic dermatitis, asthma, appendicitis, atopic dermatitis, asthma, allergies, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrosis group Tissue inflammation, gastritis, gastroenteritis, Henlein-Schönlein purpura, hepatitis, suppurative hidradenitis, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, eustachian tube inflammation, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, Uveitis, vaginitis, vasculitis or vulvitis, B-cell proliferative disorders (e.g., diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, multiple myeloma (also known as plasma cell myeloma), non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmacytoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphomalymphoma / leukemia or lymphomatoid granulomatosis), breast cancer, prostate cancer, or mast cell cancer (e.g., mast cell tumor, mast cell leukemia, mast cell sarcoma, systemic mastocytosis), bone cancer, colorectal cancer, pancreatic cancer, bone and joint diseases (including but not limited to rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis, and Reiter's disease), systemic sclerosis, osteoporosis, bone cancer, bone metastases), thrombosis Embolic disorders (e.g., myocardial infarction, angina, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transient ischemia, peripheral arterial occlusive disorder, pulmonary embolism, deep vein thrombosis), inflammatory pelvic disease, urethritis, sunburn, sinusitis, pneumonia, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholecystitis, agammaglobulinemia, arginine Psoriasis, allergies, Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjogren's disease, tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, arteriosclerosis Atherosclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, cutaneous lupus erythematosus, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, scleroderma, mycosis fungoides, and acute inflammatory reactions (such as acute respiratory distress syndrome and ischemia / reperfusion injury).
[0626] In another embodiment, the method of treating or lessening the severity of a disease may comprise administering to a patient in need thereof a formulation comprising Compound 1 as disclosed herein and a PI3K inhibitor, wherein the disease is selected from cancer, neurodegenerative disorders, angiogenic disorders, viral diseases, autoimmune diseases, inflammatory disorders, hormone-related diseases, disorders associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, disorders associated with cell death, thrombin-induced platelet aggregation, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), liver disease, pathological immune disorders involving T cell activation, cardiovascular disorders, and CNS disorders.
[0627] In another embodiment, the method of treating or lessening the severity of a disease may comprise administering to a patient in need thereof a formulation comprising Compound 1 disclosed herein and a PI3K inhibitor, wherein the disease is selected from benign or malignant tumors, cancers or solid tumors of the brain, kidney (e.g., renal cell carcinoma (RCC)), liver, adrenal glands, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, endometrium, cervix, testicles, urogenital tract, esophagus, larynx, skin, bone or thyroid, sarcomas, glioblastomas, neuroblastomas, The invention relates to a leukemia, adenocarcinoma, multiple myeloma or gastrointestinal cancer (particularly colon cancer or colorectal adenoma) or head and neck tumor, epidermal hyperproliferation, psoriasis, prostatic hyperplasia, neoplasia, neoplasia of epithelial character, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer, lymphoma (including, for example, non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (also known as Hodgkin's or Hodgkin's disease)), breast cancer, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma or leukemia, including Cowden syndrome, Lhermitte-Dudos disease and Bannayan-Zonana syndrome. syndrome) or abnormal activation of the PI3K / PKB pathway, asthma of any type or origin (including both intrinsic (non-allergic) asthma and non-intrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitis asthma, exercise-induced asthma, occupational asthma and asthma induced after bacterial infection), acute lung injury (ALI), adult / acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airway or lung disease (COPD, COAD or COLD) (including chronic bronchitis or dyspnea associated therewith, emphysema) and exacerbation of airway hypersensitivity with other drug therapy (particularly other inhaled drug therapy), bronchitis of any type or origin (including but not limited to acute, arachidic, catarrhal, croupus, chronic or tuberculous bronchitis), pneumoconiosis of any type or origin (an inflammatory, usually occupational lung disease,The most common inflammatory diseases are eosinophilic pneumonia, eosinophilic pneumonia, parasitic (particularly metazoan) infections (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), and polyarteritis nodosa. syndrome), eosinophilic granulomas and eosinophil-related disorders affecting the airways triggered by drug-reactions, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, allergic vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphigus, acquired epidermolysis bullosa, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, disorders affecting the nose (including allergic rhinitis), and inflammatory disorders involving autoimmune reactions or having an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), cutaneous lupus erythematosus, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener's granulomatosis, Dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), endocrine eye disease, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary sclerosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, and glomerulonephritis (with and without nephrotic syndrome, including, for example, idiopathic nephrotic syndrome or minimal change disease), restenosis, cardiomegaly, atherosclerosis, myocardial infarction, ischemic stroke and congestive heart failure, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease disease) and cerebral ischemia, as well as neurodegenerative diseases caused by traumatic injury, glutamate neurotoxicity, and hypoxia.
[0628] In some embodiments, a method of treating a disease or reducing its severity may include administering a formulation comprising Compound 1 disclosed herein and a Bcl-2 inhibitor to a patient in need thereof, wherein the disease is an inflammatory disorder, an autoimmune disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder. In some embodiments, the disorder is a proliferative disorder, lupus, or lupus nephritis. In some embodiments, the proliferative disorder is chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Hodgkin's disease, small cell lung cancer, non-small cell lung cancer, myelodysplastic syndrome, lymphoma, hematological neoplasm, or solid tumor.
[0629] In some embodiments, the method of treating a disease or reducing its severity may include administering a TYK2 pseudokinase (JH2) domain binding compound and a TYK2 kinase (JH1) domain binding compound to a patient in need. In some embodiments, the disease is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation. In some embodiments, the JH2 domain binds to compound 1. Other suitable JH2 domain binding compounds include those described in WO2014074660A1, WO2014074661A1, and WO2015089143A1, and the entire contents of each of the applications are incorporated herein by reference. Suitable JH1 domain binding compounds include those described in WO2015131080A1, and the entire contents of the applications are incorporated herein by reference.
[0630] The compound 1 composition can be administered using any amount and any route of administration that is effective in treating an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder or reducing its severity. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the specific agent, its mode of administration, and the like. Compound 1 is preferably formulated in a unit dosage form for ease of administration and uniform dosage. The expression "unit dosage form" as used herein refers to a physically discrete unit of an agent suitable for a patient to be treated. However, it should be understood that the total daily dosage of the compounds and compositions described herein will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient or organism will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound being used; the specific composition being used; the patient's age, weight, general health, sex, and diet; the administration time, route of administration, and excretion rate of the specific compound being used; the duration of treatment; the drugs used in combination with the specific compound being used or happen to be used together and similar factors well known in the medical field. As used herein, the term "patient" means an animal, preferably a mammal, and most preferably a human.
[0631] Depending on the severity of the infection being treated, the pharmaceutically acceptable compositions described herein can be administered to humans and other animals orally, rectally, parenterally, intracisternal, intravaginal, intraperitoneal, topically (such as by powders, ointments or drops), buccally (in the form of oral or nasal sprays), or the like. In certain embodiments, the compounds described herein can be administered orally or parenterally at a dosage level of about 0.01 mg / kg to about 50 mg / kg and preferably about 0.01 mg / kg to about 5 mg / kg of subject body weight per day, once or more a day to obtain the desired therapeutic effect.
[0632] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form may also contain an inert diluent commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (specifically cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof. In addition to the inert diluent, the oral composition may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and aromatics.
[0633] Injectable preparations (e.g., sterile injectable aqueous or oily suspensions) can be prepared according to known techniques using suitable dispersants or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions in nontoxic parenterally acceptable diluents or solvents, for example as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used are especially water, Ringer's solution USP and isotonic sodium chloride solution. In addition, sterile fixed oils are often used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectables.
[0634] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0635] To prolong the effect of compound 1, it is generally desirable to slow down the absorption of the compound from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material with poor water solubility. Therefore, the absorption rate of the compound depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, delayed absorption of the compound form administered parenterally is achieved by dissolving or suspending the compound in an oily vehicle. Injectable reservoir forms are prepared by forming a microcapsule matrix of the compound in a biodegradable polymer (such as polylactide-polyglycolide). Depending on the ratio of the compound to the polymer and the properties of the specific polymer used, the rate at which compound 1 is released can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable preparations are also prepared by encapsulating the compound in a liposome or microemulsion compatible with body tissues.
[0636] Compositions for rectal or vaginal administration are preferably suppositories, which can be prepared by mixing Compound 1 with suitable non-irritating excipients or carriers (such as cocoa butter, polyethylene glycol or suppository wax), which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0637] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier, such as sodium citrate or calcium hydrogen phosphate, and / or a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and silicic acid, b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic, c) humectants, such as glycerol, d) disintegrators, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) dissolution retardants, such as paraffin, f) absorption promoters, such as quaternary ammonium compounds, g) wetting agents, such as cetyl alcohol and glyceryl monostearate, h) absorbents, such as kaolin and bentonite, and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0638] In soft and hard filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycol, similar types of solid compositions can also be used as fillers. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in pharmaceutical formulation technology. It can optionally contain an opacifier and can also have a composition that optionally releases the active ingredient only or preferentially in a certain part of the intestinal tract in a delayed manner. Examples of usable embedded compositions include polymeric substances and waxes. In soft and hard filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycol, similar types of solid compositions can also be used as fillers.
[0639] The active compound may also be in a microencapsulated form with one or more excipients as described above. In some embodiments, a hydroxypropylmethylcellulose (HMPC) capsule encapsulates a composition or formulation described herein. In some embodiments, the capsule is a No. 2 hard Swedish orange HPMC capsule. Solid dosage forms of tablets, dragees, capsules, pills and granules with coatings and shells (such as enteric coatings, release-controlling coatings and other coatings known in pharmaceutical formulation technology) can be prepared. In such solid dosage forms, the active compound may be mixed with at least one inert diluent (such as sucrose, lactose or starch). As in general practice, such dosage forms may also include other substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form may also include a buffer. It may optionally contain an opacifier and may also have a composition that optionally releases the active ingredient only or preferentially in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0640] Dosage forms for topical or transdermal administration of preparations comprising compound 1 as described herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. As required, the active ingredient may be mixed with a pharmaceutically acceptable carrier and any desired preservatives or buffers under sterile conditions. It is also contemplated that ophthalmic preparations, ear drops and eye drops are within the scope of the compositions and preparations described herein. In addition, the preparations and compositions described herein may be used as transdermal patches, which have the additional advantage of controlled delivery of compounds to the body. Such dosage forms may be prepared by dissolving or distributing the compound in an appropriate medium. Absorption enhancers may also be used to increase the flux of the compound through the skin. The rate may be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0641] According to one embodiment, a method of inhibiting protein kinase activity in a biological sample may comprise the step of contacting the biological sample with a formulation comprising Compound 1 as described herein.
[0642] According to another embodiment, the method of inhibiting the activity of TYK2 or a mutant thereof in a biological sample may include the step of contacting the biological sample with Compound 1 described herein or a composition comprising the compound. In certain embodiments, the method of irreversibly inhibiting the activity of TYK2 or a mutant thereof in a biological sample may include the step of contacting the biological sample with a formulation comprising Compound 1 described herein.
[0643] In another embodiment, described herein is a method of selectively inhibiting TYK2 relative to one or more of JAK1, JAK2, and JAK3. In some embodiments, the selectivity of the formulation comprising compound 1 described herein is more than 2 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound described herein is more than 5 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound described herein is more than 10 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound described herein is more than 50 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compound described herein is more than 100 times that of JAK1 / 2 / 3.
[0644] As used herein, the term "biological sample" includes, but is not limited to, cell cultures or extracts thereof; biopsy material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears or other body fluids or extracts thereof.
[0645] Inhibiting TYK2 (or its mutant) activity in a biological sample can be used for a variety of purposes known to those skilled in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological sample storage, and bioassays.
[0646] Another embodiment is directed to a method of inhibiting protein kinase activity in a patient, comprising the step of administering to said patient a formulation comprising Compound 1 as described herein.
[0647] According to another embodiment, a method of inhibiting the activity of TYK2 or a mutant thereof in a patient may comprise the step of administering to the patient a formulation comprising compound 1 as described herein. According to certain embodiments, a method of reversibly or irreversibly inhibiting one or more TYK2 or a mutant thereof activity in a patient may comprise the step of administering to the patient a formulation comprising compound 1 as described herein. In other embodiments, a method for treating a TYK2 or mutant thereof mediated disorder in a patient in need thereof may comprise the step of administering to the patient a formulation comprising compound 1 as described herein. Such disorders are described in detail herein.
[0648] Depending on the particular disorder or disease to be treated, additional therapeutic agents that are normally administered to treat that disorder may also be present in the compositions described herein. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or disorder are referred to as "appropriate for the disease or disorder being treated."
[0649] The formulations containing Compound 1 described herein can also be used in combination with other therapeutic compounds. In some embodiments, the other therapeutic compound is an antiproliferative compound. Such antiproliferative compounds include, but are not limited to, aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule-active compounds; alkylating compounds; histone deacetylase inhibitors; compounds that induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; anti-tumor antimetabolites; platinum compounds; compounds that target / reduce protein or lipid kinase activity and other anti-angiogenic compounds; compounds that target, reduce or inhibit protein or lipid phosphatase activity; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds for the treatment of hematological malignancies; compounds that target, reduce or inhibit Flt-3 activity; Hsp90 inhibitors, such as from Conforma Therapeutics' 17-AAG (allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010; temozolomide Kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine / chlorpromazine from CombinatoRx; MEK inhibitors, such as ARRY142886 from Array BioPharma, AZD6244 from AstraZeneca, PD181461 from Pfizer, and leucovorin. As used herein, the term "aromatase inhibitor" refers to a compound that inhibits estrogen production (e.g., the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively). The term includes, but is not limited to, steroids, especially atamestane, exemestane and formestane, and specifically nonsteroids, especially aminoglutethimide, rogletimide, pyridoglutethimide, trilostane, testolactone, ketoconazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is sold under the trade name Aromasin TM Formestane is sold under the trade name Lentaron TM Fadroxil is sold under the trade name Afema TM Anastrozole is sold under the trade name Arimidex TM Letrozole is sold under the trade name Femara TM or Femar TM Aminoglutethimide is sold under the trade name Orimeten TM The compositions or combinations of formulations described herein comprising a chemotherapeutic aromatase inhibitor are particularly useful for treating hormone receptor positive tumors, such as breast tumors.
[0650] As used herein, the term "anti-estrogen" refers to a compound that antagonizes the effects of estrogen at the estrogen receptor level. The term includes, but is not limited to, tamoxifen, fulvestrant, raloxifene, and raloxifene hydrochloride. Tamoxifen is marketed under the trade name Nolvadex. TM Raloxifene hydrochloride is sold under the trade name Evista TM Fulvestrant is sold under the trade name Faslodex TMAdministration. The combinations of compositions or formulations described herein comprising a chemotherapeutic anti-estrogen are particularly useful for treating estrogen receptor positive tumors, such as breast tumors.
[0651] As used herein, the term "antiandrogen" refers to any substance that is capable of inhibiting the biological effects of androgens and includes, but is not limited to, bicalutamide (Casodex TM As used herein, the term "gonadorelin agonist" includes, but is not limited to, abarelix, goserelin, and goserelin acetate. Goserelin is available under the trade name Zoladex TM Application.
[0652] As used herein, the term "topoisomerase I inhibitors" include, but are not limited to, topotecan, gimatecan, irinotecan, camptothecian and its analogs, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be marketed, for example, in its commercial form (e.g., under the trademark Camptosar TM ) administration. Topotecan is sold under the trade name Hycamptin TM Sale.
[0653] As used herein, the term "topoisomerase II inhibitors" include, but are not limited to, anthracyclines such as doxorubicin (including liposomal formulations such as Caelyx TM ), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxine etoposide and teniposide. Etoposide is sold under the trade name Etopophos TM Teniposide is sold under the trade name VM 26-Bristol. Doxorubicin is sold under the trade name Acriblastin TM or Adriamycin TM Epirubicin is sold under the trade name Farmorubicin TM Idarubicin is sold under the trade name Zavedos TM Mitoxantrone is sold under the trade name Novantron.
[0654] The term "microtubule active agent" refers to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors, including but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate and vinorelbine; discodermolide; cochicine and epothilone and its derivatives. Paclitaxel is sold under the trade name Taxol TM Docetaxel is sold under the trade name Taxotere TM Vinblastine sulfate is sold under the trade name Vinblastin RP TM Vincristine sulfate is sold under the trade name Farmistin TM Sale.
[0655] As used herein, the term "alkylating agent" includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan, or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name Cyclostin TM Ifosfamide is sold under the trade name Holoxan TM Sale.
[0656] The term "histone deacetylase inhibitor" or "HDAC inhibitor" refers to compounds that inhibit histone deacetylase and have antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
[0657] The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name Xeloda TM Gemcitabine is sold under the trade name Gemzar TM Sale.
[0658] As used herein, the term "platinum compound" includes, but is not limited to, carboplatin, cis-platin (cisplatinum) and oxaliplatin. Carboplatin can be obtained, for example, in its commercially available form (e.g., under the trademark Carboplat TM ) is administered. Oxaliplatin can be administered, for example, in the form as it is marketed (e.g. under the trademark Eloxatin TM ) application.
[0659] As used herein, the term "compounds that target / reduce the activity of a protein or lipid kinase, or a protein or lipid phosphatase; or other anti-angiogenic compounds" includes, but is not limited to, protein tyrosine kinase and / or serine and / or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds that target, reduce or inhibit the activity of platelet-derived growth factor receptor (PDGFR), such as compounds that target, reduce or inhibit the activity of PDGFR, especially compounds that inhibit PDGF receptor, such as N-phenyl-2-pyrimidine-amine derivatives, such as imatinib, SU101, SU6668 and GFB-111; b) compounds that target, reduce or inhibit the activity of fibroblast growth factor receptor (FGFR); c) compounds that target, reduce or inhibit the activity of insulin-like growth factor receptor I (IGF-IR), such as compounds that target, reduce or inhibit the activity of IGF-IR, especially compounds that inhibit the kinase activity of IGF-I receptor or antibodies that target the extracellular domain of IGF-I receptor or its growth factor; d) compounds that target, reduce or inhibit Tr k receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds that target, reduce or inhibit the activity of the AxI receptor tyrosine kinase family; f) compounds that target, reduce or inhibit the activity of the Ret receptor tyrosine kinase; g) compounds that target, reduce or inhibit the activity of the Kit / SCFR receptor tyrosine kinase, such as imatinib; h) compounds that target, reduce or inhibit the activity of the c-kit receptor tyrosine kinase, which is part of the PDGFR family, such as compounds that target, reduce or inhibit the activity of the c-Kit receptor tyrosine kinase. i) compounds that target, reduce or inhibit the activity of members of the c-Abl family, their gene fusion products (e.g., BCR-Abl kinase) and mutants, such as compounds that target, reduce or inhibit the activity of c-Abl family members and their gene fusion products, such as N-phenyl-2-pyrimidine-amine derivatives, such as imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825); j) compounds that target, decrease or inhibit the activity of members of the Raf family of protein kinase C (PKC) and serine / threonine kinases, MEK, SRC, JAK / pan-JAK, FAK, PDK1, PKB / Akt, Ras / MAPK, PI3K, SYK, BTK and TEC families and / or members of the cyclin-dependent kinase family (CDK), including staurosporine derivatives such as midostaurin;Examples of other compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; Ilmofosine; RO 318220 and RO320432; GO 6976; Isis 3521; LY333531 / LY379196; Isoquinoline compounds; FTIs; PD184352 or QAN697 (P13K inhibitors) or AT7519 (CDK inhibitors); k) compounds that target, decrease or inhibit the activity of protein tyrosine kinase inhibitors, such as compounds that target, decrease or inhibit the activity of protein tyrosine kinase inhibitors include imatinib mesylate (Gleevec; TM ) or tyrosine phosphorylation inhibitors, such as tyrosine phosphorylation inhibitor A23 / RG-50810; AG99; tyrosine phosphorylation inhibitor AG 213; tyrosine phosphorylation inhibitor AG 1748; tyrosine phosphorylation inhibitor AG490; tyrosine phosphorylation inhibitor B44; tyrosine phosphorylation inhibitor B44(+) spiegelmer; tyrosine phosphorylation inhibitor AG 555; AG 494; tyrosine phosphorylation inhibitor AG 556, AG957 and adaphostin (4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); 1) targeting, decreasing or inhibiting the epidermal growth factor family of receptor tyrosine kinases (EGFR1 in the form of homodimers or heterodimers) Compounds that target, reduce or inhibit the activity of epidermal growth factor receptor family, such as compounds that target, reduce or inhibit the activity of EGF receptor tyrosine kinase family members (such as EGF receptor, ErbB2, ErbB3 and ErbB4) or bind to EGF or EGF related ligands, proteins or antibodies, CP 358774, ZD 1839, ZM105180; trastuzumab (Herceptin TM ), cetuximab (Erbitux TM), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569, GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives; m) compounds that target, decrease or inhibit the activity of c-Met receptors, such as compounds that target, decrease or inhibit the activity of c-Met, especially compounds that inhibit c-Met receptors or target c- Compounds that target, decrease or inhibit the kinase activity of one or more JAK family members (JAK1 / JAK2 / JAK3 / TYK2 and / or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-1 o) compounds that target, decrease or inhibit the kinase activity of PI3 kinase (PI3K), including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, sib), XL-147, XL-765 and idelalisib; and q) compounds that target, reduce or inhibit the signaling effects of the hedgehog protein (Hh) or smoothened receptor (SMO) pathway, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib and IPI-926 (saridegib).
[0660] The term "PI3K inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3-kinase family, including but not limited to PI3Kα, PI3Kγ, PI3Kδ, PI3Kβ, PI3K-C2α, PI3K-C2β, PI3K-C2γ, Vps34, p110-α, p110-β, p110-γ, p110-δ, p85-α, p85-β, p55-γ, p150, p101 and p87. Examples of PI3K inhibitors that can be used in such compositions, formulations, and methods described herein include, but are not limited to, ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparis, pitrilis, PF-4691502, BYL-719, datelix, XL-147, XL-765, and idelalisib.
[0661] As used herein, the term "BTK inhibitor" includes, but is not limited to, compounds having inhibitory activity against Bruton's Tyrosine Kinase (BTK), including, but not limited to, AVL-292 and ibrutinib.
[0662] The term "SYK inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against spleen tyrosine kinase (SYK), including, but not limited to, PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.
[0663] The term "Bcl-2 inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including, but not limited to, ABT-199, ABT-731, ABT-737, apogossypol, Ascenta's pan-Bcl-2 inhibitor, curcumin (and its analogs), dual Bcl-2 / Bcl-xL inhibitors (Infinity Pharmaceuticals / Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and its analogs; see WO2008118802), navitoclax (and its analogs, see US7390799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and its analogs, see WO2004106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ. of Michigan) and venetoclax. In some embodiments, the Bcl-2 inhibitor is a small molecule therapeutic. In some embodiments, the Bcl-2 inhibitor is a peptidomimetic.
[0664] Other examples of BTK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2008039218 and WO2011090760, the entire contents of which are incorporated herein by reference.
[0665] Other examples of SYK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2003063794, WO2005007623 and WO2006078846, the entire contents of which are incorporated herein by reference.
[0666] Other examples of PI3K inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2004019973, WO2004089925, WO2007016176, US8138347, WO2002088112, WO2007084786, WO2007129161, WO2006122806, WO2005113554 and WO2007044729, the entire contents of which are incorporated herein by reference.
[0667] Other examples of JAK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2009114512, WO2008109943, WO2007053452, WO2000142246 and WO2007070514, the entire contents of which are incorporated herein by reference.
[0668] Other antiangiogenic compounds include compounds that have another mechanism for their activity (e.g., not related to protein or lipid kinase inhibition), such as thalidomide. TM ) and TNP-470.
[0669] Examples of proteasome inhibitors that can be used in combination with a formulation comprising Compound 1 described herein include, but are not limited to, bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.
[0670] Compounds that target, decrease or inhibit the activity of a protein or lipid phosphatase are, for example, inhibitors of phosphatase 1, phosphatase 2A or CDC25, such as okadaic acid or a derivative thereof.
[0671] Compounds that induce cell differentiation processes include, but are not limited to, retinoic acid, α-, γ- or δ-tocopherol or α-, γ- or δ-tocotrienol.
[0672] The term cyclooxygenase inhibitors as used herein include, but are not limited to, Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acids and derivatives such as celecoxib (Celebrex TM ), etoricoxib, valdecoxib or 5-alkyl-2-arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, lumiracoxib.
[0673] As used herein, the term "bisphosphonates" includes, but is not limited to, etridonic acid, clodronic acid, tiludronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, and zoledronic acid. TM Clodronic acid is sold under the trade name Bonefos TM Tiludronic acid is sold under the trade name Skelid TM Pamidronate is sold under the trade name Aredia TM Alendronate is sold under the trade name Fosamax TM Ibandronic acid is sold under the trade name Bondranat TM Risedronate is sold under the trade name Actonel TM Zoledronic acid is sold under the trade name Zometa TM The term "mTOR inhibitor" refers to compounds that inhibit the mammalian target of rapamycin (mTOR) and have antiproliferative activity, such as sirolimus Everolimus (Certican TM ), CCI-779 and ABT578.
[0674] As used herein, the term "heparanase inhibitor" refers to a compound that targets, reduces or inhibits the degradation of heparan sulfate. The term includes, but is not limited to, PI-88. As used herein, the term "biological response modifier" refers to a lymphokine or interferon.
[0675] As used herein, the term "inhibitor of an oncogenic isoform of Ras (such as H-Ras, K-Ras or N-Ras)" refers to a compound that targets, decreases or inhibits the oncogenic activity of Ras; for example, a "farnesyl transferase inhibitor" such as L-744832, DK8G557 or R115777 (Zarnestra TM ). As used herein, the term "telomerase inhibitor" refers to a compound that targets, reduces or inhibits telomerase activity. Compounds that target, reduce or inhibit telomerase activity are particularly compounds that inhibit telomerase receptors, such as telomestatin.
[0676] The term "methionine aminopeptidase inhibitor" as used herein refers to a compound that targets, reduces or inhibits the activity of methionine aminopeptidase. Compounds that target, reduce or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or its derivatives.
[0677] As used herein, the term "proteasome inhibitor" refers to a compound that targets, decreases or inhibits the activity of the proteasome. Compounds that target, decrease or inhibit the activity of the proteasome include, but are not limited to, bortezomib (Velcade TM ) and MLN341.
[0678] As used herein, the term "matrix metalloproteinase inhibitors" or ("MMP" inhibitors) includes, but is not limited to, collagen peptide mimetics and non-peptide mimetic inhibitors, tetracycline derivatives, such as the hydroxamate peptide mimetic inhibitor batimastat and its orally bioavailable analogs marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211, MMI270B or AAJ996.
[0679] The term "compounds for treating hematological malignancies" as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds that target, decrease or inhibit the activity of FMS-like tyrosine kinase receptor (Flt-3R); interferons, 1-β-D-arabinofuranosylcytosine (ara-c) and bisulfan; ALK inhibitors, which are compounds that target, decrease or inhibit anaplastic lymphoma kinase; and Bcl-2 inhibitors.
[0680] Compounds that target, decrease or inhibit the activity of the FMS-like tyrosine kinase receptor (Flt-3R) are especially compounds, proteins or antibodies that inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, staurosporine derivatives, SU11248 and MLN518.
[0681] As used herein, the term "HSP90 inhibitor" includes, but is not limited to, compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90; compounds that degrade, target, reduce or inhibit HSP90 client proteins via the ubiquitin proteasome pathway. Compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies that inhibit the ATPase activity of HSP90, such as 17-allylamino, 17-demethoxygeldanamycin (17AAG, a geldanamycin derivative); other geldanamycin-related compounds; radicicol and HDAC inhibitors.
[0682] As used herein, the term "anti-proliferative antibodies" includes, but is not limited to, trastuzumab (Herceptin TM ), trastuzumab-DM1, erbitux, bevacizumab (Avastin TM ), rituximab PRO64553 (anti-CD40) and 2C4 antibodies. Antibodies refer to intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibody fragments, so long as the fragments exhibit the desired biological activity.
[0683] For the treatment of acute myeloid leukemia (AML), the compounds described herein can be used in combination with standard leukemia therapies, particularly in combination with therapies for the treatment of AML. Specifically, formulations comprising compound 1 described herein can be administered in combination with, for example, farnesyl transferase inhibitors and / or other drugs useful for the treatment of AML, such as daunomycin, adriamycin, Ara-C, VP-16, teniposide, mitoxantrone, idarubicin, carboplatin, and PKC412. In some embodiments, methods for treating AML associated with ITD and / or D835Y mutations may include administering a formulation comprising compound 1 described herein together with one or more FLT3 inhibitors. In some embodiments, the FLT3 inhibitor is selected from quizartinib (AC220), a staurosporine derivative (e.g., midostaurin or lestaurtinib), sorafenib, tandutinib, LY-2401401, LS-104, EB-10, famitinib, NOV-110302, NMS-P948, AST-487, G-749, SB-1317, S-209, SC-110219, AKN-028, fedratinib, tozasertib, and sunitinib. In some embodiments, the FLT3 inhibitor is selected from quizartinib, midostaurin, lestaurtinib, sorafenib, and sunitinib.
[0684] Other anti-leukemic compounds include, for example, Ara-C (a pyrimidine analog), which is a 2'-α-hydroxyribose (arabinoside) derivative of deoxycytidine. Also included are purine analogs of hypoxanthine, 6-mercaptopurine (6-MP), and fludarabine phosphate. Compounds that target, reduce, or inhibit the activity of histone deacetylase (HDAC) inhibitors, such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA), inhibit the activity of an enzyme called histone deacetylase. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly known as FR901228), Trichostatin A and compounds disclosed in US 6,552,065, including but not limited to N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-acrylamide or a pharmaceutically acceptable salt thereof and N-hydroxy-3-[4-[(2-hydroxyethyl){2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-acrylamide or a pharmaceutically acceptable salt thereof, especially lactate. As used herein, a somatostatin receptor antagonist refers to a compound that targets, treats or inhibits a somatostatin receptor, such as octreotide and SOM230. Tumor cell destruction methods refer to methods such as ionizing radiation. The term "ionizing radiation" as referred to above and below means ionizing radiation that occurs in the form of electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, Principles and Practice of Oncology, Devita et al., eds., 4th edition, volume 1, pages 248-275 (1993).
[0685] Also included are EDG binders and ribonucleotide reductase inhibitors. As used herein, the term "EDG binder" refers to a class of immunosuppressants that regulate lymphocyte recirculation, such as FTY720. The term "ribonucleotide reductase inhibitor" refers to pyrimidine or purine nucleoside analogs, including but not limited to fludarabine and / or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C to resist ALL) and / or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1H-isoindole-1,3-dione derivatives.
[0686] Specifically, compounds, proteins or monoclonal antibodies of VEGF, such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; Angiostatin TM ;Endostatin TM ; anthranilamide; ZD4190; ZD6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamers, such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibodies, Angiozyme (RPI 4610) and bevacizumab (Avastin TM ).
[0687] As used herein, photodynamic therapy refers to therapy that uses certain chemicals known as photosensitive compounds to treat or prevent cancer. Examples of photodynamic therapy include the use of photosensitive agents such as Visudyne TM and porfimersodium.
[0688] As used herein, angiostatic steroids refer to compounds that block or inhibit angiogenesis, such as anecortave, triamcinolone, hydrocortisone, 11-alpha-epihydrocortisol, cortexolone, 17alpha-hydroxyprogesterone, corticosterone, deoxycorticosterone, testosterone, estrone, and dexamethasone.
[0689] Implants containing corticosteroids refer to compounds such as fluocinolone and dexamethasone.
[0690] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormone compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or various compounds or compounds with other or unknown mechanisms of action.
[0691] Formulations comprising Compound 1 as described herein may also be used as co-therapeutic compounds for use in combination with other APIs, such as anti-inflammatory, bronchodilatory or antihistamine APIs, particularly for the treatment of obstructive or inflammatory airway diseases, such as those mentioned above, for example as a potentiator of the therapeutic activity of such drugs or as a means of reducing the required dose or potential side effects of such drugs. Formulations comprising Compound 1 as described herein may be mixed with other APIs in a fixed pharmaceutical composition, or they may be administered separately before, simultaneously with, or after other APIs. Thus, the combination of formulations may include Compound 1 as described herein with an anti-inflammatory, bronchodilatory, antihistamine or antitussive API, the compound as described herein and the API being in the same or different pharmaceutical compositions.
[0692] Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids, such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate; nonsteroidal glucocorticoid receptor agonists; LTB4 antagonists, such as LY293111, CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247; LTD4 antagonists, such as montelukast and zafirlukast; PDE4 inhibitors, such as cilomilast ( GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SeICID ( TM)CC-10004 (Celgene), VM554 / UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo); A2a agonists; A2b antagonists; and beta-2 adrenergic receptor agonists, such as albuterol, salbutamol, iproterol, terbutaline, salmeterol, fenoterol, procaterol and especially formoterol and pharmaceutically acceptable salts thereof. Suitable bronchodilators include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium bromide salts and CHF 4226 (Chiesi) and glycopyrrolate.
[0693] Suitable antihistamine APIs include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine.
[0694] Other useful combinations of the compounds described herein with anti-inflammatory drugs are those with chemokine receptor (e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5) antagonists, particularly CCR-5 antagonists such as the Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D, and Takeda antagonists such as N-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-ammonium chloride (TAK-770).
[0695] The structures of the active compounds identified by code names, generic names or trade names can be taken from the current edition of the standard compendium "The Merck Index" or from databases of, for example, international patents (eg IMS World Publications).
[0696] Formulations comprising Compound 1 described herein may also be used in combination with known treatment procedures, such as administration of hormones or radiation. In certain embodiments, provided compounds are used as radiosensitizers, which are particularly useful in treating tumors that exhibit poor sensitivity to radiation therapy.
[0697] The formulations comprising compound 1 described herein may be administered alone or in combination with one or more other therapeutic compounds, with possible combination therapies taking the form of a fixed combination, or staggered administration of compound 1 in the form of a formulation described herein with one or more other therapeutic compounds or administered independently of one another, or a fixed combination with one or more other therapeutic compounds. In addition or in addition, compound 1 may be administered in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these therapies for tumor therapy. As described above, long-term therapy is equally possible, as is adjuvant therapy in the context of other treatment strategies. Other possible treatments are therapies used to maintain the patient's status after tumor regression, or even, for example, chemopreventive therapy in patients at risk.
[0698] Those other agents may be administered separately from the composition containing the compounds of the invention as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with Compound 1 in a single formulation or composition. If administered as part of a multiple dosage regimen, the two active agents may be presented simultaneously, sequentially, or within a certain time period of each other, usually within five hours of each other.
[0699] As used herein, the terms "combination", "combined" and related terms refer to the simultaneous or sequential administration of therapeutic agents according to the methods described herein. For example, Compound 1 can be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms or together in a single unit dosage form. Thus, a single unit dosage form can include Compound 1, other therapeutic agents, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[0700] The amount of both the compound of the invention and the other therapeutic agent (in those compositions containing other therapeutic agents as described above) that can be combined with the carrier material to produce a single dosage form will vary depending on the host being treated and the particular mode of administration. Preferably, the compositions described herein should be formulated so that a dose of 0.01-10 mg / kg body weight / day of Compound 1 or a solvate or pharmaceutically acceptable salt thereof can be administered.
[0701] In those compositions comprising an additional therapeutic agent, the additional therapeutic agent and Compound 1 may act synergistically. Thus, the amount of the additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only the therapeutic agent. In such compositions, a dosage of 0.01-1,000 μg / kg body weight / day of the additional therapeutic agent may be administered.
[0702] The amount of the additional therapeutic agent present in the composition comprising Compound 1 will not exceed the amount normally administered in a composition comprising that therapeutic agent as the only active agent. Preferably, the amount of the additional therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[0703] Compound 1 and its pharmaceutical compositions can also be incorporated into compositions for coating implantable medical devices such as prostheses, artificial valves, vascular grafts, stents and catheters. For example, vascular stents have been used to overcome restenosis (restenosis of the blood vessel wall after injury). However, patients using stents or other implantable devices are at risk of blood clot formation or platelet activation. These unwanted effects can be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with the compounds described herein are another embodiment of the compositions and formulations described herein.
[0704] In some embodiments, a medicament may include at least Compound 1 formulated as described herein.
[0705] Pharmaceutical preparation components
[0706] The compositions described herein are administered using any amount and any route of administration that is effective for treating the diseases described above or alleviating their severity. The exact amount required will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the infection, the specific agent, its mode of administration, etc. Compound 1 is preferably formulated in a unit dosage form for ease of administration and uniform dosage. The expression "unit dosage form" as used herein refers to a physically discrete unit of a dose suitable for a patient to be treated. However, it should be understood that the total daily dosage of the compounds and compositions described herein will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient or organism (e.g., cats, dogs, cattle, horses, pigs or birds) will depend on a variety of factors, including the condition being treated and the severity of the condition; the activity of the specific compound employed; the specific composition employed; the patient's age, weight, general health, sex and diet; the administration time, route of administration and excretion rate of the specific compound employed; the duration of treatment; the drugs used in combination with the specific compound employed or used together with the drugs and similar factors well known in the medical field.
[0707] Depending on the severity of the disease being treated, the pharmaceutically acceptable compositions described herein can be administered to humans and other animals orally, rectally, parenterally, intracisternal, intrathecal, transdermal, transmucosal, ocularly, via inhalation, intravaginally, intraperitoneally, topically (such as by powders, ointments or drops), buccally, intranasally, in the form of oral or nasal sprays, or the like. In certain embodiments, the compounds described herein are administered orally or parenterally at a dosage level of about 0.01 mg / kg to about 50 mg / kg and, for example, about 1 mg / kg to about 25 mg / kg of subject body weight per day, once or more a day to obtain the desired therapeutic effect.
[0708] The unit dosage forms described herein can be formulated for oral administration. Pharmaceutical compositions / preparations suitable for oral administration can be provided as discrete dosage forms, such as, but not limited to, tablets, fast-melt tablets, chewable tablets, capsules, pills, strips, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral sprays, solutions, emulsions, suspensions, wafers, sprays, elixirs, and syrups. In some embodiments, such dosage forms contain a predetermined amount of active ingredient and can be prepared by pharmaceutical methods known to those skilled in the art. Typically, see Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing, Easton Pa. (1990). As used herein, oral administration also includes buccal, lingual, and sublingual administration.
[0709] In some embodiments, the formulations further comprise one or more pharmaceutically acceptable excipients or carriers.
[0710] Those of ordinary skill in the art will recognize that pharmaceutical formulation ingredients can be used for a variety of purposes within a formulation. Thus, those skilled in the art will recognize that certain formulation components can be classified according to a variety of functions (e.g., a component can be both a filler and a binder).
[0711] In some embodiments, according to conventional pharmaceutical compounding technology, the unit dosage form provided herein is prepared by combining the active ingredient with one or more pharmaceutically acceptable excipients or carriers into a close mixture, wherein the pharmaceutically acceptable excipients or carriers include but are not limited to adhesives, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, colorants, dye migration inhibitors, sweeteners, flavoring agents, emulsifiers, suspending agents and dispersants, preservatives, solvents, non-aqueous liquids, organic acids and carbon dioxide sources. Excipients or carriers can take various forms depending on the form of the preparation desired to be applied. For example, excipients or carriers suitable for oral liquid or aerosol dosage forms include but are not limited to water, glycols, oils, alcohols, flavoring agents, preservatives and colorants. Examples of excipients or carriers suitable for solid oral dosage forms (e.g., powders, tablets, capsules and capsule-type tablets) include but are not limited to starch, sugar, microcrystalline cellulose, diluents, granulators, lubricants, adhesives and disintegrants.
[0712] In some embodiments, active ingredients (such as compound 1 or its pharmaceutically acceptable salt) are incorporated into pharmaceutical compositions as spray-dried powders or particles. It is well known to produce powders from fluid raw materials using spray drying, and its application range ranges from milk powder to bulk chemicals and drugs. See U.S. Patent No. 4,187,617 and Mujumbar et al., 91 Drying, pp. 56-73 (1991). It is also known to use spray drying to form a solid amorphous dispersion of a drug and a thickening polymer. See co-owned European patent applications No. 0901 786, No. 1 027 886, No. 1 027 887, No. 1 027 888 and co-owned PCT applications No. WO 00 / 168092 and No. WO 00 / 168055, each of which is incorporated herein by reference. A typical spray drying apparatus comprises a drying chamber, an atomizing device for atomizing a solvent-containing liquid fed into the drying chamber, a source of heated drying gas directed into the drying chamber, and a dried product collecting device for separating the dried product from the cooled drying gas and vaporized solvent streams after the dried product leaves the drying chamber. Examples of such apparatus include Niro Models PSD-1, PSD-2, and PSD-4 (Niro A / S, Soeborg, Denmark).
[0713] The spray-dried powder or granules typically include a combination of an active compound and a polymer (such as a thickening polymer). A class of polymers suitable for use in the compositions and formulations described herein includes non-ionizable (neutral) non-cellulose polymers. Exemplary polymers include: vinyl polymers and copolymers having at least one substituent selected from the group consisting of hydroxyl, alkyl acyloxy, and cyclic amide groups; polyvinyl alcohol in which at least a portion of the repeating units is in the unhydrolyzed (vinyl acetate) form; polyvinyl alcohol polyvinyl acetate copolymers; polyvinyl pyrrolidone; and polyethylene polyvinyl alcohol copolymers; and polyoxyethylene-polyoxypropylene copolymers.
[0714] Exemplary neutral non-cellulosic polymers include vinyl copolymers of at least one hydrophilic hydroxyl-containing repeating unit and at least one hydrophobic alkyl or aryl-containing repeating unit. Such neutral vinyl copolymers are referred to as "amphiphilic hydroxyl-functional vinyl copolymers". It is believed that amphiphilic hydroxyl-functional vinyl copolymers provide high concentration enhancement due to the amphiphilicity of these copolymers, which provide both sufficient hydrophobic groups to interact with hydrophobic, low solubility drugs and sufficient hydrophilic groups to have sufficient water solubility to achieve good dissolution. The copolymeric structure of the amphiphilic hydroxyl-functional vinyl copolymer also allows its hydrophilicity and hydrophobicity to be adjusted to maximize the performance of specific low solubility drugs.
[0715] Another class of polymers suitable for use in the compositions and formulations described herein comprises ionizable non-cellulosic polymers. Exemplary polymers include: carboxylic acid functionalized vinyl polymers such as carboxylic acid functionalized polymethacrylates and carboxylic acid functionalized polyacrylates such as EUDRAGIT manufactured by Rohm Tech Inc., Malden, Mass. TM series; amine-functionalized polyacrylates and polymethacrylates; proteins, such as gelatin and albumin; and carboxylic acid-functionalized starches, such as glycolic acid starch.
[0716] Non-cellulosic polymers that are amphiphilic are copolymers of relatively hydrophilic and relatively hydrophobic monomers. Examples include acrylate and methacrylate copolymers. Exemplary commercial grades of such copolymers include EUDRAGIT TM Series, which is a copolymer of methacrylate and acrylate.
[0717] Another class of polymers comprises ionizable and neutral (or non-ionizable) cellulosic polymers having at least one ester-linked and / or ether-linked substituent, wherein the degree of substitution of each substituent of the polymer is at least 0.05. It should be noted that in the polymer nomenclature used herein, the ether-linked substituent is listed before "cellulose" as the moiety to which the ether group is linked; for example, "cellulose ethylbenzoate" has an ethoxybenzoic acid substituent. Similarly, the ester-linked substituent is listed before "cellulose" as a carboxylate group; for example, one carboxylic acid of each phthalate moiety of "cellulose phthalate" is ester-linked to the polymer, and the other carboxylic acid is unreacted.
[0718] It should also be noted that polymer names such as "cellulose acetate phthalate" (CAP) refer to a family of cellulose polymers having either acetate or phthalate groups attached to a majority of the hydroxyl groups of the cellulose polymer via ester linkages. In general, the degree of substitution for each substituent can range from 0.05 to 2.9, as long as the other criteria for the polymer are met. The "degree of substitution" refers to the average number of hydroxyl groups that have been substituted in each sugar repeat unit on the cellulose chain. For example, if all of the hydroxyl groups on the cellulose chain have been substituted with phthalate groups, the degree of phthalate substitution is 3. Also included within each polymer family type are cellulose polymers with other substituents that are added in relatively small amounts and do not substantially change the properties of the polymer.
[0719] Amphiphilic cellulose preparations include polymers in which any or all of the three hydroxyl groups present on each sugar repeating unit of the parent cellulose polymer are substituted with at least one relatively hydrophobic substituent. The hydrophobic substituent can be essentially any substituent that, if substituted to a sufficiently high level or degree of substitution, can render the cellulose polymer substantially insoluble in water. Examples of hydrophobic substituents include ether-linked alkyl groups, such as methyl, ethyl, propyl, butyl, etc.; or ester-linked alkyl groups, such as acetate, propionate, butyrate, etc.; and ether-linked and / or ester-linked aryl groups, such as phenyl, benzoate, or phenyl ether. The hydrophilic regions of the polymer can be those portions that are relatively unsubstituted, because the unsubstituted hydroxyl groups themselves are relatively hydrophilic, or those regions substituted with hydrophilic substituents. Hydrophilic substituents include ether-linked or ester-linked non-ionizable groups, such as hydroxyalkyl substituents hydroxyethyl, hydroxypropyl, and alkyl ether groups, such as ethoxyethoxy or methoxyethoxy. Particularly preferred hydrophilic substituents are those which are ether-linked or ester-linked ionizable groups, such as carboxylic acids, thiocarboxylic acids, substituted phenoxy groups, amines, phosphate groups, or sulfonate groups.
[0720] One class of cellulose polymers comprises neutral polymers, meaning that the polymer is substantially non-ionizable in aqueous solution. Such polymers contain non-ionizable substituents, which may be ether-linked or ester-linked. Exemplary ether-linked non-ionizable substituents include: alkyl groups, such as methyl, ethyl, propyl, butyl, etc.; hydroxyalkyl groups, such as hydroxymethyl, hydroxyethyl, hydroxypropyl, etc.; and aryl groups, such as phenyl. Exemplary ester-linked non-ionizable substituents include: alkyl groups, such as acetate, propionate, butyrate, etc.; and aryl groups, such as phenyl ether. However, when aryl groups are included, the polymer may need to include a sufficient amount of hydrophilic substituents so that the polymer has at least some water solubility at any physiologically relevant pH from 1 to 8.
[0721] Exemplary non-ionizable cellulosic polymers useful as the polymer include hydroxypropyl methylcellulose acetate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, hydroxyethyl methylcellulose, hydroxyethyl cellulose acetate, and hydroxyethyl ethyl cellulose.
[0722] One class of exemplary neutral cellulose polymers are those that are amphiphilic. Exemplary polymers include hydroxypropyl methylcellulose and hydroxypropyl acetate cellulose, in which cellulose repeating units having a relatively high number of methyl or acetate substituents relative to unsubstituted hydroxyl or hydroxypropyl substituents constitute hydrophobic regions relative to other repeating units on the polymer.
[0723] A class of specific cellulose polymers comprises polymers that are at least partially ionizable at physiologically relevant pH and include at least one ionizable substituent (which may be ether-linked or ester-linked). Exemplary ether-linked ionizable substituents include: carboxylic acids such as acetic acid, propionic acid, benzoic acid, salicylic acid; alkoxybenzoic acids such as ethoxybenzoic acid or propoxybenzoic acid; various isomers of alkoxyphthalic acid such as ethoxyphthalic acid and ethoxyisophthalic acid; various isomers of alkoxynicotinic acid such as ethoxynicotinic acid; and various isomers of picolinic acid such as ethoxypicolinic acid, etc.; thiocarboxylic acids such as thioacetic acid; substituted phenoxy groups such as hydroxyphenoxy, etc.; amines such as aminoethoxy, diethylaminoethoxy, trimethylaminoethoxy, etc.; phosphate groups such as phosphateethoxy; and sulfonate groups such as sulfonateethoxy. Ionizable substituents of exemplary ester connection include: carboxylic acid, such as succinate, citrate, phthalate, terephthalate, isophthalate, trimellitate and various isomers of picolinic acid, etc.; thiocarboxylic acid, such as sulfosuccinate; substituted phenoxy, such as aminosalicylic acid; amine, such as natural or synthetic amino acid, such as alanine or phenylalanine; phosphate, such as acetyl phosphate; and sulfonate, such as acetyl sulfonate. In order to make the aromatic substituted polymer also have the necessary water solubility, it is also desirable to connect a sufficiently hydrophilic group (such as a hydroxypropyl or carboxylic acid functional group) to the polymer so that the polymer is water-soluble at least at the pH value at which any ionizable group is ionized. In some cases, the aromatic substituent itself can be ionizable, such as a phthalate or trimellitate substituent.
[0724] Exemplary cellulosic polymers that are at least partially ionized at physiologically relevant pH include hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methylcellulose succinate, hydroxyethyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxyethyl methylcellulose acetate succinate, hydroxyethyl methylcellulose acetate phthalate, carboxyethyl cellulose, carboxymethyl cellulose, carboxymethyl ethyl cellulose, ethyl carboxymethyl cellulose, cellulose acetate phthalate, methylcellulose acetate phthalate, ethylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl cellulose acetate succinate, hydroxypropyl cellulose acetate phthalate succinate, hydroxypropyl cellulose acetate phthalate succinate, hydroxypropyl cellulose acetate phthalate succinate, hydroxypropyl cellulose acetate phthalate succinate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate ... Propyl methylcellulose, hydroxypropyl methylcellulose phthalate succinate, cellulose propionate phthalate, hydroxypropyl cellulose phthalate butyrate, cellulose acetate trimellitate, methylcellulose acetate trimellitate, ethylcellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate succinate, cellulose propionate, cellulose butyrate trimellitate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate picolinate, cellulose acetate salicylate, cellulose acetate hydroxypropyl salicylate, ethyl cellulose acetate benzoate, hydroxypropyl ethyl cellulose acetate benzoate, ethyl cellulose acetate phthalate, cellulose acetate ethyl nicotinate, and cellulose acetate ethyl picolinate.
[0725] Exemplary cellulosic polymers meeting the definition of amphiphilic, having hydrophilic and hydrophobic regions, include polymers such as cellulose acetate phthalate and cellulose acetate trimellitate, in which the cellulose repeating units having one or more acetate substituents are hydrophobic relative to those cellulose repeating units having no acetate substituents or having one or more ionized phthalate or trimellitate substituents.
[0726] Another subset of cellulose ionizable polymers are those ionizable polymers that have both carboxylic acid functional aromatic substituents and alkylated substituents and are therefore amphiphilic. Exemplary polymers include cellulose acetate phthalate, methylcellulose acetate phthalate, ethylcellulose acetate phthalate, hydroxypropylcellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate phthalate, hydroxypropylcellulose acetate phthalate succinate, cellulose propionate phthalate, hydroxypropylcellulose butyrate phthalate, cellulose acetate trimellitate, methylcellulose acetate trimellitate, ethylcellulose acetate trimellitate, hydroxypropylcellulose acetate ... Hydroxypropyl cellulose, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate succinate, cellulose trimellitate propionate, cellulose trimellitate butyrate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate picolinate, cellulose acetate salicylate, cellulose acetate hydroxypropyl salicylate, cellulose acetate ethyl benzoate, cellulose acetate hydroxypropyl ethyl benzoate, cellulose acetate ethyl phthalate, cellulose acetate ethyl nicotinate, and cellulose acetate ethyl picolinate.
[0727] Another subset of cellulose ionizable polymers is those ionizable polymers with non-aromatic carboxylate substituents. Exemplary polymers include hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methylcellulose acetate succinate, hydroxyethyl methylcellulose succinate, hydroxyethyl cellulose acetate succinate and carboxymethyl ethyl cellulose. In the cellulose polymer at least partially ionized under physiologically relevant pH, for example hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethyl ethyl cellulose. In some embodiments, polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS).
[0728] Another class of polymers consists of neutralized acidic polymers. "Neutralized acidic polymer" means any acidic polymer in which the majority of the "acidic moieties" or "acidic substituents" have been "neutralized"; that is, present in its deprotonated form. "Neutralized acidic cellulose polymer" means any cellulose "acidic polymer" in which the majority of the "acidic moieties" or "acidic substituents" have been "neutralized." "Acidic polymer" means any polymer having a substantial amount of acidic moieties. Generally speaking, the substantial amount of acidic moieties will be greater than or equal to about 0.1 milliequivalents of acidic moieties per kilogram of polymer. "Acidic moieties" include any sufficiently acidic functional group that, when in contact with or dissolved in water, can at least partially donate hydrogen cations to the water and thereby increase the hydrogen ion concentration. This definition includes any functional group or "substituent" such as when the functional group is covalently attached to the pK aThe term "substituent" refers to a polymer having less than about 10 functional groups. Exemplary functional group categories included in the above description include carboxylic acids, thiocarboxylic acids, phosphate groups, phenolic groups, and sulfonate groups. Such functional groups may constitute the primary structure of a polymer (such as polyacrylic acid), but are more typically covalently attached to the backbone of the parent polymer and are therefore referred to as "substituents."
[0729] Relative to the amount of drug (compound 1) present in the spray-dried dispersion, the amount of the thickening polymer depends on the drug and the thickening polymer, and the drug to polymer weight ratio can vary widely from 0.01 to 5. However, in most cases, except when the drug dose is extremely low (e.g., 25 mg or less), the drug to polymer ratio is generally greater than 0.05 and less than 2.5, and generally when the drug to polymer ratio is 1 or less or even 0.2 or less for some drugs, an enhancement of drug concentration or relative bioavailability is observed. In the case where the drug dose is about 25 mg or less, the drug to polymer weight ratio can be significantly less than 0.05. In general, regardless of the dose, the enhancement of drug concentration or relative bioavailability increases with the decrease of the drug to polymer weight ratio. However, due to the actual limit of keeping the total mass of the tablet, capsule or suspension at a lower level, it is generally desirable to use a relatively high drug to polymer ratio as long as satisfactory results are obtained. The maximum drug to polymer ratio that produces satisfactory results varies from drug to drug and is best determined in the dissolution test described below.
[0730] The spray-dried solid as described herein may be a solid dispersion containing a compound as described herein and a pharmaceutically acceptable polymer. Certain compounds described herein generally have low water solubility, and their in vivo absorption is limited by dissolution rate. Solid dispersions containing compounds can increase compound solubility / dissolution, thereby improving the bioavailability of the compound.
[0731] The term "solid dispersion" refers herein to a dispersion of a pharmaceutically active ingredient (e.g., a compound described herein) in a solid inert polymer matrix. Solid dispersions can be prepared by methods well known in the art, such as spray drying or hot melt extrusion. The matrix can be crystalline or amorphous. Solid dispersions contain a coprecipitate of a pharmaceutically active ingredient and one or more water-soluble polymers, wherein the pharmaceutically active ingredient is uniformly dispersed in a polymer matrix formed by the polymer. The pharmaceutically active ingredient can exist in an amorphous state, a crystalline dispersed form, or a combination thereof. It can also be finely dispersed or dissolved in a polymer matrix as a single molecule. Solid dispersions are usually prepared by spray drying or hot melt extrusion.
[0732] The method for preparing a solid dispersion comprises the steps of: (i) mixing a compound as described herein and a polymer in an organic solvent to provide a feed solution, and (ii) spray drying the feed solution in a fine spray form via a nozzle into a chamber, where the solvent evaporates rapidly to produce particles containing the compound and the polymer. After the solid dispersion is formed, the resulting spray-dried particles may undergo a secondary drying step to remove residual solvent. The secondary drying step may be performed in a static dryer or an agitated dryer. Gas, humidified gas, vacuum may be applied to the secondary drying step, and such application may be used to more rapidly remove residual solvent remaining in the spray-dried particles.
[0733] Any organic solvent that can easily dissolve or disperse the compounds and polymers described above can be used. Examples of organic solvents include low carbon alcohols such as methanol, ethanol, propanol, and isopropanol; ketones such as methyl ethyl ketone and butanone; and combinations thereof.
[0734] In some embodiments, pharmaceutically acceptable excipients and carriers are selected from fillers, binders, diluents, disintegrants, glidants, and lubricants.
[0735] In some embodiments, a capsule or tablet may include a provided pharmaceutical composition in a solid dosage form. In some embodiments, the solid dosage form may be a capsule. In some embodiments, the solid dosage form may be a tablet.
[0736] In certain embodiments, the dosage form is a tablet, wherein the tablet is manufactured using a standard, tablet processing procedure and equipment generally recognized in the art. In certain embodiments, the method for forming a tablet is to directly compress a powdery, crystalline and / or granular composition, the composition comprising a solid form provided herein alone or in combination with one or more excipients or carriers (such as carriers, additives, polymers or the like). In certain embodiments, as a substitute for direct compression, wet granulation or dry granulation methods can be used to prepare tablets. In certain embodiments, starting with moist or otherwise tractable materials, tablets are molded rather than compressed. In certain embodiments, compression and granulation techniques are used.
[0737] In certain embodiments, the dosage form is a capsule, wherein the capsule can be manufactured using standard, art-recognized capsule processing procedures and equipment. In certain embodiments, soft gelatin capsules can be prepared, wherein the capsule contains a mixture comprising a solid form provided herein and a vegetable oil or a non-aqueous water-miscible material (such as polyethylene glycol, etc.). In certain embodiments, hard gelatin capsules can be prepared, which contain particles of a solid form provided herein combined with a solid powdered carrier (such as lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, amylopectin, a cellulose derivative or gelatin). In certain embodiments, a hard gelatin capsule shell can be prepared from a capsule composition comprising gelatin and a small amount of a plasticizer (such as glycerol). In certain embodiments, as an alternative to gelatin, a capsule shell can be made from a carbohydrate material. In certain embodiments, the capsule composition can additionally include a polymer, a colorant, a flavoring agent, and a sunscreen as needed. In certain embodiments, the capsule comprises HPMC.
[0738] In some embodiments, the pharmaceutical composition comprises one or more fillers. In certain embodiments, the filler is selected from ammonium alginate, calcium carbonate, calcium lactate, calcium phosphate, calcium silicate, calcium sulfate, cellulose acetate, compressible sugars (e.g., lactose, glucose and sucrose), corn starch, dextrate, erythritol, ethyl cellulose, stearyl palmitin, isomalt, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, medium chain triglycerides, microcrystalline cellulose, pregelatinized starch, polydextrose, polymethacrylate, silicic acid, simethicone, sodium alginate, sodium chloride, sorbitol, starch, sugar spheres, sulfobutyl ether beta-cyclodextrin, talc, tragacanth, trehalose and xylitol or a combination thereof.
[0739] In some embodiments, the filler is selected from talc, calcium carbonate (eg, granules or powder), microcrystalline cellulose, powdered cellulose, dextran, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof.
[0740] In some embodiments, the filler is microcrystalline cellulose. In some embodiments, the filler is lactose. In some embodiments, the filler is starch. In some embodiments, the filler is a combination of starch and lactose. In some embodiments, the filler is a combination of lactose and microcrystalline cellulose. In some embodiments, the filler is a combination of two or three of the components listed above. In some embodiments, the filler comprises at least microcrystalline cellulose, lactose and mannitol.
[0741] In certain embodiments, the dosage form provided herein comprises one or more diluents. Diluents can be used, for example, to increase volume so that a tablet or capsule of practical size is finally provided. Suitable diluents especially include calcium hydrogen phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch, microcrystalline cellulose (e.g., AVICEL), microfine cellulose, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextran binder, dextrin, dextrose, calcium hydrogen phosphate dihydrate, calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylate (e.g., EUDRAGIT), potassium chloride, sodium chloride, sorbitol and talc. Diluents also include, for example, ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose acetate, compressible sugar, confectioner's sugar, dextran, dextrin, dextrose, erythritol, ethylcellulose, fructose, fumaric acid, stearyl palmitostearin, isomalt, kaolin, lactitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, microcrystalline cellulose, microcrystalline silicified cellulose, powdered cellulose, polydextrose, polymethacrylate, simethicone, sodium alginate, sodium chloride, sorbitol, starch, pregelatinized starch, sucrose, sulfobutyl ether-β-cyclodextrin, talc, tragacanth, trehalose, and xylitol.
[0742] In some embodiments, the pharmaceutical composition comprises one or more adhesives. Adhesives can be used, for example, to give tablets or capsules adhesive quality, and thus ensure that the preparation remains intact after compression. In some embodiments, the adhesive is selected from gum arabic, agar, alginic acid, calcium carbonate, calcium lactate, carbomer (carbomer) (e.g., acrylic acid polymers, carboxypolymethylene, polyacrylic acid, carboxyvinyl polymers), sodium carboxymethylcellulose, carrageenan, cellulose acetate phthalate, carob bean gum, chitosan, copolyvidone, corn starch, cottonseed oil, dextran binder, dextrin, dextrose, ethylcellulose, gelatin, behenic acid glyceride, guar gum (guar gum gum), type I hydrogenated vegetable oil, hydroxyethylcellulose, hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hypromellose, inulin, lactose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, microcrystalline cellulose, pectin, poloxamer, polycarbohil, polydextrose, polyethylene oxide, polymethacrylate, polyvinyl pyrrolidone, pregelatinized starch, povidone, sodium alginate, starch, stearic acid, sucrose, tricaprylin, vitamin E polyethylene glycol succinate, and zein.
[0743] Suitable binders include, but are not limited to, starch (including potato starch, corn starch and pregelatinized starch), gelatin, sugars (including sucrose, glucose, dextrose and lactose), polyethylene glycol, propylene glycol, waxes and natural and synthetic gums such as gum arabic, sodium alginate, polyvinylpyrrolidone (PVP), cellulose polymers (including hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), methyl cellulose, ethyl cellulose, hydroxyethyl cellulose (HEC), carboxymethyl cellulose, etc.), veegum, carbomer (e.g., carbopol), sodium, dextrin, guar gum, hydrogenated vegetable oil, magnesium aluminum silicate, maltodextrin, polymethacrylate, povidone (e.g., KOLLIDON, PLASDONE), and microcrystalline cellulose. Binders also include, for example, gum arabic, agar, alginic acid, carbomer, carrageenan, cellulose acetate phthalate, locust bean gum, chitosan, powdered sugar, copovidone, dextran, dextrin, dextrose, ethylcellulose, gelatin, glyceryl behenate, guar gum, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropyl starch, hydroxypropyl methylcellulose, inulin, lactose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylate, povidone, sodium alginate, sodium carboxymethylcellulose, starch, pregelatinized starch, stearic acid, sucrose and zein.
[0744] Suitable forms of microcrystalline cellulose include, but are not limited to, materials sold as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corporation, Marcus Hook, Pa.), and mixtures thereof. In some embodiments, the specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, which is sold as AVICEL RC-581. Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103, AVICEL RC-581, AVICEL RC-581, and AVICEL PH-105 (FMC Corporation, Marcus Hook, Pa.). TM and starch 1500LM.
[0745] In some embodiments, the pharmaceutical composition comprises one or more disintegrants. In certain embodiments, the disintegrant is selected from alginic acid, calcium alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, cellulose, chitosan, colloidal silicon dioxide, corn starch, cross-linked carboxymethylcellulose sodium, crospovidone, docusate sodium, glycine, guar gum, hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, pregelatinized starch, polacrilin potassium, povidone, silicates, sodium alginate, sodium carbonate and sodium starch glycolate.
[0746] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses such as methylcellulose and carboxymethylcellulose; wood products; natural sponges; cation exchange resins; alginic acid; gums such as guar gum and magnesium aluminum silicate HV; citrus pulp; cross-linked celluloses such as cross-linked carboxymethylcellulose; cross-linked polymers such as crospovidone; cross-linked starch; calcium carbonate; microcrystalline cellulose such as sodium starch glycolate; polacrilin potassium; starches such as corn starch, potato starch, tapioca starch, and pregelatinized starch; clays; alginate; and mixtures thereof.
[0747] In some embodiments, the pharmaceutical composition comprises one or more surfactants. In some embodiments, the surfactant is selected from polyoxyethylene (20) sorbitan monolaurate (e.g., Tween-20), polyoxyethylene (20) sorbitan monooleate (e.g., Tween-80), sodium lauryl sulfate, and sodium dodecyl sulfate.
[0748] In some embodiments, the pharmaceutical composition comprises one or more pore formers. In some embodiments, the pore former is selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, poloxamer 188, povidone (e.g., Kollidon K25 / K30) or sugar (e.g., glucose, mannose, fructose and sucrose).
[0749] In some embodiments, the pharmaceutical composition comprises one or more glidants. In some embodiments, the glidant is selected from calcium phosphate, cellulose, colloidal silicon dioxide, fumed silica, magnesium oxide, magnesium silicate, magnesium stearate, magnesium trisilicate and talc. Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL TM (Cabot Co., Boston, MA) and asbestos-free talc.
[0750] In some embodiments, the pharmaceutical composition comprises one or more lubricants. In some embodiments, the lubricant is selected from calcium stearate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, myristic acid, poloxamer, polyethylene glycol, sodium benzoate, sodium chloride, sodium lauryl sulfate, sodium stearyl fumarate, solid polyethylene glycol, stearic acid and talc.
[0751] Lubricants that can be used in pharmaceutical compositions and dosage forms include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, and mixtures thereof. Other lubricants include, for example, syloid silica gel (AEROSIL 200, manufactured by WR Grace Co., Baltimore, Md.), condensation aerosols of synthetic silica (sold by Degussa Co., Plano, Tex.), CAB-O-SIL (a pyrogenic silica product sold by Cabot Co., Boston, Mass.), and mixtures thereof.
[0752] In some embodiments, the pharmaceutical composition comprises one or more film coating agents. In some embodiments, the film coating comprises a poly(vinyl alcohol) matrix. In some embodiments, the film coating comprises a colorant or pigment. In some embodiments, the film coating is Opadry Such as Opadry yellow.
[0753] Suitable coloring agents include, but are not limited to, any of the approved identified water-soluble FD&C dyes and water-insoluble FD&C dyes suspended on alumina hydrate and lakes, and mixtures thereof. Lakes are combinations of water-soluble dyes produced by adsorbing them onto hydrated oxides of heavy metals to produce an insoluble form of the dye.
[0754] Suitable flavoring agents include, but are not limited to, natural flavoring agents extracted from plants, such as fruits, and synthetic blends of compounds that produce a pleasant taste sensation, such as peppermint and methyl salicylate.
[0755] Suitable sweeteners include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners such as saccharin and aspartame.
[0756] Suitable emulsifiers include, but are not limited to, gelatin, gum arabic, gum tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate (Tween-20), polyoxyethylene sorbitan monooleate 80 (Tween-80), and triethanolamine oleate.
[0757] Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, gum tragacanth, magnesium aluminum silicate, gum arabic, sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone.
[0758] Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic acid, sodium benzoate, and alcohol.
[0759] Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether.
[0760] Suitable solvents include, but are not limited to, glycerol, sorbitol, ethanol, and syrups.
[0761] Suitable non-aqueous liquids for use in emulsions include, but are not limited to, mineral oil and cottonseed oil.
[0762] Suitable organic acids include, but are not limited to, citric acid and tartaric acid.
[0763] Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.
[0764] The pharmaceutical composition for oral administration provided herein can be provided in the following forms: compressed tablets, tablets, chewable lozenges, quick-dissolving tablets, multiple compressed tablets or enteric-coated tablets, sugar-coated tablets or film-coated tablets. Enteric-coated tablets are compressed tablets, which are coated with materials that resist gastric acid but dissolve or disintegrate in the intestine, thereby protecting the active ingredients from the acidic environment in the stomach. Enteric coatings include but are not limited to fatty acids, fats, phenyl salicylate, wax, shellac, aminated shellac and cellulose acetate phthalate. Sugar-coated tablets are compressed tablets surrounded by sugar coatings, which can be useful in hiding unpleasant tastes or smells and protecting tablets from oxidation. Film-coated tablets are compressed tablets, which are covered with a thin layer or film of a water-soluble material. Film coatings include but are not limited to hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate. Film coatings impart the same general characteristics as sugar coatings. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including multilayer tablets and press-coated tablets or dry-coated tablets.
[0765] Tablet dosage forms may be prepared from the active ingredient in powdered, crystalline or granular form, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled release polymers, lubricants, diluents and / or colorants.
[0766] The tablets of the present disclosure may be formulated for quick, sustained, extended, or modified release.
[0767] In some embodiments, the unit dosage forms described herein comprise one or more pharmaceutically acceptable excipients selected from microcrystalline cellulose, lactose monohydrate (modified), croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate.
[0768] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form may also contain an inert diluent commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (specifically cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof. In addition to the inert diluent, the oral composition may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and aromatics.
[0769] Injectable preparations (e.g., sterile injectable aqueous or oily suspensions) can be prepared using suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions in nontoxic parenterally acceptable diluents or solvents, for example as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used are especially water, Ringer's solution USP and isotonic sodium chloride solution. In addition, sterile fixed oils are routinely used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectables.
[0770] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0771] To prolong the effect of the compounds described herein, it is generally desirable to slow down the absorption of the compounds from subcutaneous or intramuscular injections. This can be achieved by using a liquid suspension of crystalline or amorphous materials with poor water solubility. Therefore, the absorption rate of the compound depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, delayed absorption of the compound form administered parenterally is achieved by dissolving or suspending the compound in an oily vehicle. Injectable depot forms are prepared by forming a microcapsule matrix of the compound in a biodegradable polymer (such as polylactide-polyglycolide). Depending on the ratio of the compound to the polymer and the properties of the specific polymer used, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable preparations are also prepared by encapsulating the compound in a liposome or microemulsion compatible with body tissues.
[0772] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing a compound described herein with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active compound.
[0773] The active compound may also be in the form of microencapsulation with one or more excipients as described above. Solid dosage forms of tablets, dragees, capsules, pills and granules with coatings and shells (such as enteric coatings, release-controlled coatings and other coatings known in pharmaceutical formulation techniques) may be prepared. In such solid dosage forms, the active compound may be mixed with at least one inert diluent (such as sucrose, lactose or starch). As in general practice, such dosage forms may also include other substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form may also include a buffer. It may optionally contain an opacifier, and may also have a composition that optionally releases the active ingredient only or preferentially in a certain part of the intestinal tract in a delayed manner. Examples of usable embedded compositions include polymeric substances and waxes.
[0774] The dosage form for topical or transdermal administration of the compounds described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. As required, the active ingredient is mixed with a pharmaceutically acceptable carrier and any desired preservatives or buffers under sterile conditions. Ophthalmic preparations, ear drops and eye drops are also contemplated. In addition, transdermal patches may be used, which have the additional advantage of controlled delivery of the compound to the body. Such dosage forms may be prepared by dissolving or distributing the compound in an appropriate medium. Absorption enhancers may also be used to increase the flux of the compound through the skin. The rate may be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0775] In some embodiments, a composition as described herein may include a prodrug of Compound 1. As used herein, the term "prodrug" means a compound that can be converted into a compound in vivo by metabolic means (eg, by hydrolysis). Various general forms of prodrugs are known in the art, such as those discussed in Bundgaard (ed.), Design of Prodrugs, Elsevier (1985); Widder et al. (eds.), Methods in Enzymology. Vol. 4, Academic Press (1985); Krogsgaard-Larsen et al. (eds.), Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991), Bundgaard, 99=., Journal of Drug Delivery Reviews, 8: 1-38 (1992), Bundgaard, J. of Pharmaceutical Sciences, 77: 285 et seq. (1988); and Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975), each of which is incorporated herein by reference in its entirety.
[0776] For oral administration in the form of tablets or capsules (e.g., gelatin capsules), active drug components can be combined with oral non-toxic pharmaceutically acceptable inert carriers (such as ethanol, glycerol, water, etc.). In addition, when desired or necessary, suitable binders, lubricants, disintegrants, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, and / or polyvinyl pyrrolidone, natural sugars (such as glucose or beta-lactose), corn sweeteners, natural and synthetic gums (such as gum arabic, tragacanth, or sodium alginate), polyethylene glycol, wax, etc. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silicon dioxide, talcum, stearic acid, its magnesium salt or calcium salt, and / or polyethylene glycol, etc. Disintegrators include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, starch, agar, alginic acid or its sodium salt, or effervescent mixture, cross-linked carboxymethylcellulose or its sodium salt, etc. Diluents include, for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine.
[0777] Tablets contain a mixture of the active ingredient and non-toxic pharmaceutically acceptable excipients suitable for the manufacture of tablets. These excipients may be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating agents and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. Tablets may be uncoated, or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time.
[0778] The therapeutically effective dose of the compounds described herein in oral formulations may vary from 0.15 mg / kg to 20 mg / kg patient body weight / day, more specifically 0.015 mg / kg to 1.0 mg / kg, which may be administered in a single or multiple doses per day. For oral administration, the drug may be in the form of a tablet or capsule containing 1 mg to 100 mg of active ingredient (specifically 1 mg, 5 mg, 10 mg, 20 mg, 50 mg or 100 mg) or in the form of a tablet or capsule containing at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% (w / w) of active ingredient. For example, a capsule may contain 50 mg of active ingredient, or 5%-10% (w / w) of active ingredient. For example, a tablet may contain 100 mg of active ingredient, or 20%-50% (w / w) of active ingredient. For example, in addition to the active ingredient, tablets may contain disintegrants or softeners (e.g., cross-linked carboxymethylcellulose or its sodium salt and methylcellulose), diluents (e.g., microcrystalline cellulose), and lubricants (e.g., sodium stearate and magnesium stearate). The drug may be administered daily, once, twice, or more times a day.
[0779] For administration by inhalation, the compounds may be delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant (eg, a gas such as carbon dioxide) or a nebulizer.
[0780] For transmucosal or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are well known in the art, and for transmucosal administration, include, for example, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gels, or creams as well known in the art. Penetration enhancers promote drug penetration through the corneal barrier and change the integrity of the epithelial cell layer. Commonly used penetration enhancers in ophthalmic preparations include cyclodextrin, dimethyl sulfoxide (DMSO), ethylenediaminetetraacetic acid (EDTA), sodium glycocholate and related cholates, Tween 20 (nonionic polysorbate surfactant), Brij 35 (polyoxyethylene lauryl ether), saponin, and bile salts. Typically, penetration enhancers (such as EDTA and cholate) temporarily loosen the tight junctions between adjacent cells of the corneal epithelium. Thus, penetration enhancers have been successfully used to deliver proteins and peptides across the corneal epithelium when applied topically to the eye.In some embodiments, the formulations described herein include a penetration enhancer such as polyoxyethylene-9-lauryl ether, sodium deoxycholate, sodium glycocholate, or sodium taurocholate.
[0781] In some embodiments, the pharmaceutically acceptable excipient in the ophthalmic solution or transmucosal preparation described herein is cyclodextrin. It is known that cyclodextrin acts as a penetration enhancer and mucoadhesive. In some embodiments, cyclodextrin is α-, β- or γ-cyclodextrin. In some embodiments, cyclodextrin is a pharmaceutically acceptable cyclodextrin derivative, including but not limited to α-, β- and γ-cyclodextrin hydroxyalkyl derivatives (especially β-cyclodextrin and γ-cyclodextrin hydroxyethyl and hydroxypropyl derivatives), random methylated β-cyclodextrin, sulfobutyl ether β-cyclodextrin, sulfobutyl ether γ-cyclodextrin and so-called branched β- and γ-cyclodextrin derivatives, such as glucosyl-β-cyclodextrin and glucosyl-γ-cyclodextrin. Natural cyclodextrins are used alone or as a mixture of two or more cyclodextrins, non-limiting examples being mixtures of γ-cyclodextrin with the more water-soluble hydroxypropyl γ-cyclodextrin, or γ-cyclodextrin with sulfobutyl ether γ-cyclodextrin, or β-cyclodextrin with hydroxypropyl-β-cyclodextrin, or β-cyclodextrin with sulfobutyl ether β-cyclodextrin.
[0782] In some embodiments, the concentration of cyclodextrin in the ophthalmic solution or transmucosal formulation described herein is 0% w / v to 20% w / v. In some embodiments, the concentration of cyclodextrin in the ophthalmic solution described herein is 1% w / v to 18% w / v, 1% w / v to 16% w / v, 1% w / v to 14% w / v, 2% w / v to 12% w / v, 4% w / v to 10% w / v, 5% w / v to 9% w / v, or 6% w / v to 8% w / v. In some embodiments, the concentration of cyclodextrin in the ophthalmic solution described herein is 7% w / v to 11% w / v. In some embodiments, the concentration of cyclodextrin in the ophthalmic solutions described herein is about 1% w / v, 2% w / v, 3% w / v, 4% w / v, 5% w / v, 6% w / v, 7% w / v, 8% w / v, 9% w / v, 10% w / v, 11% w / v, 12% w / v, 13% w / v, 14% w / v, 15% w / v, 16% w / v, 17% w / v, 18% w / v, 19% w / v, or 20% w / v.
[0783] In some embodiments, the pharmaceutically acceptable excipient in the ophthalmic solutions or transmucosal formulations described herein is sulfobutyl ether-β-cyclodextrin, specifically any one of the concentrations and concentration ranges specified above, such as about 7% w / v. In some embodiments, the pharmaceutically acceptable excipient in the ophthalmic solutions described herein is hydroxypropyl-β-cyclodextrin, specifically any one of the concentrations and concentration ranges specified above, such as about 7% w / v.
[0784] In some embodiments, the ophthalmic solutions described herein comprise a pharmaceutically acceptable buffer. In some embodiments, the pharmaceutically acceptable buffer is a phosphate buffer, a citrate buffer, a tris buffer, a histidine buffer, or an acetate buffer.
[0785] In some embodiments, the pharmaceutically acceptable buffer is disodium hydrogen phosphate. In some embodiments, the pharmaceutically acceptable buffer is sodium dihydrogen phosphate. In some embodiments, the pharmaceutically acceptable buffer is a mixture of disodium hydrogen phosphate and sodium dihydrogen phosphate. In some embodiments, the ophthalmic solutions described herein comprise about 0.083% w / v disodium hydrogen phosphate and about 0.017% w / v sodium dihydrogen phosphate.
[0786] In some embodiments, the ophthalmic solutions described herein are at approximately neutral pH. In some embodiments, the pH of the ophthalmic solutions described herein is 6.5 to 8. In some embodiments, the pH of the ophthalmic solutions described herein is 6.9 to 7.7. In some embodiments, the pH of the ophthalmic solutions described herein is 7.1 to 7.5. In some embodiments, the pH of the ophthalmic solutions described herein is about 7.3.
[0787] Pharmaceutically acceptable acids and / or bases can be used in ophthalmic solutions to adjust the pH. In some embodiments, the ophthalmic solutions described herein comprise a pharmaceutically acceptable acid. In some embodiments, the ophthalmic solutions described herein comprise a pharmaceutically acceptable base. In some embodiments, the ophthalmic solutions described herein comprise a pharmaceutically acceptable acid and a base. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable base is sodium hydroxide.
[0788] In some embodiments, the ophthalmic solutions described herein include a tonicity agent. In some embodiments, the tonicity agent is selected from the group consisting of: dextrose, potassium chloride, propylene glycol, and sodium chloride. In some embodiments, the ophthalmic solutions described herein include a tonicity agent at a concentration of less than about 0.5% w / v. In some embodiments, the ophthalmic solutions described herein include a tonicity agent at a concentration of about 0.45%, 0.4%, 0.35%, 0.3%, 0.25%, 0.2%, 0.15%, or 0.1% w / v. In some embodiments, the tonicity agent is sodium chloride.
[0789] Parenteral formulations containing the compounds described herein can be prepared in isotonic aqueous solutions or suspensions, and suppositories are advantageously prepared from fat emulsions or suspensions. The formulations can be sterilized and / or contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers, solubilizers, salts for regulating osmotic pressure, and / or buffers. In addition, it may also contain other therapeutically valuable substances. The compositions are prepared according to conventional methods and may contain about 0.1% to 75%, preferably about 1% to 50%, of the compounds described herein.
[0790] The phrases "parenteral administration" and "administered parenterally" are art-recognized terms and include modes of administration other than enteral and topical administration, such as by injection, and include, but are not limited to, intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraframe, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.
[0791] Preparations for topical application to the skin may include, for example, ointments, creams, gels and pastes comprising primary amine compounds in a pharmaceutically acceptable carrier. As is well known to those skilled in the art, preparations for topical primary amine compounds include preparing oily or water-soluble ointment bases. For example, these preparations may include vegetable oils, animal fats, and semisolid hydrocarbons such as obtained from petroleum. The specific components used may include white ointment, yellow ointment, spermaceti wax, oleic acid, olive oil, paraffin, petrolatum, white petrolatum, spermaceti, glycerol starch, white wax, yellow wax, lanolin, anhydrous lanolin and glyceryl monostearate. Various water-soluble ointment bases may also be used, including glycol ethers and derivatives, polyethylene glycol, polyoxyl 40 stearate and polysorbate.
[0792] Formulations for topical administration may contain concentrations used herein within the range of 0.001%-10%, 0.05%-10%, 0.1%-10%, 0.2%-10%, 0.5%-10%, 1%-10%, 2%-10%, 3%-10%, 4%-10%, 5%-10%, or 7%-10% (weight / volume), or within the range of 0.001%-2.0%, 0.001%-1.5%, or 0.001%-1.0% (weight / volume), or within the range of 0.05%-2 0%, 0.05%-1.5% or 0.05%-1.0% (w / v), or in the range of 0.1%-5.0%, 0.1%-2.0%, 0.1%-1.5% or 0.1%-1.0% (w / v), or in the range of 0.5%-5.0%, 0.5%-2.0%, 0.5%-1.5% or 0.5%-1.0% (w / v), or in the range of 1%-5.0%, 1%-2.0% or 1%-1.5% (w / v). Formulations for topical administration may also contain a compound used herein at a concentration within the range of 0.001%-2.5%, 0.01%-2.5%, 0.05%-2.0%, 0.1%-2.0%, 0.2%-2.0%, 0.5%-2.0%, or 1%-2.0% (weight / weight), or within the range of 0.001%-2.0%, 0.001%-1.5%, 0.001%-1.0%, or 0.001%-5% (weight / weight).
[0793] In some embodiments, the compound or a pharmaceutically acceptable salt thereof is administered systemically. In some embodiments, the compound or a pharmaceutically acceptable salt thereof is administered orally as part of a solid pharmaceutical composition. In some embodiments, the pharmaceutical composition is a liquid. In some embodiments, the pharmaceutical composition is administered as a liquid via a nasogastric tube.
[0794] In some embodiments, the compound or its pharmaceutically acceptable salt is administered once, twice, three times, or four times a day. In some embodiments, the compound or its pharmaceutically acceptable salt is administered twice a day. In some embodiments, the dose of the compound or its pharmaceutically acceptable salt is between about 1 mg BID (i.e., twice a day) to about 20 mg BID.
[0795] In some embodiments, the pharmaceutical composition is administered daily in one or more divided doses. In some embodiments, the composition is administered once a day (once a day; QD). In some embodiments, the composition is administered twice a day (twice a day; BID). In some embodiments, the composition is administered three times a day (three times a day; TID). In some embodiments, the composition is administered four times a day (four times a day; QID). In some embodiments, the composition is administered every four (4) hours (every four hours; q4h).
[0796] In some embodiments, the solid form of Compound 1 is substantially amorphous or crystalline, or a mixture thereof. In some embodiments, the solid form is substantially free of impurities.
[0797] In certain embodiments, Compound 1 is a crystalline solid. In some embodiments, Compound 1 is a crystalline solid that is substantially free of amorphous Compound 1. As used herein, the term "substantially free of amorphous Compound 1" means that the compound does not contain a significant amount of amorphous Compound 1. In some embodiments, at least about 95% by weight of crystalline Compound 1 is present. In other embodiments described herein, at least about 99% by weight of crystalline Compound 1 is present.
[0798] The compound can be formulated as an SDD formulation. As used herein, "SDD" refers to a pharmaceutical formulation that is a spray-dried formulation (e.g., a pharmaceutical formulation of compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the formulation comprises a compound of the present disclosure (e.g., compound 1 or a pharmaceutically acceptable salt thereof) and hydroxypropylmethylcellulose acetate succinate (HPMCAS). In one embodiment, HMPCAS is HPMCAS-M, where "M" indicates (acetyl content 7.0% to 11.0%, succinyl content 10% to 14%). It is well known that powders are produced from fluid raw materials using spray drying, and its application ranges from milk powder to bulk chemicals and drugs. See U.S. Patent No. 4,187,617 and Mujumbar et al., 91Drying, pp. 56-73 (1991). It is also known to use spray drying to form solid amorphous dispersions of drugs and thickening polymers. See European Patent Application Nos. 0 901 786, 1 027 886, 1 027 887, 1 027 888, and PCT Application Nos. WO 00 / 168092 and WO 00 / 168055, each of which is incorporated herein by reference. Typical spray drying equipment comprises a drying chamber, an atomizing device for atomizing a solvent-containing liquid fed into the drying chamber, a heated drying gas source directed into the drying chamber, and a dried product collecting device for separating the dried product from the cooled drying gas and vaporized solvent stream after the dried product leaves the drying chamber. Examples of this equipment include Niro Models PSD-1, PSD-2, and PSD-4 (Niro A / S, Soeborg, Denmark).
[0799] As used herein, "TPGS" or "Vitamin E TPGS" as a descriptor of a pharmaceutical formulation of a compound of the present disclosure refers to a pharmaceutical formulation (e.g., a pharmaceutical formulation of Compound 1 or a pharmaceutically acceptable salt thereof) that includes the following components: (a) an active compound (e.g., Compound 1 or a pharmaceutically acceptable salt thereof); (b) one or more diluents (e.g., microcrystalline cellulose); (c) one or more solubilizers (e.g., D-α-tocopheryl polyethylene glycol succinate [Vitamin E TPGS]); and (d) one or more binders (e.g., povidone). The formulation can be prepared using a granulation process (e.g., wet granulation). As used herein, "granulation" refers to a process that produces larger or smaller particles or granules of a substance or mixture of substances. The process can also remove fine particles and improve flowability within the formulation. Both wet granulation and / or dry granulation can be used. Dry granulation is achieved using only a combination of particles without any liquid on them. Tablet compression uses a tablet press to form large tablets, the weight of which varies due to the poor flowability of the formulation. The resulting mass is then passed through a granulator to break it into granules, and then pressed again to obtain the final granulated product.
[0800] All publications, patents, patent applications, and other documents cited in this application are incorporated herein by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, and other document was individually indicated to be incorporated by reference for all purposes.
[0801] All features of each aspect of the invention apply mutatis mutandis to all other aspects.
[0802] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that the examples are for illustrative purposes only and should not be construed as limiting the present invention in any manner.
[0803] Example
[0804] Example 1: Dissolution of Compound 1 and the Effect of Excipients Thereon
[0805] The key formulation challenge presented by compound 1 is poor water solubility. This is likely to limit in vivo absorption. Two anhydrous non-solvated forms (form C and material D) of compound 1 were identified in polymorph screening, as well as two variable hydrates (form A up to three moles of water, form J 1-2 moles of water) and several solvates. Through competitive slurry studies, form C was determined to be the most stable anhydrous non-solvated form. Hydrate form A and possible form J are also converted to form C when dehydrated.
[0806] The conversion of anhydrous Form C to hydrate Form A occurs at a water activity of wThe solubility of the two polymorphic forms of compound 1 (Form C and Form A) was observed in various aqueous systems (left column) as shown in Table 1 below.
[0807] Table 1: Solubility of Compound 1 Polymorph Form C and Form A in Various Aqueous Systems
[0808]
[0809] Table 2: Solubility of Compound 1 in aqueous buffer solutions and biorelevant media
[0810] Initial buffer pH pH at 48 hours Solubility μg / mL <![CDATA[1.21 a ]]> <![CDATA[1.19 a ]]> <![CDATA[58.1 a ]]> <![CDATA[2.98 a ]]> <![CDATA[3.01 a ]]> <![CDATA[18.9 a ]]> <![CDATA[4.46 a ]]> <![CDATA[4.49 a ]]> <![CDATA[13.3 a ]]> <![CDATA[6.81 a ]]> <![CDATA[6.75 a ]]> <![CDATA[4.1 a <!-- 72 -->]]> Unbuffered water <![CDATA[8.6 b ]]> <![CDATA[5.5 b ]]> <![CDATA[FaSSIF(pH 1.64) a ]]> <![CDATA[1.50 a ]]> <![CDATA[29.1 a ]]> <![CDATA[FeSSIF(pH 5.03) a ]]> <![CDATA[5.03 a ]]> <![CDATA[41.0 a ]]> <![CDATA[FaSSGF(pH 1.42) a ]]> <![CDATA[1.42 a ]]> <![CDATA[34.6 a ]]>
[0811] a The average of two runs
[0812] b Average of three runs
[0813] Partition coefficient
[0814] ClogP = 1.96.
[0815] Dissociation constant
[0816] The pKa of the protonated form is 1.94 and the dissociation constant K a =1.15×10 -2 .
[0817] Hygroscopicity
[0818] Compound 1 Form C shows limited hygroscopicity, with a water uptake of 1.75% at 5%-95% relative humidity and no hysteresis. Form A is a variable hydrate that exhibits significant hygroscopicity, with a water uptake of 4.58% at 5%-95% RH.
[0819] Melting point
[0820] By DSC, Compound 1 Form C had an onset melting point of 244.5 °C and a peak at 244.8 °C.
[0821] pKa and pH
[0822] The pKa of the protonated form of Compound 1 was determined to be 1.94 ± 0.01. The pH of a saturated aqueous solution of Compound 1 was 8.6.
[0823] We hypothesized that using Vitamin E TPGS in drug formulation would increase the solubility of Compound 1 and overcome the solubility problem. Dissolution testing of capsules was used as a screening tool to compare different preclinical formulations. Figure 1 The dissolution of a blend of crystalline Compound 1 Form C with microcrystalline cellulose (MCC; bottom curve) is shown relative to two particles of Compound 1 Form C containing 5% (2nd curve from the bottom or middle curve) or 20% (top curve) Vitamin E TPGS and MCC. Figure 1 As can be seen, the dissolution rate and total solubility were greatly increased by adding vitamin E TPGS.
[0824] TPGS formulations were used in early Phase I clinical studies; late Phase I and current Phase II clinical trials utilize alternative SDD formulations described below. Optimization of the SDD formulation included evaluation of several polymers and comparison of drug loading with the selected polymer. Based on the SDD screening run, it was determined that a 50:50 ratio of Compound 1 to the polymer HPMC-AS-M (a medium substitution level of HPMC-AS) provided the best combination of properties, including total spray drying yield, lowest hygroscopicity under high humidity conditions, and best dissolution performance, while balancing the relatively small capsule size desired in clinical applications. X-ray powder diffraction confirmed that the SDD process produces an amorphous API dispersion. Human PK evaluation of the comparative bioavailability of TPGS formulations versus SDD formulations was performed. Overall, exposure was similar or slightly better, with a relative F% calculated to be 128%.
[0825] As described herein, SDD formulations containing 50% Compound 1:50% HPMC-AS-M were successfully developed into size 3 capsules containing 2 mg, 5 mg, 15 mg, or 25 mg of Compound 1 and size 2 capsules containing 50 mg of Compound 1. These HPMC-AS-M based SDD formulations are expected to provide good exposure of Compound 1 in a clinical setting when administered orally.
[0826] Initial toxicology studies utilized a formulation of Compound 1 in 10% Cremophor EL / 10% propylene glycol / 80% water. However, repeated administration of this formulation to rats demonstrated a "plateau" in systemic exposure such that higher doses did not produce significantly higher exposures. Therefore, other formulations were evaluated in rats and monkeys, including E5 containing 0.5% hydroxypropyl methylcellulose (HPMC) and 0.5% 80% of the nanodispersion formulation in deionized water and in a solution containing 0.5% MC400cP and 0.1% The invention relates to a spray dried dispersion (SDD) formulation in deionized water at 80°C. The copolymer used in the initial SDD formulation was polyvinyl pyrrolidone / vinyl acetate (PVP-VA) and the drug loading was 20%. This spray dried dispersion formulation showed better solubility than the crystalline material and reproducibly demonstrated the highest achievable systemic exposure in animals. This formulation was used for initial critical repeated dose toxicology testing (lasting 28 days) as well as in vivo safety pharmacology and genotoxicity studies. Subsequent development of the SDD formulation was performed to increase the drug loading and optimize the properties of the formulation for clinical use. These efforts resulted in an SDD formulation using hydroxypropylmethylcellulose acetate succinate (HPMCAS) as the polymer with a drug loading of 50%. This improved SDD formulation was used for longer term repeated dose toxicity studies and developmental toxicity testing in rabbits and formed the basis for the clinical formulation.
[0827] Example 2: Development of oral capsule formulation of compound 1
[0828] Compound 1 drug product is manufactured in 5 mg and 25 mg strengths. A description of the drug product is provided in Table 3.
[0829] Table 3: Description of Compound 1 Drug Product
[0830]
[0831] composition
[0832] The composition of Compound 1 drug product (5 mg and 25 mg doses) is presented in Tables 4 and 5.
[0833] Table 4: Unit composition, drug function, quality standards and ingredients
[0834]
[0835] NF - National Formulary; N / A - Not Applicable
[0836] Table 5: Total inactive ingredients composition
[0837]
[0838] All excipients listed are Generally Regarded as Safe (GRAS).
[0839] Overfeed
[0840] There is no overfeeding.
[0841] Container Closures
[0842] The container closure systems for Compound 1 drug product (5 mg and 25 mg) are presented in Table 6 below.
[0843] Table 6: Closure Systems for Drug Product Containers
[0844]
[0845] Components of drug products
[0846] API
[0847] Compatibility of API and excipients
[0848] Excipient compatibility was determined by conducting accelerated and real-time stability studies on formulated drug in capsules whose composition and method of preparation were consistent with the intended clinical dosage form.
[0849] Physicochemical properties of APIs
[0850] Physical properties
[0851] The physical properties of Compound 1 are summarized above. Two major polymorphic forms, A and C, were evaluated during development. Form A is a low melting point hydrate containing up to 3 equivalents of water, which can be converted to Form C upon heating or drying. Form C is the most stable polymorph observed to date and was selected for development. GLP and GMP batches of drug substance are delivered in Form C.
[0852] Table 7: Summary of physical properties of compound 1
[0853]
[0854]
[0855] SGF: simulated gastric fluid, FaSSIF: fasted simulated intestinal fluid, FeSSIF: fed simulated intestinal fluid.
[0856] Chemical properties
[0857] pKa: 1.94
[0858] Chemical stability in solid state (crystalline and amorphous) and solution:
[0859] Stress testing of Compound 1 drug substance was performed to gain insight into the intrinsic stability of the molecule, identify any potential degradation products, and facilitate the development of stability-indicating analytical methods.
[0860] excipient
[0861] MCC (microcrystalline cellulose) is used as an inert filler in capsule formulations. By adding MCC, the volume of the filling material increases, which improves the accuracy of the volume filling operation. In addition, since MCC generally has good density and powder flow properties, it helps in the capsule filling operation.
[0862] PVP K30 (polyvinyl pyrrolidone) was used as a binder during the wet granulation process. PVP is a very commonly used binder and helps to agglomerate the API and filler (MCC) particles together.
[0863] Vitamin E TPGS is a commercially available nonionic surfactant derived from vitamin E. It is often used to enhance the bioavailability of poorly water-soluble drugs administered orally. The drug substance Compound 1 was selected based on its high solubility in the excipient.
[0864] Container Closure Systems
[0865] describe
[0866] Compound 1 drug product capsules (5 mg and 25 mg) were packaged in 60 cc HDPE bottles with induction seals and child-resistant caps.
[0867] Material selection
[0868] HDPE bottles are the most common type of container closure system used in the pharmaceutical industry for capsule and tablet formulations and are readily available. HDPE is chemically inert and provides good protection against moisture and light.
[0869] Moisture-proof
[0870] Compound 1 capsules were shown to be insensitive to moisture. Therefore, no desiccant was required.
[0871] Protect from light
[0872] ICH photostability studies showed that Compound 1 is not sensitive to light. In addition, the bottles are opaque and light exposure will be minimized during storage of the drug product.
[0873] Security
[0874] Since the Compound 1 drug product is presented in capsules, acceptance criteria for microbial limits were established as shown in Table 8. These limits are based on: USP <1111> "Acceptance Criteria for Microbiological Quality of Nonsterile Dosage Forms" as specified in "Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use".
[0875] Table 8: Microbiological testing of Compound 1 drug product
[0876]
[0877] According to USP <61> and <62> Results of the microbiological limit tests conducted for release and stability showed that the total aerobic microbial count and the combined total yeast and mold counts did not exceed the acceptance criteria and no microbial proliferation was observed. E. coli was not present in any of the batches tested.
[0878] Description of manufacturing method
[0879] According to the present disclosure Figure 2 According to the flow chart shown in , the formulation method involves wet granulation of compound 1 with MCC (microcrystalline cellulose, diluent, Avicel PH101), vitamin E TPGS (solubilizer), PVP K30 (polyvinyl pyrrolidone, binder) and water. After granulation, the wet granules are dried in a fluid bed dryer until LOD≤1.5%, passed through a Comil to break up any aggregates, and blended to provide bulk capsule filling material. Based on the weight of the input material, 5 mg capsules are filled using the Xcelodose system. Based on volume, 25 mg capsules are filled using the Profill system. Content uniformity testing is performed after capsule filling. Both 5 mg and 25 mg strength capsules are filled in No. 2 hard shell HPMC-based capsules. Each 60cc HPDE bottle is packaged with 12 counted filled capsules.
[0880] Description of process controls
[0881] Table 9: In-process controls
[0882] Method steps In-process testing Acceptance Criteria Granule drying LOD % ≤1.5LOD filling Capsule uniformity AV=15.0
[0883] Specification - Compound 1 Drug Product, Capsules
[0884] The quality control specifications for Compound 1 drug product capsules (5 mg and 25 mg) are provided in Table 10.
[0885] Table 10: Quality Control Specifications
[0886]
[0887]
[0888] HPLC Methods for Identification and Impurities
[0889] Identification
[0890] The retention time and UV spectrum of the samples were compared with the retention time and UV spectrum of the Compound 1 drug substance reference standard. The reverse phase HPLC method conditions are described in Table 11.
[0891] Impurities
[0892] The HPLC method for impurities is based on the drug substance method. The peak area of the individual related substances is divided by the total peak area to obtain the respective percentages. The total impurities are expressed as the sum of each individual impurity. The purity is obtained by subtracting the total impurities from 100%. Table 11 provides a description of the method.
[0893] Table 11: HPLC method conditions for impurities
[0894]
[0895] Potency, percent labeled, dose uniformity
[0896] Potency, percent labeled amount, and dose uniformity were determined by HPLC with UV detection. The peak area of the Compound 1 peak was compared to the peak area of the reference standard. Table 12 provides the method conditions for obtaining chromatographic purity. For percent labeled amount, the potency was compared to the potency of the nominal value. For dose uniformity, the ... according to USP <905> Calculates the accepted value.
[0897] Table 12: Method conditions for determining potency, percent labeled amount, and dose uniformity by HPLC
[0898]
[0899] Dissolution
[0900] According to USP <711> Dissolution was performed. USP Apparatus II was used at 37°C in 900 mL of dissolution medium with the paddle speed set at 75 rpm. After the 60 minute time point, the paddle speed was increased to 200 rpm. The dissolution medium was 0.1 N HCl containing 1% sodium lauryl sulfate. Samples were removed and analyzed by HPLC at 343 nm with UV detection relative to a reference standard. The chromatographic conditions for the HPLC method are described in Table 13.
[0901] Table 13: Method conditions for determining potency, percent labeled amount, and dose uniformity by HPLC
[0902]
[0903] Validation of Analytical Procedures - Compound 1 Drug Product, Capsules
[0904] The analytical procedures were evaluated at a level appropriate for the current stage of development. The HPLC method used to identify and quantify the impurities of the Compound 1 drug product passed in terms of accuracy, precision, linearity, specificity, limits of quantitation and detection, range, peak purity, and solution stability. The methods for potency, percent labeled amount, and dose uniformity passed in terms of accuracy, precision, linearity, specificity, range, and solution stability. The method for dissolution passed in terms of accuracy, precision, repeatability, linearity, specificity, limits of quantitation and detection, range, filter compatibility, and solution stability.
[0905] Batch analysis [drug product, capsules]
[0906] Batch Description
[0907] Table 14: Batch analysis results of Compound 1 drug product
[0908]
[0909]
[0910]
[0911] Characterization of impurities
[0912] Compound 1 does not contain any impurities that are specific to new drug products.
[0913] Stability Summary and Conclusions
[0914] Summary of Stability Studies
[0915] One month data were available for representative non-GMP batches of Compound 1 drug product (5 mg and 25 mg) at proposed long-term 2°C-8°C and accelerated 25°C / 60% RH and 40°C / 75% RH storage conditions.
[0916] No significant changes were observed in any of the tested parameters.
[0917] Design of stability studies
[0918] The stability of Compound 1 is shown in Table 15. This protocol was conducted under the proposed long-term 2°C-8°C as well as accelerated 25°C / 60% RH and 40°C / 75% RH storage conditions.
[0919] Table 15: Stability protocol for non-GMP Compound 1 drug product batches
[0920]
[0921]
[0922] A: Appearance, potency, impurities, water content, dissolution
[0923] A representative stability protocol for Compound 1 stability is presented in Table 16. This protocol was designed as a 2-year study under proposed long-term 2°C-8°C as well as accelerated 25°C / 60% RH and 40°C / 75% RH storage conditions.
[0924] Table 16: Stability profile of GMP Compound 1 drug substance
[0925]
[0926] A: Appearance, potency, impurities, water content, dissolution
[0927] B: Microbial Limits
[0928] --: No measurement planned
[0929] Test batches and packaging
[0930] Table 17 summarizes Compound 1 drug product batches with respect to stability.
[0931] Table 17: Summary of Compound 1 Drug Product Stability
[0932]
[0933]
[0934] Stability Data
[0935] Results of stability data under established storage and stress conditions
[0936] The available stability data for the demonstration batches (5 mg and 25 mg, respectively) are described in the following tables.
[0937] Table 18: Stability data for 5 mg drug product stored at 2°C-8°C
[0938]
[0939]
[0940] ND - Not Detected
[0941] Table 19: Stability data for 5 mg drug product stored at 25°C / 60% RH
[0942]
[0943] ND - Not Detected
[0944] Table 20: Stability data for 5 mg drug product stored at 40°C / 75% RH
[0945]
[0946]
[0947] ND - Not Detected
[0948] Table 21: Stability data for 25 mg drug product stored at 2°C-8°C
[0949]
[0950] ND - Not Detected
[0951] Table 22: Stability data for 25 mg batches of drug product stored at 25°C / 60% RH
[0952]
[0953] ND - Not Detected
[0954] Table 23: Stability data for 25 mg drug product stored at 40°C / 75% RH
[0955]
[0956]
[0957] ND - Not Detected
[0958] Example 3: Batch Formulation of IMPD Drug Product Capsules (2 mg etc.).
[0959] The following tables provide a summary of batch materials for various dosage forms.
[0960] Table 24: Batch formulation of Compound 1 SDD drug product capsules (2 mg)
[0961]
[0962] *The spray dried intermediate is also described as 50:50 Compound 1:HPMC-AS-M SDD, which contains 50 wt% Compound 1.
[0963] NF-National Formulary; USP-United States Pharmacopeia
[0964] Table 25: Batch formulation of Compound 1 SDD drug product capsules (5 mg)
[0965]
[0966] *The spray dried intermediate is also described as 50:50 Compound 1:HPMC-AS-M SDD, which contains 50 wt% Compound 1.
[0967] NF-National Formulary; USP-United States Pharmacopeia
[0968] Table 26: Batch formulation of Compound 1 SDD drug product capsules (15 mg)
[0969]
[0970]
[0971] *The spray dried intermediate is also described as 50:50 Compound 1:HPMC-AS-M SDD, which contains 50 wt% Compound 1.
[0972] NF-National Formulary; USP-United States Pharmacopeia
[0973] Table 27: Batch formulation of Compound 1 SDD drug product capsules (25 mg)
[0974]
[0975]
[0976] *The spray dried intermediate is also described as 50:50 Compound 1:HPMC-AS-M SDD, which contains 50 wt% Compound 1.
[0977] NF-National Formulary; USP-United States Pharmacopeia
[0978] Table 28: Batch formulation of Compound 1 SDD drug product capsules (50 mg)
[0979]
[0980]
[0981] *The spray dried intermediate is also described as 50:50 Compound 1:HPMC-AS-M SDD, which contains 50 wt% Compound 1.
[0982] NF-National Formulary; USP-United States Pharmacopeia
[0983] Table 29: Total Inactive Ingredients Composition in Compound 1 SDD Drug Product
[0984]
[0985] a Total potential excipient doses are within human experience as cited in the FDA Inactive Ingredient Database).
[0986] b HPMC-AS-M (hydroxypropylmethylcellulose acetate succinate, M grade) was part of a spray dried intermediate containing 50:50 Compound 1:HPMC-AS-M by weight.
[0987] Description of manufacturing methods and process controls
[0988] follow Figure 4 The flow chart for manufacturing compound 1 SDD drug product shown in the, the formulation method prepares SDD by dissolving compound 1 and HPMC-AS in an organic solvent, then passing the liquid through a 100 mesh screen, then spray drying to produce SDI (spray drying intermediate), and secondary tray drying to remove residual solvent. After spray drying, in-process testing is performed to confirm that the residual solvent is below the ICH level.
[0989] After drying, SDI is blended with intragranular excipients, then de-agglomerated with a grinder (Comil), blended again, and finally dry granulated on a 1.00 mm screen using a roller press, which also grinds the ribbons when producing them. The resulting dry granules are further blended with extragranular excipients, and then filled into capsules using a Profill capsule filling system. Fill weights can be adjusted based on in-process control results for efficacy. Different amounts of intragranular and extragranular excipients are used to produce blends that will constitute 2 mg, 5 mg, 15 mg, 25 mg, and 50 mg strength capsules, so that the 2 mg, 5 mg, 15 mg, and 25 mg blends can be loaded into No. 3 HPMC capsules and the 50 mg blends are loaded into No. 2 HPMC capsules.
[0990] The spray-dried intermediate of compound 1 was stored in double-layered bags in HDPE bags with desiccant placed between the bags, and then further packaged in heat-sealed mylar bags. The storage condition was 15°C-30°C.
[0991] To support its long-term storage, stability studies were performed on compound 1SDI, and data for 12 months in the long term and 6 months in accelerated conditions were available. The stability program was performed under the proposed long-term 25°C / 60% RH and accelerated 40°C / 75% RH storage conditions. The available data are provided in Table 30 and Table 31, respectively. No changes were observed under any conditions. The stability study can be extended to more than 24 months to support longer-term storage of this intermediate.
[0992] Table 29: Stability profile of non-GMP Compound 1
[0993]
[0994] A: Appearance, assay, purity, water content, X-ray powder diffraction.
[0995] Table 30: Stability data of Compound 1SDI Batch No. FP-19056 stored at 25°C / 60% RH
[0996]
[0997] Table 31: Stability data of Compound 1SDI Batch No. FP-19056 stored at 40°C / 75% RH
[0998]
[0999] Dose Uniformity, Assays and Impurities
[1000] Dose uniformity and determination were determined by HPLC with UV detection. The peak area of the Compound 1 peak was compared to the peak area of the reference standard. The peak area of the individual related substances was divided by the total peak area to obtain the respective percentages. Total impurities are expressed as the sum of each individual impurity. Purity is obtained by subtracting the total impurities from 100%. Table 32 provides the process conditions. In a typical batch produced by these methods, the purity of Compound 1 in the chromatogram produced by the SDD drug product is extremely high (retention time approximately 14.57 minutes) and the impurity level is extremely low.
[1001] Table 32: HPLC Method Conditions for Impurities in Compound 1 SDD Drug Product
[1002]
[1003] Table 33: Batch Analysis Results of Compound 1 SDD Drug Product
[1004]
[1005] Table 34: Batch Analysis Results of Compound 1 SDD Drug Product
[1006]
[1007]
[1008] Dissolution
[1009] According to USP <711> Dissolution was performed. USP apparatus II was used at 37°C in 900 mL of dissolution medium with a paddle speed set at 100 rpm. After the 60 minute time point, the paddle speed was increased to 250 rpm. The dissolution medium was a 20 mM KH2PO4 aqueous solution containing 1% sodium lauryl sulfate, pH 6.8. Samples were removed and analyzed by HPLC with UV detection at 266 nm relative to a reference standard. The chromatographic conditions for the HPLC method are described in Table 35, and purity was assessed by chromatogram.
[1010] Table 35: Method conditions for dissolution of Compound 1 SDD drug product by HPLC
[1011]
[1012] Validation of analytical procedures
[1013] The analytical procedures described herein have been evaluated at a level appropriate for the current stage of development.
[1014] The HPLC methods for identification, determination, dose uniformity, and quantification of impurities in the Compound 1 SDD drug product passed in terms of accuracy, precision, linearity, specificity, limit of quantitation, range, and solution stability. The methods for dissolution passed in terms of accuracy, precision, linearity, specificity, range, and solution stability. The Karl Fischer water content method passed in terms of accuracy and precision.
[1015] Summary of Stability Studies
[1016] For Compound 1 SDD drug product, 12 month data were available for representative non-GMP batches (5 mg and 50 mg) at proposed long-term 25°C / 60% RH storage conditions, and 6 month data at accelerated 40°C / 75% RH storage conditions.
[1017] For Compound 1 GMP SDD drug product, data were available for GMP batches (5 mg, 25 mg and 50 mg) at 18 months at proposed long-term 25°C / 60% RH storage conditions and 6 months at accelerated 40°C / 75% RH storage conditions.
[1018] To reflect the change in blister packaging, stability studies were conducted on Compound 1 SDD drug product capsules 2 mg, 5 mg, 15 mg, and 25 mg. Six-month data were available for 2 mg, 5 mg, and 15 mg strengths at both the proposed long-term 25°C / 60% RH and accelerated 40°C / 75% RH storage conditions.
[1019] No significant changes were observed for any of the parameters tested.For capsules in blisters, some changes in individual impurities were observed at 3 months and monitored at subsequent time points.
[1020] A stability program was conducted for the vialed non-GMP Compound 1 SDD drug product at the proposed long-term 25°C / 60% RH and accelerated 40°C / 75% RH storage conditions. This stability program supports the clinical use of the Compound 1 SDD drug product.
[1021] The stability program for the blister packaged GMP drug product was designed as a 3-year study at the proposed long-term 25°C / 60% RH and accelerated 40°C / 75% RH storage conditions.
[1022] Test batches and packaging
[1023] Table 36 summarizes the SDD drug product batches currently under stability studies.
[1024] Table 36: Summary of Compound 1 SDD Drug Product Batches Under Stability Study
[1025]
[1026]
[1027] Shelf life
[1028] Based on achievable stability, the shelf life of the SDD drug product will be 30 months from the date of manufacture.
[1029] Stability Data
[1030] The available stability data for the SDD drug product presentations (5 mg and 50 mg) are described in the following tables, respectively.
[1031] The available stability data for the SDD drug product GMP batches (5 mg, 25 mg and 50 mg) are described in the following tables, respectively.
[1032] The available stability data for SDD drug product GMP batches (2 mg, 5 mg and 15 mg) in blister packs are described in the following tables, respectively.
[1033] The acceptance criteria and analytical methods used for stability testing are the same as for release specifications.
[1034] Table 37: Stability data of SDD display batch drug product (5 mg) stored at 25°C / 60% RH
[1035]
[1036] NR: Not reported
[1037] Table 38: Stability data of Compound 1 SDD display (5 mg) stored at 40°C / 75% RH
[1038]
[1039]
[1040] NR: Not reported
[1041] Table 39: Stability data of Compound 1 SDD display batch drug product (50 mg) stored at 25°C / 60% RH
[1042]
[1043] NR: Not reported
[1044] Table 40: Stability data of Compound 1 SDD display batch drug product (50 mg) stored at 40°C / 75% RH
[1045]
[1046] NR: Not reported
[1047] Table 41: Stability data of Compound 1 SDD GMP drug product (5 mg) stored at 25°C / 60% RH
[1048]
[1049]
[1050] * Due to the lack of utility of the 45 minute readings and also to obtain infinite rotation data, the dissolution profiles were modified prior to the 12 month time point.
[1051] Table 42: Stability data of Compound 1 SDD GMP drug product (5 mg) stored at 40°C / 75% RH
[1052]
[1053]
[1054] Table 43: Stability data of Compound 1 SDD GMP drug product (25 mg) at 25°C / 60% RH
[1055]
[1056]
[1057] * Due to the lack of utility of the 45 minute readings and also to obtain infinite rotation data, the dissolution profiles were modified prior to the 12 month time point.
[1058] Table 44: Stability data of Compound 1 SDD GMP drug product (25 mg) stored at 40°C / 75% RH
[1059]
[1060]
[1061] Table 45: Stability data of Compound 1 SDD GMP drug product (50 mg) stored at 25°C / 60% RH
[1062]
[1063]
[1064] * Due to the lack of utility of the 45 minute readings and also to obtain infinite rotation data, the dissolution profiles were modified prior to the 12 month time point.
[1065] Table 46: Stability data of Compound 1 SDD GMP drug product (50 mg) stored at 40°C / 75% RH
[1066]
[1067] Table 47: Stability data of Compound 1 SDD GMP drug product (2 mg) stored at 25°C / 60% RH
[1068]
[1069]
[1070] Table 48: Stability data of Compound 1 SDD GMP drug product (2 mg) stored at 40°C / 75% RH
[1071]
[1072]
[1073] Table 49: Stability data of Compound 1 SDD display batch drug product (5 mg) stored at 25°C / 60% RH
[1074]
[1075]
[1076] NR: Not reported
[1077] Table 50: Stability data of Compound 1 SDD display batch drug product (5 mg) stored at 40°C / 75% RH
[1078]
[1079] NR: Not reported
[1080] Table 51: Stability data of Compound 1 SDD display batch drug product (50 mg) stored at 25°C / 60% RH
[1081]
[1082]
[1083] NR: Not reported
[1084] Table 52: Stability data of Compound 1 SDD demonstration batch drug product (50 mg) at 40°C / 75% RH
[1085]
[1086] NR: Not reported
[1087] Table 53: Stability data of Compound 1 SDD GMP drug product (5 mg) at 25°C / 60% RH
[1088]
[1089] * Due to the lack of utility of the 45 minute readings and also to obtain infinite rotation data, the dissolution profiles were modified prior to the 12 month time point.
[1090] Table 54: Stability data of Compound 1 SDD GMP drug product (5 mg) stored at 40°C / 75% RH
[1091]
[1092] Table 55: Stability data of Compound 1 SDD GMP drug product (25 mg) stored at 25°C / 60% RH
[1093]
[1094]
[1095] * Due to the lack of utility of the 45 minute readings and also to obtain infinite rotation data, the dissolution profiles were modified prior to the 12 month time point.
[1096] Table 56: Stability data of Compound 1 SDD GMP drug product (25 mg) at 40°C / 75% RH
[1097]
[1098]
[1099] Table 57: Stability data of Compound 1 SDD GMP drug product (50 mg) stored at 25°C / 60% RH
[1100]
[1101]
[1102] *Due to the lack of utility of the 45 minute readings and also to obtain infinite rotation data, the dissolution profiles were modified prior to the 12 month time point.
[1103] Table 58: Stability data of Compound 1 SDD GMP drug product (50 mg) stored at 40°C / 75% RH
[1104]
[1105]
[1106] Table 59: Stability data of Compound 1 SDD GMP drug product (2 mg batch) at 25°C / 60% RH
[1107]
[1108] Table 60: Stability data of Compound 1 SDD GMP drug product (2 mg) stored at 25°C / 60% RH
[1109]
[1110]
[1111] Table 61: Stability data of Compound 1 SDD GMP drug product (2 mg) stored at 40°C / 75% RH
[1112]
[1113]
[1114] Table 62: Stability data of Compound 1 SDD GMP drug product (5 mg) stored at 25°C / 60% RH
[1115]
[1116] Table 63: Stability data of Compound 1 SDD GMP drug product (15 mg) stored at 25°C / 60% RH
[1117]
[1118]
[1119] Table 64: Stability data of Compound 1 SDD GMP drug product (15 mg) stored at 40°C / 75% RH
[1120]
[1121]
[1122] The details of one or more embodiments are set out in the drawings and description. Other features, objects and advantages will be apparent from the description, drawings and claims. Although a number of embodiments of the present invention have been described, it should be understood that various modifications may be made without departing from the spirit and scope of the present invention. It should also be understood that the drawings are not necessarily drawn to scale and that they present slightly simplified representations of various features and basic principles of the present invention.
Claims
1. A pharmaceutical composition, preparation or unit dosage form comprising: (a) Compound 1: or a solvate thereof, or a pharmaceutically acceptable salt thereof; (b) one or more fillers or diluents; (c) one or more solubilizing agents; and (d) one or more binders.
2. The pharmaceutical composition, formulation or unit dosage form of claim 1, wherein (a) comprises Compound 1.
3. The pharmaceutical composition, formulation or unit dosage form of claim 1 or 2, wherein the solubilizing agent comprises one or more solubilizing agents of Formula IA: or a pharmaceutically acceptable salt thereof, wherein n is about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000.
4. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 1-3, wherein the solubilizing agent comprises Vitamin E TPGS.
5. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 1-4, wherein the filler or diluent comprises microcrystalline cellulose.
6. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-5, wherein the filler or diluent comprises Avicel PH101.
7. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-6, wherein the binder comprises povidone.
8. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 1-7, wherein the binder comprises PVP K30.
9. A pharmaceutical composition, formulation or unit dosage form as described in any of claims 1-8, comprising an amount of Compound 1 from about 1 mg to about 2.5 mg, from about 2.5 mg to about 5 mg, from about 5 mg to about 7.5 mg, from about 7.5 mg to about 10 mg, from about 10 mg to about 12.5 mg, from about 12.5 mg to about 15 mg, from about 15 mg to about 17.5 mg, from about 17.5 mg to about 20 mg, from about 20 mg to about 22.5 mg, from about 22.5 mg to about 25 mg, from about 25 mg to about 27.5 mg, from about 27.5 mg to about 30 mg, from about 30 mg to about 32.5 mg, from about 32.5 mg to about 35 mg, from about 35 mg to about 37.5 mg, from about 37.5 mg to about 40 mg, from about 40 mg to about 45 mg, or from about 45 mg to about 50 mg.
10. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-9, comprising about 2 mg of Compound 1.
11. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-9, comprising about 5 mg of Compound 1.
12. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-9, comprising about 15 mg of Compound 1.
13. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-9, comprising about 25 mg of Compound 1.
14. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-9, comprising about 50 mg of Compound 1.
15. A pharmaceutical composition, formulation or unit dosage form as described in any of claims 1-14, comprising an amount of diluent from about 15 mg to about 17.5 mg, from about 17.5 mg to about 20 mg, from about 20 mg to about 22.5 mg, from about 22.5 mg to about 25 mg, from about 25 mg to about 27.5 mg, from about 27.5 mg to about 30 mg, from about 30 mg to about 32.5 mg, from about 32.5 mg to about 35 mg, from about 35 mg to about 37.5 mg, from about 37.5 mg to about 40 mg, from about 40 mg to about 45 mg, from about 45 mg to about 50 mg, from about 50 mg to about 75 mg, from about 75 mg to about 100 mg, from about 100 mg to about 125 mg, from about 125 mg to about 150 mg, from about 150 mg to about 175 mg, from about 175 mg to about 200 mg, or from about 200 mg to about 225 mg.
16. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-15, comprising about 34 mg of a filler or diluent.
17. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-15, comprising about 170 mg of a filler or diluent.
18. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 15-17, wherein the filler or diluent comprises microcrystalline cellulose.
19. A pharmaceutical composition, formulation or unit dosage form as described in any of claims 1-18, comprising the following amount of solubilizer: from about 1 mg to about 2.5 mg, from about 2.5 mg to about 5 mg, from about 5 mg to about 7.5 mg, from about 7.5 mg to about 10 mg, from about 10 mg to about 12.5 mg, from about 12.5 mg to about 15 mg, from about 15 mg to about 17.5 mg, from about 17.5 mg to about 20 mg, from about 20 mg to about 22.5 mg, from about 22.5 In some embodiments, the present invention relates to an aqueous solution of at least one embodiment of the present invention, wherein the aqueous solution contains at least one iodine, at least one iodine and at least one iodine. In some embodiments, the aqueous solution contains at least one iodine, at least one iodine and at least one iodine. In some embodiments, the aqueous solution contains at least one iodine, at least one iodine and at least one iodine. In some embodiments, the aqueous solution contains at least one iodine, at least one iodine and at least one iodine.
20. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-19, comprising 10 mg of a solubilizer.
21. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-19, comprising 50 mg of a solubilizer.
22. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 19-21, wherein the solubilizing agent comprises Vitamin E TPGS.
23. The pharmaceutical composition, formulation, or unit dosage form of any of claims 1-22, comprising a binder in an amount from about 0.25 mg to about 0.5 mg, from about 0.5 mg to about 0.75 mg, from about 0.75 mg to about 1 mg, from about 1 mg to about 2 mg, from about 2 mg to about 3 mg, from about 3 mg to about 4 mg, from about 4 mg to about 5 mg, from about 5 mg to about 6 mg, from about 6 mg to about 7 mg, from about 7 mg to about 8 mg, from about 8 mg to about 9 mg, or from about 9 mg to about 10 mg.
24. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-23, comprising 1 mg of a binder.
25. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-23, comprising 5 mg of a binder.
26. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 23-25, wherein the binder comprises povidone.
27. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1 to 8, comprising: (a) about 2.5 mg to about 7.5 mg of Compound 1; (b) from about 17 mg to about 51 mg of a filler or diluent; (c) from about 5 mg to about 15 mg of a solubilizing agent; and (d) from about 0.5 mg to about 1.5 mg of a binder.
28. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1 to 8, comprising (a), (b), (c) and (d): (a) about 2.5 mg to about 7.5 mg of Compound 1; (b) from about 17 mg to about 51 mg of microcrystalline cellulose; (c) from about 5 mg to about 15 mg of Vitamin E TPGPS; and (d) from about 0.5 mg to about 1.5 mg of povidone.
29. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1 to 8, comprising (a), (b), (c) and (d): (a) about 5 mg of Compound 1; (b) about 34 mg of microcrystalline cellulose; (c) about 10 mg of Vitamin E TPGS; and (d) about 1 mg of povidone.
30. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1-8, comprising (a), (b), (c) and (d): (a) about 12.5 mg to about 37.5 mg of Compound 1; (b) from about 85 mg to about 255 mg of a filler or diluent; (c) from about 25 mg to about 75 mg of a solubilizing agent; and (d) from about 2.5 mg to about 7.5 mg of a binder.
31. A pharmaceutical composition, formulation or unit dosage form according to any one of claims 1 to 8, comprising (a), (b), (c) and (d): (a) about 25 mg of Compound 1; (b) about 170 mg of a filler or diluent; (c) about 10 mg of a solubilizing agent; and (d) About 5 mg of binder.
32. A pharmaceutical composition, formulation or unit dosage form according to any one of claims 1 to 8, comprising (a), (b), (c) and (d): (a) about 12.5 mg to about 37.5 mg of Compound 1; (b) from about 85 mg to about 255 mg of microcrystalline cellulose; (c) from about 25 mg to about 75 mg of Vitamin E TPGS; and (d) from about 2.5 mg to about 7.5 mg of povidone.
33. A pharmaceutical composition, formulation or unit dosage form according to any one of claims 1 to 8, comprising (a), (b), (c) and (d): (a) about 25 mg of Compound 1; (b) about 170 mg of microcrystalline cellulose; (c) about 10 mg of Vitamin E TPGS; and (d) about 5 mg of povidone.
34. A pharmaceutical composition, formulation or unit dosage form according to any one of claims 1 to 8, comprising: a) about 5% to about 15% (w / w) of Compound 1; b) from about 32% to about 80% (w / w) of a filler or diluent; c) from about 10% to about 30% (w / w) of a solubilizing agent; and d) from about 1% to about 3% (w / w) of a binder.
35. The pharmaceutical composition, formulation or unit dosage form of any one of claims 1 to 8, comprising: a) about 10% (w / w) of Compound 1; b) about 68% (w / w) of a filler or diluent; c) about 20% (w / w) of a solubilizing agent; and d) about 2% (w / w) binder.
36. A pharmaceutical composition, formulation or unit dosage form according to any one of claims 1 to 8, comprising: a) about 20% (w / w) of Compound 1; b) about 58% (w / w) of a filler or diluent; c) about 20% (w / w) of a solubilizing agent; and d) about 2% (w / w) binder.
37. A pharmaceutical composition, formulation or unit dosage form according to any one of claims 1 to 8, comprising: a) about 30% (w / w) of Compound 1; b) about 48% (w / w) of a filler or diluent; c) about 20% (w / w) of a solubilizing agent; and d) about 2% (w / w) binder.
38. A pharmaceutical composition, formulation or unit dosage form according to any one of claims 1 to 8, comprising: a) about 40% (w / w) of Compound 1; b) about 38% (w / w) of a filler or diluent; c) about 20% (w / w) of a solubilizing agent; and d) about 2% (w / w) binder.
39. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 27-38, wherein the diluent is microcrystalline cellulose, the solubilizer is Vitamin E TPGS, and the binder is povidone.
40. A pharmaceutical composition, formulation or unit dosage form comprising Compound 1: or a solvate thereof, or a pharmaceutically acceptable salt thereof; Wherein compound 1 is in the form of a spray dried dispersion (SDD).
41. The pharmaceutical composition, formulation, or unit dosage form of claim 40, wherein the SDD comprises a cellulose polymer selected from the group consisting of hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methylcellulose acetate succinate, hydroxyethyl methylcellulose succinate, hydroxyethyl cellulose acetate succinate, carboxymethyl ethylcellulose, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, and carboxymethyl ethylcellulose.
42. The pharmaceutical composition, formulation, or unit dosage form of claim 40, wherein the SDD comprises a mixture of Compound 1 and HPMC-AS-M (hydroxypropylmethylcellulose acetate succinate, grade M) in an amount of about 2:1 to about 1:2 (w / w).
43. A pharmaceutical composition, formulation or unit dosage form as described in any one of claims 40-42, comprising: a) about 1-4 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof as an about 2:1 to about 1:2 (w / w) mixture of Compound 1 and HPMC-AS; b) about 35-140 mg of a first bulking agent comprising mannitol; c) optionally, about 35-140 mg of a second filler comprising microcrystalline cellulose; d) about 4 to 18 mg of a disintegrant comprising croscarmellose sodium; e) about 0.5-3.0 mg of a glidant comprising colloidal silicon dioxide; f) about 0.4-2.0 mg of a lubricant comprising sodium stearyl fumarate; and g) Optionally, about 0.5-2 mg of a wetting agent comprising sodium lauryl sulfate.
44. A pharmaceutical composition, formulation or unit dosage form as described in any one of claims 40-42, comprising: a) about 2.5-10 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof as an about 2:1 to about 1:2 (w / w) mixture of Compound 1 and HPMC-AS; b) about 30-130 mg of a first bulking agent comprising mannitol; c) optionally, about 30-130 mg of a second filler comprising microcrystalline cellulose; d) about 4 to 20 mg of a disintegrant comprising croscarmellose sodium; e) about 0.5-4.0 mg of a glidant comprising colloidal silicon dioxide; f) optionally, about 0.5-4.0 mg of a wetting agent comprising sodium lauryl sulfate; and g) about 0.4-2.5 mg of a lubricant comprising sodium stearyl fumarate.
45. A pharmaceutical composition, formulation or unit dosage form as described in any one of claims 40-42, comprising: a) about 7.5-30 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof as an about 2:1 to about 1:2 (w / w) mixture of Compound 1 and HPMC-AS; b) about 25-130 mg of a first bulking agent comprising mannitol; c) optionally, about 25-130 mg of a second filler comprising microcrystalline cellulose; d) about 4 to 20 mg of a disintegrant comprising croscarmellose sodium; e) about 0.5-4.0 mg of a glidant comprising colloidal silicon dioxide; f) optionally, about 0.5-4.0 mg of a wetting agent comprising sodium lauryl sulfate; and g) about 0.4-4.0 mg of a lubricant comprising sodium stearyl fumarate.
46. A pharmaceutical composition, formulation or unit dosage form as described in any one of claims 40-42, comprising: a) about 12.5-50 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof as an about 2:1 to about 1:2 (w / w) mixture of Compound 1 and HPMC-AS; b) about 20-95 mg of a first bulking agent comprising mannitol; c) optionally, about 20-95 mg of a second filler comprising microcrystalline cellulose; d) about 4 to 20 mg of a disintegrant comprising croscarmellose sodium; e) about 0.5-4.0 mg of a glidant comprising colloidal silicon dioxide; f) optionally, about 0.5-4.0 mg of a wetting agent comprising sodium lauryl sulfate; and g) about 0.4-4.0 mg of a lubricant comprising sodium stearyl fumarate.
47. A pharmaceutical composition, formulation or unit dosage form as described in any one of claims 40-42, comprising: a) about 25-75 mg of Compound 1 or a solvate or pharmaceutically acceptable salt thereof as an about 2:1 to about 1:2 (w / w) mixture of Compound 1 and HPMC-AS; b) about 24-96 mg of a first bulking agent comprising mannitol; c) optionally, about 24-96 mg of a second filler comprising microcrystalline cellulose; d) about 6 to 25 mg of a disintegrant comprising croscarmellose sodium; e) about 1.0-5.0 mg of a glidant comprising colloidal silicon dioxide; f) optionally, about 1.0-5.0 mg of a wetting agent comprising sodium lauryl sulfate; and g) about 0.7-2.6 mg of a lubricant comprising sodium stearyl fumarate.
48. The pharmaceutical composition, formulation, or unit dosage form of any one of claims 43-47, wherein each of b), c), d) and g) is distributed between the particles comprising a) and the extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
49. A pharmaceutical composition, formulation or unit dosage form as described in any one of claims 40-47, comprising the ingredients shown below in one of the following w / w %: wherein the spray-dried intermediate comprises a spray-dried solid comprising Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a w / w ratio of 1.5:1 to 1:1.
5.
50. The pharmaceutical composition, formulation or unit dosage form of any one of claims 40-47, comprising the ingredients shown below in one of the following w / w %: wherein the spray-dried intermediate comprises a spray-dried solid comprising Compound 1:HPMC-AS (hydroxypropylmethylcellulose acetate succinate) in a w / w ratio of 1.5:1 to 1:1.
5.
51. A method of producing a pharmaceutical composition, formulation or unit dosage form, the method comprising: or a solvate or a pharmaceutically acceptable salt thereof; and one or more solubilizers are wet granulated.
52. The method of claim 51, wherein the mixture further comprises a filler or diluent and a binder.
53. The method of claim 51 or 52, wherein the solubilizing agent comprises one or more solubilizing agents of Formula IA: or a pharmaceutically acceptable salt thereof, wherein n is between about 10 to about 50, about 50 to about 100, about 100 to about 200, about 200 to about 500, about 500 to about 1,000, about 1,000 to about 2,000, about 2,000 to about 5,000, or about 5,000 to about 10,000.
54. The method of any one of claims 51-53, wherein the solubilizing agent comprises Vitamin E TPGS.
55. The method of any one of claims 51-54, wherein the filler or diluent comprises microcrystalline cellulose.
56. The method of any one of claims 51-55, wherein the filler or diluent comprises Avicel PH101.
57. The method of any one of claims 55-56, wherein the binder comprises povidone.
58. The method of any one of claims 49-51, wherein the adhesive comprises PVP K30.
59. The method of any one of claims 51 to 58, wherein the method comprises: (1) wet granulating the mixture; as well as (2) Drying the mixture.
60. The method of any one of claims 51 to 59, wherein the method comprises: (1) wet granulating the mixture; (2) drying the mixture; as well as (3) Dry grinding the mixture.
61. The method of any one of claims 51 to 60, wherein the method comprises: (1) wet granulating the mixture; (2) drying the mixture; (3) dry grinding the mixture; as well as (4) Blending the mixture.
62. The method of any one of claims 51 to 61, wherein the method comprises: (1) wet granulating the mixture; (2) drying the mixture; (3) dry grinding the mixture; (4) blending the mixture; and (5) Encapsulating the mixture.
63. The process of any one of claims 51-62, wherein the mixture is de-agglomerated prior to wet granulation.
64. A method of manufacturing the formulation of any one of claims 40-50, the method comprising the steps of: (1) providing an SDD (spray dried dispersion), wherein the SDD comprises Compound 1 or a solvate or a pharmaceutically acceptable salt thereof and a cellulose polymer; (2) blending the SDD with intragranular excipients; (3) de-agglomerating the mixture; (4) blending the mixture; (5) dry granulating the mixture; (6) blending the dried granules with extragranular excipients; as well as (7) Optionally, the preparation is filled into capsules.
65. The method of claim 64, wherein the SDD is prepared as follows: (1) providing a solution of Compound 1 or a pharmaceutically acceptable salt thereof and the cellulose polymer; (2) filtering the solution; (3) spray drying the solution to produce SDI (spray dried intermediate); and (4) optionally, drying the SDI by secondary tray drying; The SDD is thereby provided.
